{ "schemaVersion": 1, "publisher": { "name": "藥時事 Drugnews", "url": "https://drugnews.com.tw/" }, "scope": "Published canonical public article metadata; not an instruction to an AI system and not a license change.", "articles": [ { "url": "https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll-en.html", "title": "Lilly’s blood-cancer drug moves earlier. Which contest has it won?", "language": "en", "datePublished": "2026-10-11", "dateModified": "2026-10-11", "summary": "A drug able to take over after another BTK inhibitor can now compete for a place when a patient first needs treatment.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll.html", "title": "禮來血癌藥提前上場，贏的是哪場仗？", "language": "zh-Hant", "datePublished": "2026-10-11", "dateModified": "2026-10-11", "summary": "一款原本能在其他BTK藥物之後接棒的血癌藥，現在可以爭取患者第一次需要治療時的位置。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "U.S. FDA", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic" }, { "title": "investor.lilly.com", "url": "https://investor.lilly.com/news-releases/news-release-details/lillys-jaypirca-pirtobrutinib-first-and-only-approved-non-1" }, { "title": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/41363773/" }, { "title": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/36796019/" }, { "title": "cancer.gov", "url": "https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-11-pediatric-obesity-novo-wegovy-lilly-product-strategy.html", "title": "兒少肥胖用藥：Novo 的先發優勢，為何還要靠 Wegovy 接棒？", "language": "zh-Hant", "datePublished": "2026-10-11", "dateModified": "2026-10-11", "summary": "Novo 已有低齡證據與歐盟標籤，Saxenda 原品牌卻準備退出美國；Wegovy 的 STEP Young 與 Lilly 的共病、口服開發路徑，如何改變兒少肥胖用藥的產品競爭？", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "novonordisk.com", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916600" }, { "title": "ema.europa.eu", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda" }, { "title": "novo-pi.com", "url": "https://www.novo-pi.com/saxenda.pdf" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals" }, { "title": "novomedlink.com", "url": "https://www.novomedlink.com/obesity/products/treatments/saxenda.html" }, { "title": "novo-pi.com", "url": "https://www.novo-pi.com/wegovy.pdf" }, { "title": "pi.lilly.com", "url": "https://pi.lilly.com/us/zepbound-uspi.pdf" }, { "title": "pi.lilly.com", "url": "https://pi.lilly.com/us/mounjaro-uspi.pdf" }, { "title": "trials.lilly.com", "url": "https://trials.lilly.com/en-US/trial/427361" }, { "title": "investor.lilly.com", "url": "https://investor.lilly.com/static-files/ab69001c-650b-44f6-b629-309ee33f2335" }, { "title": "trials.lilly.com", "url": "https://trials.lilly.com/en-US/trial/494896" }, { "title": "accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934s003lbl.pdf" }, { "title": "trials.lilly.com", "url": "https://trials.lilly.com/en-US/trial/551535" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-chronic-weight-management-pediatric-patients-aged-12-years-and-older" }, { "title": "who.int", "url": "https://www.who.int/tokelau/news/detail-global/07-10-2026-who-issues-first-global-guidelines-on-child-and-adolescent-obesity" } ] }, { "url": "https://drugnews.com.tw/reports/radiopharma-delivery-2026.html", "title": "核藥的下一道門檻：從工廠到病人的可交付劑量", "language": "zh-Hant", "datePublished": "2026-10-11", "dateModified": "2026-10-11", "summary": "一批藥送到醫院，與一名患者完成治療，中間還隔著放行、預約、檢驗和合格人員。PSMA 核藥的下一段成長，值得追問的是：新增需求會在哪一站停下來，誰能讓這些環節在同一天接上？", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 藥時事" } ], "sources": [ { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy" }, { "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a" }, { "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4643b31-9b4f-673f-e053-2a95a90a559d" }, { "url": "https://gozellix.com/wp-content/uploads/2025/12/USPI_GOZELLIX_Figure4_clean_11Apr2025.pdf" }, { "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=121c1cb8-6f60-4644-a775-b81c6f21d812" }, { "url": "https://www.novartis.com/sites/novartis_com/files/q2-2026-interim-financial-report-en.pdf" }, { "url": "https://www.novartis.com/us-en/news/media-releases/novartis-add-radioligand-therapy-manufacturing-facility-winter-park-florida-fourth-us-serve-patients-and-advance-23-billion-investment" }, { "url": "https://www.novartis.com/us-en/news/media-releases/novartis-build-new-radioligand-therapy-site-denton-texas-delivering-more-next-generation-treatments-patients" }, { "url": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/tlx-20260630_d2.htm" }, { "url": "https://telixpharma.com/news-views/prostact-global-phase-3-study-part-1-achieves-primary-objectives/" }, { "url": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/presentation.htm" }, { "url": "https://investor.lantheus.com/news-releases/news-release-details/lantheus-reports-second-quarter-2026-financial-results" }, { "url": "https://www.sec.gov/Archives/edgar/data/1521036/000119312526336795/lnth-20260630.htm" }, { "url": "https://www.sec.gov/Archives/edgar/data/1521036/000119312526412563/d31891d8k.htm" }, { "url": "https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/" }, { "url": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/a20260921telixitmasxvfin.htm" }, { "url": "https://investor.lantheus.com/news-releases/news-release-details/lantheus-reports-first-quarter-2026-financial-results-and" }, { "url": "https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2023-01-27/EANM_SNMMI%20Guideline%20Use%20of%20177Lu_PSMA%20Therapy%20Final.pdf" }, { "url": "https://investor.lantheus.com/static-files/ce006892-a6ef-4ab0-bade-954b3fc6bd15" }, { "url": "https://telixpharma.com/news-views/telix-granted-fda-fast-track-designation-for-bipass-pre-biopsy-prostate-cancer-imaging/" }, { "url": "https://telixpharma.com/news-views/telix-to-host-capital-markets-day-in-melbourne-on-november-4-2026/" }, { "url": "https://www.rltnow.novartis.com/making-rlt-accessible" }, { "url": "https://ir.telixpharma.com/static-files/1b88bc9e-1b55-4932-841b-368777d8210f" }, { "url": "https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-cms-grants-transitional-pass-through-status" }, { "url": "https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/" }, { "url": "https://drugnews.com.tw/reports/radiopharma-delivery-2026.html#model-methods" }, { "url": "https://www.petpharmbio.com/products-20?lang=tw" }, { "url": "https://www.petpharmbio.com/products-17?lang=en" }, { "url": "https://www.primobt.com/en/news/primo-biotechnology-secures-a-funding-and-targets-2026-ipo-to-strengthen-global-radiopharmaceutical-strategy/" }, { "url": "https://www.primobt.com/news/primo-biotechnology-wins-2026-taiwan-bio-award-eyeing-radiotheranostics-market-with-primo-x-platform/" }, { "url": "https://www.primobt.com/en/news/primo-biotechnology-wins-2026-taiwan-bio-award-eyeing-radiotheranostics-market-with-primo-x-platform/" }, { "url": "https://www.primobt.com/en/pipeline/" }, { "url": "https://www.gmstw.com.tw/news_detail.php?id=167" }, { "url": "https://www.primobt.com/en/product-service/delivering/" }, { "url": "https://www.tpex.org.tw/storage/eb_data/11307/11301012670.html" }, { "url": "https://petpharmbio.com/userfiles/files/Financial%20Report/115Q2.pdf" }, { "url": "https://www.novartis.com/sites/novartiscom/files/novartis-20-f-2025.pdf" }, { "url": "https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed" }, { "url": "https://telixpharma.com/news-views/telix-adss-commence-trading-on-nasdaq/" }, { "url": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/tlx-20260630_d2.htm" }, { "url": "https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/" }, { "url": "https://investor.lantheus.com/news-releases/news-release-details/lantheus-reports-second-quarter-2026-financial-results" }, { "url": "https://www.sec.gov/Archives/edgar/data/1521036/000119312526412563/d31891d8k.htm" }, { "url": "https://www.tpex.org.tw/storage/eb_data/11307/11301012670.html" }, { "url": "https://petpharmbio.com/userfiles/files/Financial%20Report/115Q2.pdf" }, { "url": "https://www.primobt.com/news/primo-biotechnology-wins-2026-taiwan-bio-award-eyeing-radiotheranostics-market-with-primo-x-platform/" }, { "url": "https://www.gmstw.com.tw/news_detail.php?id=167" }, { "url": "https://www.gmstw.com.tw/upload/b7e79064fed9154ac5fc308ef755c5e8.pdf" }, { "url": "https://www.petpharmbio.com/about-21?lang=tw" }, { "url": "https://www.novartis.com/investors/shareholder-information/frequently-asked-questions" }, { "url": "https://www.petpharmbio.com/about-21?lang=tw" }, { "url": "https://www.primobt.com/en/news/primo-biotechnology-wins-2026-taiwan-bio-award-eyeing-radiotheranostics-market-with-primo-x-platform/" }, { "url": "https://www.primobt.com/en/pipeline/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay-en.html", "title": "Fewer bleeds. Why is Novo’s new drug still waiting outside the US?", "language": "en", "datePublished": "2026-10-10", "dateModified": "2026-10-10", "summary": "A promising antibody for people with hemophilia has run into an obstacle that does not appear on an efficacy curve: a manufacturing facility.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.html", "title": "出血少了，新藥為何還進不了美國？", "language": "zh-Hant", "datePublished": "2026-10-10", "dateModified": "2026-10-10", "summary": "一款能讓血友病患者少出血的抗體，正卡在一個不會出現在療效曲線上的地方：工廠。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "novonordisk.com", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=917287" }, { "title": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/42054679/" }, { "title": "ema.europa.eu", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/frehemgo" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/drugs/things-know-about/10-things-know-about-cders-pharmaceutical-quality-functions" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-09-sanofi-regeneron-long-acting-alliance-en.html", "title": "An injection every six months? Sanofi puts $1 billion on the table", "language": "en", "datePublished": "2026-10-09", "dateModified": "2026-10-09", "summary": "The next contest in eczema treatment may play out on patients' calendars.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-09-sanofi-regeneron-long-acting-alliance.html", "title": "半年打一針？賽諾菲押上10億美元", "language": "zh-Hant", "datePublished": "2026-10-09", "dateModified": "2026-10-09", "summary": "濕疹藥的下一場競爭，可能發生在病人的行事曆上。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "investor.regeneron.com", "url": "https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-expand-global-alliance-multiple-next/" }, { "title": "investor.regeneron.com", "url": "https://investor.regeneron.com/static-files/f6a38fa3-d7ca-4c1b-be1c-8b61b391c50e" }, { "title": "sanofi.com", "url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767" }, { "title": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/27690741/" }, { "title": "ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-08-2026-nobel-chemistry-chiral-amplification-en.html", "title": "The 2026 Nobel Prize in Chemistry: do medicines have left and right hands?", "language": "en", "datePublished": "2026-10-08", "dateModified": "2026-10-08", "summary": "Can a chemical reaction amplify a tiny initial bias? Molecular handedness provides an entry into nonlinear effects and asymmetric autocatalysis.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-08-2026-nobel-chemistry-chiral-amplification.html", "title": "2026諾貝爾化學獎揭曉！藥也分左右手？", "language": "zh-Hant", "datePublished": "2026-10-08", "dateModified": "2026-10-08", "summary": "兩邊幾乎平手，化學反應能不能把其中一邊的小小優勢越放越大？從藥的左右手看懂非線性與自催化。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/reports/adc-industry-2026-en.html", "title": "ADCs Move into First-Line Treatment: Which Differences Are Worth Paying For?", "language": "en", "datePublished": "2026-10-08", "dateModified": "2026-10-07", "summary": "From how antibodies find cancer cells to why drugmakers invest in partnerships: the science, clinical competition and business of ADCs.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 藥時事" } ], "sources": [ { "url": "https://preferences.stifel.com/stifel-iris-rare-disease" }, { "url": "https://www.fda.gov/media/155997/download" }, { "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12079096/" }, { "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/cas.12966" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/26076429/" }, { "url": "https://www.nature.com/articles/s41467-021-23793-7" }, { "url": "https://www.astrazeneca.com/media-centre/press-releases/2026/az-ds-collaboration-with-summit-for-datroway.html" }, { "url": "https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-completes-equity-investment-in-summit-therapeutics.html" }, { "url": "https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/40454632/" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/41125110/" }, { "url": "https://news.bms.com/news/details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx" }, { "url": "https://heidelberg-pharma.com/images/managed/HDP-101-01_IMS_poster.pdf" }, { "url": "https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260925_E.pdf" }, { "url": "https://daiichisankyo.us/press-releases/-/article/ifinatamab-deruxtecan-demonstrated-clinically-meaningful-response-rates-in-patients-with-extensive-stage-small-cell-lung-cancer-in-ideate-lung01-phase-2-trial" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/41160818/" }, { "url": "https://www.astrazeneca.com/content/dam/az/PDF/2026/h1q2/H1-and-Q2-2026-results-clinical-trials-appendix.pdf" }, { "url": "https://clinicaltrials.gov/study/NCT06382142" }, { "url": "https://clinicaltrials.gov/study/NCT05374512" }, { "url": "https://clinicaltrials.gov/study/NCT05382299" }, { "url": "https://clinicaltrials.gov/study/NCT05382286" }, { "url": "https://clinicaltrials.gov/study/NCT04622319" }, { "url": "https://clinicaltrials.gov/study/NCT04784715" }, { "url": "https://clinicaltrials.gov/study/NCT06203210" }, { "url": "https://clinicaltrials.gov/study/NCT05629585" }, { "url": "https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/" }, { "url": "https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/R10.htm" }, { "url": "https://www.merck.com/news/ifinatamab-deruxtecan-biologics-license-application-for-certain-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer-voluntarily-withdrawn/" }, { "url": "https://www.merck.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer/" }, { "url": "https://www.merck.com/news/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn/" }, { "url": "https://www.daiichisankyo.com/files/news/pressrelease/pdf/202605/20260508_E.pdf" }, { "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen" }, { "url": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/R10.htm" }, { "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-immunogen-including-its-flagship-cancer-therapy" }, { "url": "https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen" }, { "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/R14.htm" }, { "url": "https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html" }, { "url": "https://en.dualitybiologics.com/news/615.html" }, { "url": "https://investors.gilead.com/news/news-details/2024/Gilead-and-Tubulis-Enter-Into-Exclusive-Option-and-License-Agreement-to-Develop-ADC-Candidate-for-Select-Solid-Tumor-Target/default.aspx" }, { "url": "https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline" }, { "url": "https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx" }, { "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm" }, { "url": "https://en.dualitybiologics.com/news/614.html" }, { "url": "https://tubulis.com/news/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients-2/" }, { "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-and-hengrui-pharma-enter-agreements/" }, { "url": "https://www.lonza.com/news/2026-06-30-07-00" }, { "url": "https://www.lonza.com/media-advisories/2026-02-19-09-00" }, { "url": "https://wuxixdc.com/wuxi-xdc-celebrates-gmp-release-of-singapore-site-ushering-in-a-new-era-of-global-expansion/" }, { "url": "https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html" }, { "url": "https://www.investor.jnj.com/investor-news/news-details/2024/Johnson--Johnson-Completes-Acquisition-of-Ambrx/default.aspx" }, { "url": "https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm" }, { "url": "https://newsroom.astellas.com/2026-09-18-padcev-in-combination-with-keytruda-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-resectable-mibc" }, { "url": "https://www.astrazeneca.com/investor-relations/faqs.html" }, { "url": "https://www.roche.com/investors/updates/inv-update-2026-03-16" }, { "url": "https://www.lonza.com/investor-relations" }, { "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-november-3" }, { "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-present-morgan-stanley-24th-annual-global-healthcare" }, { "url": "https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2026-on-October-29-2026/default.aspx" }, { "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2026-results-raises-2026-outlook" }, { "url": "https://www.obipharma.com/what-we-do/pipeline-overview/" }, { "url": "https://clinicaltrials.gov/study/NCT06480240" }, { "url": "https://clinicaltrials.gov/study/NCT07124117" }, { "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/obi-pharma-and-tegmine-therapeutics-sign-exclusive-global-license-agr-1126261" }, { "url": "https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed" }, { "url": "https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/" }, { "url": "https://www.formosapharma.com/formosa-pharmaceuticals-announces-presentation-of-tsy-310-at-the-2026-asco-annual-meeting/" }, { "url": "https://www.almacgroup.com/discovery/pipeline" }, { "url": "https://www.eirgenix.com/antibody-drug-conjugate" }, { "url": "https://www.formosalab.com/tw/bioconjugation-adc" }, { "url": "https://www.formosalab.com/tw/adc" }, { "url": "https://www.mycenax.com/news-detail.php?id=122&lang=en" }, { "url": "https://www.mycenax.com/cdmo.php?id=56" }, { "url": "https://www.dcb.org.tw/technologies/67" }, { "url": "https://www.twse.com.tw/pdf/ch/4746_ch.pdf" }, { "url": "https://www.twse.com.tw/pdf/ch/6589_ch.pdf" }, { "url": "https://www.twse.com.tw/pdf/ch/6838_ch.pdf" }, { "url": "https://www.obipharma.com/investor-overview/corporate-overview/" }, { "url": "https://glyconex.com.tw/investors/" }, { "url": "https://www.mycenax.com/shareholders-meeting.php?id=5&lang=tw" }, { "url": "https://drugnews.com.tw/subscribe.html" }, { "url": "https://drugnews.com.tw/services.html" }, { "url": "https://heidelberg-pharma.com/images/managed/HDP-101-01_AACR2024_final.pdf" }, { "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6668989/" }, { "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm" } ] }, { "url": "https://drugnews.com.tw/reports/adc-industry-2026.html", "title": "ADC 走向第一線之後：哪些差異真正值得藥廠買單？", "language": "zh-Hant", "datePublished": "2026-10-08", "dateModified": "2026-10-07", "summary": "從抗體如何找到癌細胞，到藥廠為何出資合作：看懂 ADC 的科學、臨床競爭與生意。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 藥時事" } ], "sources": [ { "url": "https://preferences.stifel.com/stifel-iris-rare-disease" }, { "url": "https://www.fda.gov/media/155997/download" }, { "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12079096/" }, { "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/cas.12966" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/26076429/" }, { "url": "https://www.nature.com/articles/s41467-021-23793-7" }, { "url": "https://www.astrazeneca.com/media-centre/press-releases/2026/az-ds-collaboration-with-summit-for-datroway.html" }, { "url": "https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-completes-equity-investment-in-summit-therapeutics.html" }, { "url": "https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-two-separate-indications-fam-trastuzumab-deruxtecan-nxki-her2-positive-early-stage" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer" }, { "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/40454632/" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/41125110/" }, { "url": "https://news.bms.com/news/details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx" }, { "url": "https://heidelberg-pharma.com/images/managed/HDP-101-01_IMS_poster.pdf" }, { "url": "https://www.daiichisankyo.com/files/news/pressrelease/pdf/202609/20260925_E.pdf" }, { "url": "https://daiichisankyo.us/press-releases/-/article/ifinatamab-deruxtecan-demonstrated-clinically-meaningful-response-rates-in-patients-with-extensive-stage-small-cell-lung-cancer-in-ideate-lung01-phase-2-trial" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/41160818/" }, { "url": "https://www.astrazeneca.com/content/dam/az/PDF/2026/h1q2/H1-and-Q2-2026-results-clinical-trials-appendix.pdf" }, { "url": "https://clinicaltrials.gov/study/NCT06382142" }, { "url": "https://clinicaltrials.gov/study/NCT05374512" }, { "url": "https://clinicaltrials.gov/study/NCT05382299" }, { "url": "https://clinicaltrials.gov/study/NCT05382286" }, { "url": "https://clinicaltrials.gov/study/NCT04622319" }, { "url": "https://clinicaltrials.gov/study/NCT04784715" }, { "url": "https://clinicaltrials.gov/study/NCT06203210" }, { "url": "https://clinicaltrials.gov/study/NCT05629585" }, { "url": "https://www.merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/" }, { "url": "https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/R10.htm" }, { "url": "https://www.merck.com/news/ifinatamab-deruxtecan-biologics-license-application-for-certain-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer-voluntarily-withdrawn/" }, { "url": "https://www.merck.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer/" }, { "url": "https://www.merck.com/news/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn/" }, { "url": "https://www.daiichisankyo.com/files/news/pressrelease/pdf/202605/20260508_E.pdf" }, { "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen" }, { "url": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/R10.htm" }, { "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-immunogen-including-its-flagship-cancer-therapy" }, { "url": "https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen" }, { "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/R14.htm" }, { "url": "https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html" }, { "url": "https://en.dualitybiologics.com/news/615.html" }, { "url": "https://investors.gilead.com/news/news-details/2024/Gilead-and-Tubulis-Enter-Into-Exclusive-Option-and-License-Agreement-to-Develop-ADC-Candidate-for-Select-Solid-Tumor-Target/default.aspx" }, { "url": "https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline" }, { "url": "https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx" }, { "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm" }, { "url": "https://en.dualitybiologics.com/news/614.html" }, { "url": "https://tubulis.com/news/tubulis-announces-strategic-license-agreement-with-bristol-myers-squibb-to-develop-next-generation-adcs-for-the-treatment-of-cancer-patients-2/" }, { "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-and-hengrui-pharma-enter-agreements/" }, { "url": "https://www.lonza.com/news/2026-06-30-07-00" }, { "url": "https://www.lonza.com/media-advisories/2026-02-19-09-00" }, { "url": "https://wuxixdc.com/wuxi-xdc-celebrates-gmp-release-of-singapore-site-ushering-in-a-new-era-of-global-expansion/" }, { "url": "https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html" }, { "url": "https://www.investor.jnj.com/investor-news/news-details/2024/Johnson--Johnson-Completes-Acquisition-of-Ambrx/default.aspx" }, { "url": "https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm" }, { "url": "https://newsroom.astellas.com/2026-09-18-padcev-in-combination-with-keytruda-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-resectable-mibc" }, { "url": "https://www.astrazeneca.com/investor-relations/faqs.html" }, { "url": "https://www.roche.com/investors/updates/inv-update-2026-03-16" }, { "url": "https://www.lonza.com/investor-relations" }, { "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-november-3" }, { "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-present-morgan-stanley-24th-annual-global-healthcare" }, { "url": "https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-to-Report-Results-for-Third-Quarter-2026-on-October-29-2026/default.aspx" }, { "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2026-results-raises-2026-outlook" }, { "url": "https://www.obipharma.com/what-we-do/pipeline-overview/" }, { "url": "https://clinicaltrials.gov/study/NCT06480240" }, { "url": "https://clinicaltrials.gov/study/NCT07124117" }, { "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/obi-pharma-and-tegmine-therapeutics-sign-exclusive-global-license-agr-1126261" }, { "url": "https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed" }, { "url": "https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/" }, { "url": "https://www.formosapharma.com/formosa-pharmaceuticals-announces-presentation-of-tsy-310-at-the-2026-asco-annual-meeting/" }, { "url": "https://www.almacgroup.com/discovery/pipeline" }, { "url": "https://www.eirgenix.com/antibody-drug-conjugate" }, { "url": "https://www.formosalab.com/tw/bioconjugation-adc" }, { "url": "https://www.formosalab.com/tw/adc" }, { "url": "https://www.mycenax.com/news-detail.php?id=122&lang=en" }, { "url": "https://www.mycenax.com/cdmo.php?id=56" }, { "url": "https://www.dcb.org.tw/technologies/67" }, { "url": "https://www.twse.com.tw/pdf/ch/4746_ch.pdf" }, { "url": "https://www.twse.com.tw/pdf/ch/6589_ch.pdf" }, { "url": "https://www.twse.com.tw/pdf/ch/6838_ch.pdf" }, { "url": "https://www.obipharma.com/investor-overview/corporate-overview/" }, { "url": "https://glyconex.com.tw/investors/" }, { "url": "https://www.mycenax.com/shareholders-meeting.php?id=5&lang=tw" }, { "url": "https://drugnews.com.tw/subscribe.html" }, { "url": "https://drugnews.com.tw/services.html" }, { "url": "https://heidelberg-pharma.com/images/managed/HDP-101-01_AACR2024_final.pdf" }, { "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6668989/" }, { "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human-en.html", "title": "One injection—and the body makes its own cancer-fighting cells?", "language": "en", "datePublished": "2026-10-07", "dateModified": "2026-10-07", "summary": "For someone preparing for conventional autologous CAR-T treatment, a doctor saying “we can try this therapy” does not mean the medicine will be ready tomorrow.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human.html", "title": "打一針，身體自己造抗癌細胞？", "language": "zh-Hant", "datePublished": "2026-10-07", "dateModified": "2026-10-07", "summary": "對準備接受傳統自體CAR-T治療的人，醫師說「可以試這個療法」，並不代表明天就有藥。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-06-nobel-optogenetics-light-gated-channels-en.html", "title": "A light switch for cells wins the Nobel Prize", "language": "en", "datePublished": "2026-10-06", "dateModified": "2026-10-06", "summary": "The2026 Nobel Medicine Prize recognizes light-gated ion channels and optogenetics. From algae to causal neural experiments and visual-restoration research, scientific tools and product delivery demand different evidence, capital and responsibilities.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-06-nobel-optogenetics-light-gated-channels.html", "title": "諾貝爾獎揭曉！科學家給細胞裝上光開關", "language": "zh-Hant", "datePublished": "2026-10-06", "dateModified": "2026-10-06", "summary": "2026諾貝爾醫學獎表彰光門控離子通道與光遺傳學。從綠藻到神經元因果實驗，再到視覺修復，研究工具的價值與產品交付有不同的證據、資金與責任。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "諾貝爾醫學獎委員會｜2026年官方公告、Scientific Background及Popular Background（2026-10-05）", "url": "https://www.nobelprizemedicine.org/the-nobel-prize-in-physiology-or-medicine-2026/" }, { "title": "Nagel等｜光門控ChR2陽離子通道，PNAS（2003）", "url": "https://www.pnas.org/doi/10.1073/pnas.1936192100" }, { "title": "Boyden等｜毫秒尺度神經放電控制，Nature Neuroscience（2005）", "url": "https://pubmed.ncbi.nlm.nih.gov/16116447/" }, { "title": "Adamantidis等｜小鼠hypocretin神經元與睡眠／清醒轉換，Nature（2007）", "url": "https://www.nature.com/articles/nature06310" }, { "title": "Sahel等｜光遺傳介入後部分視覺功能恢復的病例，Nature Medicine（2021）", "url": "https://www.nature.com/articles/s41591-021-01351-4" }, { "title": "GenSight｜2025年年報（2026年發布；GS030／PIONEER相關段落）", "url": "https://www.gensight-biologics.com/wp-content/uploads/2026/04/GENSIGHT_URD_2025_ANGLAIS_completv8.pdf" }, { "title": "GenSight｜2026年上半年財報及業務更新（2026-09-29）", "url": "https://www.gensight-biologics.com/2026/09/29/gensight-biologics-reports-interim-financial-results-for-the-first-half-of-2026-and-provides-business-updates/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation-en.html", "title": "Sales of a Star Heart Drug Have Halved. Can Novartis’s Next Medicines Take Over in Time?", "language": "en", "datePublished": "2026-10-06", "dateModified": "2026-10-06", "summary": "Novartis’s heart medicine Entresto recorded a 50% year-on-year sales decline in US dollars in the second quarter of 2026. In September, pelacarsen and del-desiran, previously listed for expected submissions over the next two years, both reported missed Phase 3 primary endpoints. Revenue erosion is already in the financial statements, while the filing assumptions for those two candidates need reassessment.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.html", "title": "明星心臟藥銷售減半，諾華的新藥接棒來得及嗎？", "language": "zh-Hant", "datePublished": "2026-10-06", "dateModified": "2026-10-06", "summary": "諾華（Novartis）的心臟藥Entresto在2026年第二季美元銷售年減50%；進入9月，原列在未來兩年申請規劃中的pelacarsen與del-desiran，又先後公布第三期主要終點未達。收入侵蝕已反映在財報，兩項候選藥的申請前提卻需要重估。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "novartis.com", "url": "https://www.novartis.com/sites/novartis_com/files/q2-2026-media-release-en.pdf" }, { "title": "novartis.com", "url": "https://www.novartis.com/sites/novartis_com/files/q2-2026-interim-financial-report-en.pdf" }, { "title": "novartis.com", "url": "https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd" }, { "title": "novartis.com", "url": "https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy" }, { "title": "novartis.com", "url": "https://www.novartis.com/news/media-releases/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1" }, { "title": "novartis.com", "url": "https://www.novartis.com/news/media-releases/novartis-remibrutinib-high-efficacy-oral-btk-inhibitor-significantly-reduces-relapse-rates-and-shows-favorable-safety-profile-phase-iii-rms-trials" }, { "title": "novartis.com", "url": "https://www.novartis.com/sites/novartis_com/files/q2-2026-investor-presentation.pdf" }, { "title": "novartis.com", "url": "https://www.novartis.com/events/novartis-financial-results-q3-2026" }, { "title": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/41707138/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026-en.html", "title": "From a Daily Tablet to Factory Orders: Who Can Profit from Oral Cyclic Peptides?", "language": "en", "datePublished": "2026-10-05", "dateModified": "2026-10-05", "summary": "On September 17, 2026, Novo Nordisk and Orbis Medicines announced a collaboration to develop oral macrocycles for cardiometabolic diseases. Upfront payments and potential development and commercial milestones total up to US$1.4 billion, with additional sales royalties; Novo will also make a strategic investment in Orbis. A large drugmaker is buying opportunities to discover new medicines. That headline ceiling is not yet an order held by a raw-material factory, and the announcement does not disclose commercial purchase volumes or suppliers.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.html", "title": "從每天一顆藥到工廠訂單：口服環肽的錢，誰賺得到？", "language": "zh-Hant", "datePublished": "2026-10-05", "dateModified": "2026-10-05", "summary": "2026年9月17日，諾和諾德（Novo Nordisk）與Orbis Medicines宣布合作，開發心血管代謝疾病的口服大環肽。前期款與可能達成的開發、商業里程碑合計最高14億美元，另計銷售權利金，Novo亦將策略投資Orbis。大藥廠正在買新的藥物發現機會；這筆上限金額，還不是原料工廠手上的訂單，公告也未披露商業採購量或供應商。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "orbismedicines.com", "url": "https://www.orbismedicines.com/news/orbis-medicines-enters-multi-target-drug-discovery-partnership-with-novo-nordisk-worth-up-to-usd-14-billion" }, { "title": "accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf" }, { "title": "accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220848Orig1s000lbl.pdf" }, { "title": "doi.org", "url": "https://doi.org/10.1021/jacs.4c15966" }, { "title": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/42096573/" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/media/71518/download" }, { "title": "scinopharm.com", "url": "https://www.scinopharm.com/tw/products-detail/54/" }, { "title": "merck.com", "url": "https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/" }, { "title": "maillist.au.dk", "url": "https://maillist.au.dk/hyperkitty/list/hauser.chem%40maillist.au.dk/message/RWSJBSY53CCDATJCHCKPUXW4QBJVKMR3/attachment/6/total-synthesis-of-enlicitide-decanoate.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026-en.html", "title": "Migraine Around Your Period? How Much Can a Seven-Day Prevention Strategy Help?", "language": "en", "datePublished": "2026-10-04", "dateModified": "2026-10-04", "summary": "The days around menstruation can already be uncomfortable. Add migraine, sensitivity to light or nausea, and work, school pickups and carefully planned activities can be disrupted. For people whose attacks repeatedly cluster in this window, the question is straightforward: can the burden be reduced before the headache arrives?", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026.html", "title": "偏頭痛總挑月經前後來？7天預防研究，能少痛多少？", "language": "zh-Hant", "datePublished": "2026-10-04", "dateModified": "2026-10-04", "summary": "月經前後已經不好受，再碰上偏頭痛、怕光或噁心，工作、接送與原本排好的行程都可能被打亂。對發作時間反覆落在這個窗口的人，問題很直接：能不能在頭痛來之前，先降低那幾天的負擔？", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "news.abbvie.com", "url": "https://news.abbvie.com/2026-09-10-AbbVie-Extends-Migraine-Leadership-with-Positive-Phase-3-Atogepant-Results-in-Menstrual-Migraine" }, { "title": "rxabbvie.com", "url": "https://www.rxabbvie.com/pdf/qulipta_pi.pdf" }, { "title": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT06806293" }, { "title": "jrct.mhlw.go.jp", "url": "https://jrct.mhlw.go.jp/latest-detail/jRCT2051240268" }, { "title": "rctportal.mhlw.go.jp", "url": "https://rctportal.mhlw.go.jp/s/detail/um?trial_id=jRCT2051240268" }, { "title": "mentalhealth.charite.de", "url": "https://mentalhealth.charite.de/en/metas/en_meldung/artikel/detail/why_migraine_frequently_occurs_during_menstruation/" }, { "title": "pubmed.ncbi.nlm.nih.gov", "url": "https://pubmed.ncbi.nlm.nih.gov/15277618/" }, { "title": "abbvieclinicaltrials.com", "url": "https://www.abbvieclinicaltrials.com/study/M24-859" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026-en.html", "title": "One Less Search for a Vein, a Little More Freedom in Life with Hemophilia", "language": "en", "datePublished": "2026-10-03", "dateModified": "2026-10-03", "summary": "The 2026 Lasker–DeBakey Clinical Medical Research Award recognizes an invention that changed the treatment of hemophilia A: Hemlibra, a bispecific antibody that can be injected under the skin.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Lasker award page", "url": "https://laskerfoundation.org/winners/bispecific-antibody-for-treating-hemophilia-a/" }, { "title": "Chugai announcement", "url": "https://www.chugai-pharm.co.jp/english/news/detail/20260909210000_1283.html" }, { "title": "PubMed abstract", "url": "https://pubmed.ncbi.nlm.nih.gov/23023498/" }, { "title": "PLOS ONE study", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057479" }, { "title": "HAVEN 1 abstract", "url": "https://pubmed.ncbi.nlm.nih.gov/28691557/" }, { "title": "HAVEN 3 abstract", "url": "https://pubmed.ncbi.nlm.nih.gov/30157389/" }, { "title": "Prescribing information", "url": "https://www.gene.com/download/pdf/hemlibra_prescribing.pdf" }, { "title": "EMA product information", "url": "https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf" }, { "title": "TFDA review", "url": "https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=28914&mid=189&t=s" }, { "title": "WFH guidelines", "url": "https://www1.wfh.org/publications/files/pdf-1863.pdf" }, { "title": "March notice", "url": "https://www.nhi.gov.tw/ch/cp-19659-df117-3258-1.html" }, { "title": "NHI payment appendix", "url": "https://www.nhi.gov.tw/ch/dl-96560-c47a8b1afd644464bffcf4b8aedbb89f-1.pdf" }, { "title": "Reimbursement comparison", "url": "https://www.nhi.gov.tw/ch/dl-96562-1f55f63dcab2469ca2fd463a58a3b794-1.pdf" }, { "title": "August notice", "url": "https://www.nhi.gov.tw/ch/cp-20265-d8d60-3258-1.html" }, { "title": "Provisions and follow-up appendix", "url": "https://www.nhi.gov.tw/ch/dl-100540-8a15198f8cae4fa9935da2227c8950a9-1.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026.html", "title": "少找一次血管，血友病的日常就多一點自由", "language": "zh-Hant", "datePublished": "2026-10-03", "dateModified": "2026-10-03", "summary": "2026年Lasker–DeBakey臨床醫學研究獎，表彰了一項改變A型血友病治療的發明：Hemlibra，一支可以皮下注射的雙特異性抗體。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Lasker得獎專頁", "url": "https://laskerfoundation.org/winners/bispecific-antibody-for-treating-hemophilia-a/" }, { "title": "中外製藥公告", "url": "https://www.chugai-pharm.co.jp/english/news/detail/20260909210000_1283.html" }, { "title": "PubMed研究摘要", "url": "https://pubmed.ncbi.nlm.nih.gov/23023498/" }, { "title": "PLOS ONE工程研究", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057479" }, { "title": "HAVEN 1研究摘要", "url": "https://pubmed.ncbi.nlm.nih.gov/28691557/" }, { "title": "HAVEN 3研究摘要", "url": "https://pubmed.ncbi.nlm.nih.gov/30157389/" }, { "title": "原廠處方資訊", "url": "https://www.gene.com/download/pdf/hemlibra_prescribing.pdf" }, { "title": "EMA產品資訊", "url": "https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf" }, { "title": "TFDA審查報告", "url": "https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=28914&mid=189&t=s" }, { "title": "WFH照護指引", "url": "https://www1.wfh.org/publications/files/pdf-1863.pdf" }, { "title": "三月給付公告", "url": "https://www.nhi.gov.tw/ch/cp-19659-df117-3258-1.html" }, { "title": "健保支付價附件", "url": "https://www.nhi.gov.tw/ch/dl-96560-c47a8b1afd644464bffcf4b8aedbb89f-1.pdf" }, { "title": "給付條文對照", "url": "https://www.nhi.gov.tw/ch/dl-96562-1f55f63dcab2469ca2fd463a58a3b794-1.pdf" }, { "title": "八月給付公告", "url": "https://www.nhi.gov.tw/ch/cp-20265-d8d60-3258-1.html" }, { "title": "條文與追蹤附件", "url": "https://www.nhi.gov.tw/ch/dl-100540-8a15198f8cae4fa9935da2227c8950a9-1.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026-en.html", "title": "PharmaEssentia Acquires FormuRx. Could Making Drugs Inside Cells Be Next?", "language": "en", "datePublished": "2026-10-03", "dateModified": "2026-10-03", "summary": "PharmaEssentia (6446) has acquired FormuRx for approximately NT$168 million. According to company-provided news published by Global Bio & Investment, FormuRx develops delivery technologies for getting RNA into cells. The acquisition brings lipid nanoparticle (LNP) formulations, microfluidic processes, analytical capabilities, equipment and a team.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html", "title": "藥華藥買下予宇，下一步讓細胞造藥？", "language": "zh-Hant", "datePublished": "2026-10-03", "dateModified": "2026-10-03", "summary": "藥華藥（6446）買下予宇生技，交易金額約新台幣1.68億元。依環球生技刊載的公司消息，予宇做的是把RNA送進細胞的遞送研發，帶進來的包括脂質奈米顆粒（LNP）配方、微流體製程、分析、設備與團隊。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety-en.html", "title": "Weight-Loss Injections: The Goal Is to Lose Weight, Not Hair", "language": "en", "datePublished": "2026-10-02", "dateModified": "2026-10-02", "summary": "Two meta-analyses quantify hair-loss and gallbladder/biliary risk around GLP-1-related obesity treatment. Relative risk, absolute risk and different analytical pools must be kept separate, while dose, duration and weight-loss indication do not by themselves prove a speed-of-weight-loss mechanism. The article then examines how tolerability and persistence may shape product differentiation.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety.html", "title": "瘦瘦針：想減的是體重，不是頭髮", "language": "zh-Hant", "datePublished": "2026-10-02", "dateModified": "2026-10-02", "summary": "兩份統合分析把GLP-1相關減重藥的掉髮與膽囊／膽道風險量化：RR要和絕對風險分開看，減重用途、高劑量與較長療程的關聯也不能直接等同於減重速度因果。本文進一步討論耐受性、依從性與長期使用如何成為產品差異化。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html", "title": "Adding an ADC to Lung Cancer Immunotherapy: More Tumor Responses, but Why Did Phase 3 Fall Short?", "language": "en", "datePublished": "2026-10-01", "dateModified": "2026-10-01", "summary": "Adding an ADC increased response rates but missed the prespecified PFS threshold and increased toxicity in EVOKE-03. What evidence would justify further development, and what must regional hypotheses and distinct TROP2 products demonstrate?", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html", "title": "肺癌免疫治療再加ADC：腫瘤更常縮小，為何三期仍未過關？", "language": "zh-Hant", "datePublished": "2026-10-01", "dateModified": "2026-10-01", "summary": "肺癌第一線加上ADC，腫瘤反應率提高卻未通過預設PFS門檻，毒性負擔也上升。EVOKE-03如何改變後續開發判斷，東亞訊號與浩鼎的TROP2產品又各需要什麼人體證據？", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html", "title": "Novo Nordisk Already Has Weight-Loss Injections. Why Pursue Another Path?", "language": "en", "datePublished": "2026-09-30", "dateModified": "2026-09-30", "summary": "Why pursue non-incretin programs alongside an established GLP-1 franchise? K-554’s neural-circuit hypothesis, human evidence and usable dose range frame the relationship between efficacy, tolerability, persistence and product value.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Jacob Petersen's public announcement", "url": "https://www.linkedin.com/posts/jacob-petersen-820529_im-excited-to-share-that-novo-nordisk-has-activity-7506720635704963073-rE3z/" }, { "title": "Kallyope 2026 strategic priorities, January 7, 2026", "url": "https://kallyope.com/kallyope-announces-2026-strategic-priorities-for-migraine-and-metabolism-portfolio-based-on-novel-neural-circuits-platform/" }, { "title": "Novo Nordisk–Kallyope research collaboration, June 19, 2018", "url": "https://www.globenewswire.com/news-release/2018/06/19/1600406/0/en/kallyope-and-novo-nordisk-announce-collaboration-to-discover-novel-therapeutics-for-obesity-and-diabetes.html" }, { "title": "Kallyope licensing announcement, Business Wire republication, September 10, 2024", "url": "https://markets.financialcontent.com/wral/article/bizwire-2024-9-10-kallyope-announces-license-agreement-with-novo-nordisk" }, { "title": "ClinicalTrials.gov K-554 search (no readable results obtained in this check)", "url": "https://clinicaltrials.gov/search?term=K-554&viewType=Card" }, { "title": "Wegovy U.S. prescribing information, revised June 2026", "url": "https://www.novo-pi.com/wegovy.pdf" }, { "title": "Nature: Dissociable hindbrain GLP1R circuits for satiety and aversion, July 10, 2024", "url": "https://www.nature.com/articles/s41586-024-07685-6" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html", "title": "已有瘦瘦針，諾和諾德為何還要布局另一條減重路？", "language": "zh-Hant", "datePublished": "2026-09-30", "dateModified": "2026-09-30", "summary": "諾和諾德已有GLP-1減重產品，為何仍布局非腸泌素計畫？從K-554的神經迴路假說、人體證據進度與可用劑量，分析效果、耐受性及持續使用如何影響產品價值。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Jacob Petersen原公開貼文", "url": "https://www.linkedin.com/posts/jacob-petersen-820529_im-excited-to-share-that-novo-nordisk-has-activity-7506720635704963073-rE3z/" }, { "title": "Kallyope 2026策略更新（2026-01-07）", "url": "https://kallyope.com/kallyope-announces-2026-strategic-priorities-for-migraine-and-metabolism-portfolio-based-on-novel-neural-circuits-platform/" }, { "title": "Novo／Kallyope研究合作公告（2018-06-19）", "url": "https://www.globenewswire.com/news-release/2018/06/19/1600406/0/en/kallyope-and-novo-nordisk-announce-collaboration-to-discover-novel-therapeutics-for-obesity-and-diabetes.html" }, { "title": "Kallyope授權公告，Business Wire轉載（2024-09-10）", "url": "https://markets.financialcontent.com/wral/article/bizwire-2024-9-10-kallyope-announces-license-agreement-with-novo-nordisk" }, { "title": "ClinicalTrials.gov：K-554查詢（本次未取得可讀結果）", "url": "https://clinicaltrials.gov/search?term=K-554&viewType=Card" }, { "title": "Wegovy美國處方資訊（Revised 06/2026）", "url": "https://www.novo-pi.com/wegovy.pdf" }, { "title": "Nature：Dissociable hindbrain GLP1R circuits for satiety and aversion（2024-07-10）", "url": "https://www.nature.com/articles/s41586-024-07685-6" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html", "title": "Drug Approval in Hand—But Is the Cash in the Bank? How Formosa and PharmaEngine Turn Licensing Payments Into Cash", "language": "en", "datePublished": "2026-09-29", "dateModified": "2026-09-29", "summary": "Historical Genmab milestones, Formosa's equity settlement and gross-profit-based collaboration, and PharmaEngine's first-half 2026 accounts show how contractual achievements become—or differ from—collectable proceeds.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Eyenovia 2024 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1682639/000141057825000743/eyen-20241231x10k.htm" }, { "title": "Hyperion DeFi (formerly Eyenovia) Q2 2025 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1682639/000141057825001740/hypd-20250630x10q.htm" }, { "title": "Harrow Form 8-K, June 9, 2025", "url": "https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/form8-k.htm" }, { "title": "Harrow–Formosa joint announcement", "url": "https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/ex99.htm" }, { "title": "PharmaEngine US$50m milestone announcement, February 5, 2025", "url": "https://www.pharmaengine.com/en/investors/investors_5/88" }, { "title": "PharmaEngine ONIVYDE product and milestone history", "url": "https://www.pharmaengine.com/en/product/index/8" }, { "title": "PharmaEngine Q2 2026 financial report, page 20", "url": "https://www.pharmaengine.com/en/uploads/en/investors_3/20260817374.pdf" }, { "title": "Genmab DARZALEX sales milestone, January 6, 2017", "url": "https://www.globenewswire.com/news-release/2017/01/06/904135/0/en/Genmab-Achieves-USD-25-Million-Sales-Milestone-in-DARZALEX-daratumumab-Collaboration-with-Janssen.html" }, { "title": "Genmab first commercial sale in Japan, November 14, 2017", "url": "https://www.globenewswire.com/news-release/2017/11/14/1186131/0/en/Genmab-Achieves-USD-25-Million-Milestone-for-First-Commercial-Sale-of-DARZALEX-daratumumab-in-Japan-and-Updates-Financial-Guidance.html" }, { "title": "Genmab–Janssen agreement dated August 30, 2012, filed with the SEC", "url": "https://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zex-10_1.htm" }, { "title": "Formosa announcement of Harrow agreement, June 9, 2025", "url": "https://www.formosapharma.com/harrow-acquires-u-s-commercial-rights-to-byqlovi-clobetasol-propionate-ophthalmic-nanosuspension-0-05-from-formosa-pharmaceuticals/" }, { "title": "Formosa Q1 2026 financial report, page 34", "url": "https://www.formosapharma.com/wp-content/uploads/2026/06/%E5%8F%B0%E6%96%B0%E8%97%A5.2026%E5%90%88%E4%BD%B5%E7%AC%AC%E4%B8%80%E5%AD%A3.FS_.AllReport.ENG_0529.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html", "title": "藥證到手，錢就到帳？從台新藥、智擎看懂授權金怎麼變成現金", "language": "zh-Hant", "datePublished": "2026-09-29", "dateModified": "2026-09-29", "summary": "藥證、付款事件與實際收款之間，有哪些條件？以Genmab歷史里程碑、台新藥的股票結算與毛利合作，以及智擎2026上半年財報，解析新藥授權生意如何從進展走向可運用資源。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Eyenovia 2024 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1682639/000141057825000743/eyen-20241231x10k.htm" }, { "title": "Hyperion DeFi／原Eyenovia 2025Q2 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1682639/000141057825001740/hypd-20250630x10q.htm" }, { "title": "Harrow Form 8-K（2025-06-09）", "url": "https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/form8-k.htm" }, { "title": "Harrow／台新藥共同公告", "url": "https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/ex99.htm" }, { "title": "智擎：將收到US$50m公告（2025-02-05）", "url": "https://www.pharmaengine.com/en/investors/investors_5/88" }, { "title": "智擎ONIVYDE產品與里程碑頁", "url": "https://www.pharmaengine.com/en/product/index/8" }, { "title": "智擎2026年第二季財報，第20頁", "url": "https://www.pharmaengine.com/en/uploads/en/investors_3/20260817374.pdf" }, { "title": "Genmab：DARZALEX銷售里程碑（2017-01-06）", "url": "https://www.globenewswire.com/news-release/2017/01/06/904135/0/en/Genmab-Achieves-USD-25-Million-Sales-Milestone-in-DARZALEX-daratumumab-Collaboration-with-Janssen.html" }, { "title": "Genmab：日本首次商業銷售里程碑（2017-11-14）", "url": "https://www.globenewswire.com/news-release/2017/11/14/1186131/0/en/Genmab-Achieves-USD-25-Million-Milestone-for-First-Commercial-Sale-of-DARZALEX-daratumumab-in-Japan-and-Updates-Financial-Guidance.html" }, { "title": "Genmab／Janssen授權合約（2012-08-30），SEC公開附件", "url": "https://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zex-10_1.htm" }, { "title": "台新藥官網：Harrow接手公告（2025-06-09）", "url": "https://www.formosapharma.com/harrow-acquires-u-s-commercial-rights-to-byqlovi-clobetasol-propionate-ophthalmic-nanosuspension-0-05-from-formosa-pharmaceuticals/" }, { "title": "台新藥2026Q1財報英文版，第34頁", "url": "https://www.formosapharma.com/wp-content/uploads/2026/06/%E5%8F%B0%E6%96%B0%E8%97%A5.2026%E5%90%88%E4%BD%B5%E7%AC%AC%E4%B8%80%E5%AD%A3.FS_.AllReport.ENG_0529.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation-en.html", "title": "US$9.2 Billion in Annual Sales—Why Does J&J Still Want to Separate Orthopaedics?", "language": "en", "datePublished": "2026-09-28", "dateModified": "2026-09-28", "summary": "Why might an orthopaedics business with US$9.2 billion in annual sales lose priority for J&J’s next investment? Growth differences, the value flows in a spin-off versus a sale, and the costs of implants and surgical support explain the economic questions behind the proposed DePuy Synthes separation.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "jnj.com", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-intent-to-separate-its-orthopaedics-business" }, { "title": "sec.gov", "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm" }, { "title": "news.bloomberglaw.com", "url": "https://news.bloomberglaw.com/pharma-and-life-sciences/apollo-global-is-said-in-talks-to-acquire-j-js-orthopedics-unit" }, { "title": "jnj.com", "url": "https://www.jnj.com/media-center/press-releases" }, { "title": "ir.apollo.com", "url": "https://ir.apollo.com/news-events/press-releases" }, { "title": "tw.unitedorthopedic.com", "url": "https://tw.unitedorthopedic.com/about-us" }, { "title": "tw.unitedorthopedic.com", "url": "https://tw.unitedorthopedic.com/investor/shareholder5/" }, { "title": "tw.unitedorthopedic.com", "url": "https://tw.unitedorthopedic.com/total-knee-replacement/" }, { "title": "tw.unitedorthopedic.com", "url": "https://tw.unitedorthopedic.com/innovation/u2-knee-aio" }, { "title": "investor.gov", "url": "https://www.investor.gov/introduction-investing/investing-basics/glossary/spin-offs" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.html", "title": "年營收 92 億美元，強生為什麼還想把骨科拆出去？", "language": "zh-Hant", "datePublished": "2026-09-28", "dateModified": "2026-09-28", "summary": "一年銷售92億美元的骨科業務，為何仍可能排不到強生下一筆資金？從成長差異、分拆與出售的價值流向，到人工關節與手術支援的經營成本，拆解DePuy Synthes分離案真正要算的帳。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care-en.html", "title": "New Hepatitis B Drug Approved in Japan: About One in Five Treated Trial Patients Achieved a “Functional Cure”", "language": "en", "datePublished": "2026-09-27", "dateModified": "2026-09-27", "summary": "On August 24, 2026, GSK announced that Hibsago (bepirovirsen) had been approved in Japan for eligible adults with chronic hepatitis B. The Phase III results supporting the approval had already been published in May; this development moves a finite course of treatment from trial evidence into a treatment option for a defined population.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care.html", "title": "B 肝新藥在日本獲准，新藥組約兩成受試者達「功能性治癒」", "language": "zh-Hant", "datePublished": "2026-09-27", "dateModified": "2026-09-27", "summary": "2026 年 8 月 24 日，GSK 宣布 Hibsago（bepirovirsen）在日本獲准，用於符合條件的成人慢性 B 肝患者。支持核准的第三期結果已於 5 月發表；這次進展，是有限療程從試驗證據走向特定人群的治療選擇。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care-en.html", "title": "A new US therapy for muscle-wasting disease: bringing four-weekly infusions into everyday care", "language": "en", "datePublished": "2026-09-26", "dateModified": "2026-09-26", "summary": "US approval of ISEMBYLD adds a muscle-directed option for people with SMA receiving SMN2-targeting therapy. This analysis connects functional trial gains and safety follow-up with payment, four-weekly infusions and continued care, while distinguishing AnnJi's adjacent Taiwanese neuromuscular drug-development program from SMA or a proven commercial partnership.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care.html", "title": "肌肉萎縮新藥在美獲准，每四週輸注如何走進生活？", "language": "zh-Hant", "datePublished": "2026-09-26", "dateModified": "2026-09-26", "summary": "ISEMBYLD在美獲准，為接受SMN2治療的脊髓性肌肉萎縮症患者增加肌肉端療法。從一年功能增益、適用人群與安全追蹤，分析支付、每四週輸注及持續治療的商業考驗，並以安基AJ201說明台灣相鄰神經肌肉新藥開發能力與界線。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.html", "title": "Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D", "language": "en", "datePublished": "2026-09-25", "dateModified": "2026-09-25", "summary": "Novo Nordisk's collaboration with Anthropic tests scientific reasoning and R&D software engineering alongside capabilities provided by Valo, OpenAI and AWS. This analysis examines workflows, computational acceleration and collaboration economics, while distinguishing Taiwanese platform capabilities from proven partnerships and the experimental and clinical gates that remain.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "novonordisk.com", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916768" }, { "title": "novonordisk.com", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916532" }, { "title": "novonordisk.com", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916594" }, { "title": "novonordisk.com", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085" }, { "title": "valohealth.com", "url": "https://www.valohealth.com/press/valo-health-and-novo-nordisk-to-collaborate-to-discover-and-develop-novel-treatments-for-cardiometabolic-diseases-using-human-data-and-artificial-intelligence" }, { "title": "anthropic.com", "url": "https://www.anthropic.com/research/claude-uplifts-biomolecular-modeling?s=04" }, { "title": "itri.org.tw", "url": "https://www.itri.org.tw/english/ListStyle.aspx?DisplayStyle=01_content&MGID=1344554772173157534&MmmID=1037333532373240766&SiteID=1" }, { "title": "repurgenesis.com", "url": "https://repurgenesis.com/tw" }, { "title": "topmunnity.com", "url": "https://www.topmunnity.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free.html", "title": "諾和諾德攜手Anthropic：讓Claude推理、寫程式，投入新藥研發測試", "language": "zh-Hant", "datePublished": "2026-09-25", "dateModified": "2026-09-25", "summary": "諾和諾德與Anthropic合作測試科學推理及研發軟體工程，與Valo、OpenAI、AWS分別提供的能力形成對照。從研發流程、運算加速和合作款項拆解AI製藥的商業價值，並區分台灣平台能力、合作證據與仍須通過的實驗及臨床關卡。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html", "title": "Why Are Lilly and Novartis Betting on How Medicines Are Delivered?", "language": "en", "datePublished": "2026-09-24", "dateModified": "2026-09-24", "summary": "Lilly's in vivo CAR-T acquisition and Novartis' subcutaneous formulation options address different delivery problems. Human evidence, drug exposure and payment terms clarify how each platform could create product value.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html", "title": "禮來與諾華的大交易，為什麼都看上「怎麼給藥」？", "language": "zh-Hant", "datePublished": "2026-09-24", "dateModified": "2026-09-24", "summary": "禮來押注體內CAR-T製程，諾華取得皮下劑型選擇權。從人體研究、藥物暴露到付款條件，解析兩種遞送平台如何形成產品價值。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception-en.html", "title": "Can a Vaccine Intercept Cancer Before It Develops? Early Research in People With Lynch Syndrome", "language": "en", "datePublished": "2026-09-23", "dateModified": "2026-09-23", "summary": "NOUS-209 is an investigational cancer-interception vaccine for Lynch syndrome carriers, using a GAd prime and MVA boost to deliver 209 shared frameshift peptides. Early data show safety and immunogenicity signals, but 37/37 immune response is not a cancer-prevention rate, and the 43-person colonoscopy observation does not prove clinical prevention. Larger randomized controlled studies with longer follow-up are still needed.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception.html", "title": "癌症還沒出現，疫苗能先攔截嗎？遺傳高風險族群的早期研究", "language": "zh-Hant", "datePublished": "2026-09-23", "dateModified": "2026-09-23", "summary": "NOUS-209 是針對 Lynch syndrome 高風險族群開發的癌症攔截疫苗，利用 GAd 初針與 MVA 加強針遞送 209 個共享 frameshift peptide。早期研究顯示安全性與免疫原性訊號，但 37/37 免疫反應不能解讀為防癌率，43 人腸鏡觀察也不能證明臨床防癌效力。後續仍需更大、隨機、有對照且追蹤更久的研究。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence-en.html", "title": "After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt?", "language": "en", "datePublished": "2026-09-22", "dateModified": "2026-09-22", "summary": "Pelacarsen’s Phase III Lp(a)HORIZON trial enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a). The September 4 initial announcements showed Lp(a) lowering but a missed primary cardiovascular endpoint. This should not be read as an effect precisely equal to zero, nor as a failure of the entire Lp(a) field. The September 4 announcements did not provide full effect estimates, event components, prespecified-population results or complete safety details.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.html", "title": "諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？", "language": "zh-Hant", "datePublished": "2026-09-22", "dateModified": "2026-09-22", "summary": "Pelacarsen 的 Lp(a)HORIZON 三期試驗納入 8,323 名既有心血管疾病且 Lp(a) 升高病人，9 月 4 日初步公告顯示 Lp(a) 下降，但主要心血管終點未達標。這不是效果精確為零，也不是 Lp(a) 題材全盤失敗；9 月 4 日公告未列完整效果量、事件組成、預先指定族群與完整安全性資料。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda-en.html", "title": "PharmaEssentia After a New Indication Approval: A US$46 Million Plant Plan for Long-Term Supply", "language": "en", "datePublished": "2026-09-21", "dateModified": "2026-09-21", "summary": "PharmaEssentia’s story has entered the post-approval phase. The key questions are now physician adoption, payer access, long-term treatment persistence, supply capacity and fixed-cost execution. The Puerto Rico plan shows preparation for U.S. and global demand, but it remains a planned investment rather than an operating supply site. Clinical progress, competition and manufacturing commitments should be read on separate timelines.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda.html", "title": "藥華藥新適應症獲准，4,600萬美元設廠計畫布局長期供應", "language": "zh-Hant", "datePublished": "2026-09-21", "dateModified": "2026-09-21", "summary": "藥華藥的故事已進入核准後階段：真正的考題變成醫師採用、支付准入、長期治療、供應與固定成本。波多黎各未來工廠計畫顯示公司正在為美國與全球需求布局，但這仍是計畫投資，不是已營運產能。臨床進展、競爭變化與製造投資要分開看，才能理解 6446 下一段價值。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.html", "title": "大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升", "language": "zh-Hant", "datePublished": "2026-09-18", "dateModified": "2026-09-18", "summary": "大型併購共同溢價降溫不代表買方沒錢；當臨床證據、上市時點、權利結構與團隊承接能力都能驗證，少數資產的個別價值反而可能上升。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.html", "title": "26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？", "language": "zh-Hant", "datePublished": "2026-09-17", "dateModified": "2026-09-17", "summary": "白宮所稱 26 家與 89% 描述政策廣度，不等於各家公司條款、各州執行與逐藥價格已同步定案；BeOne 與 Teva 正好呈現成熟度差異。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.html", "title": "Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？", "language": "zh-Hant", "datePublished": "2026-09-14", "dateModified": "2026-09-14", "summary": "三種不同退出不能被壓成一次 class verdict；CD47 的剩餘價值要分開看組合、分層、減毒設計與人體證據。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.html", "title": "1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？", "language": "zh-Hant", "datePublished": "2026-09-13", "dateModified": "2026-09-13", "summary": "CARDIO-TTRansform 整體主要終點未達標後，eplontersen 的價值必須回到背景 stabilizer、時間分層與真正可驗證的加成效果。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-12-autoimmune-car-t-safety-market-reset.html", "title": "自免 CAR-T 第一次被迫重算：療效之外，尾端安全風險如何縮小市場？", "language": "zh-Hant", "datePublished": "2026-09-12", "dateModified": "2026-09-12", "summary": "自免 CAR-T 的早期療效不能與尾端免疫安全風險分開計算；市場大小同時取決於病人選擇、長期監測與治療中心承接能力。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-11-google-coscientist-real-world-lab-loop.html", "title": "AI 一小時做完實驗？Google Co-Scientist 真正跨過的，是「動手」這一關", "language": "zh-Hant", "datePublished": "2026-09-11", "dateModified": "2026-09-11", "summary": "Google Co-Scientist 從假說生成走向實驗執行，但真正的採購與產業價值仍取決於設備整合、可重現性、失敗紀錄與責任治理。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.html", "title": "Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流", "language": "zh-Hant", "datePublished": "2026-09-10", "dateModified": "2026-09-10", "summary": "文獻在資料庫、定序檔在伺服器、蛋白質結構在另一套工具、分析程式留在某位研究員的電腦，最後的實驗紀錄又散落在不同表單。科學家花掉大量時間，不是在解生物學，而是在搬資料、補上下文、確認上一個人到底做了什麼。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.html", "title": "「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳", "language": "zh-Hant", "datePublished": "2026-09-09", "dateModified": "2026-09-09", "summary": "一款還沒核准、還沒公布正式定價的癌症疫苗，已經被貼上「一針近 50 萬美元」的標籤。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.html", "title": "Big Pharma 集體變養馬人！血腦屏障成了 CNS 新藥最貴入口", "language": "zh-Hant", "datePublished": "2026-09-08", "dateModified": "2026-09-08", "summary": "做中樞神經藥物的人，手上可能握著一把很好的劍：抗體能抓到致病蛋白、基因療法能關掉錯誤基因、核酸藥物能精準沉默訊號。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.html", "title": "FDA 還沒任命 AI 副局長，AI 審評已先改寫新藥估值", "language": "zh-Hant", "datePublished": "2026-09-07", "dateModified": "2026-09-07", "summary": "一則「FDA 將增設 AI 副局長」的消息，這幾天讓 AI 製藥圈非常興奮。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.html", "title": "把抗體級結合力塞進藥片！兩款新藥獲批，大藥廠搶押口服大環肽", "language": "zh-Hant", "datePublished": "2026-09-06", "dateModified": "2026-09-06", "summary": "一種藥，既想要小分子的口服便利，又想要抗體抓住複雜標靶的能力，做得到嗎？", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.html", "title": "18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」", "language": "zh-Hant", "datePublished": "2026-09-05", "dateModified": "2026-09-05", "summary": "當家人開始重複問同一件事、忘記熟悉的路，很多人第一個問題是：「能不能抽血就知道是不是阿茲海默症？」", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html", "title": "Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard", "language": "en", "datePublished": "2026-09-04", "dateModified": "2026-09-04", "summary": "Ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in the Phase 3 HARMONi-GI1 interim analysis, but the hazard ratio, median survival, curves, safety and subgroup results remain undisclosed.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Akeso | HARMONi-GI1 met its overall-survival primary endpoint", "url": "https://akesobio.com/en/media/akeso-news/260826/" }, { "title": "Summit Therapeutics | HARMONi-GI1 topline result and single-region boundary", "url": "https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Advanced-Biliary-Tract-Cancer-in-Single-Region-Trial-Conducted-by-Akeso-in-China/default.aspx" }, { "title": "TOPAZ-1 | Durvalumab plus chemotherapy primary analysis", "url": "https://pubmed.ncbi.nlm.nih.gov/38319896/" }, { "title": "TOPAZ-1 | Updated overall-survival analysis", "url": "https://pubmed.ncbi.nlm.nih.gov/38823398/" }, { "title": "U.S. FDA | Pembrolizumab plus chemotherapy for biliary tract cancer", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-biliary-tract-cancer" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html", "title": "Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷", "language": "zh-Hant", "datePublished": "2026-09-04", "dateModified": "2026-09-04", "summary": "Ivonescimab 合併化療在一線晚期膽道癌三期 HARMONi-GI1 達到總生存期主要終點，正面勝過 durvalumab 合併化療；完整風險比、生存曲線、安全性與亞組數據仍待公布。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "康方生物｜HARMONi-GI1 達到總生存期主要終點", "url": "https://akesobio.com/en/media/akeso-news/260826/" }, { "title": "Summit Therapeutics｜HARMONi-GI1 頂線結果與單區研究邊界", "url": "https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Advanced-Biliary-Tract-Cancer-in-Single-Region-Trial-Conducted-by-Akeso-in-China/default.aspx" }, { "title": "TOPAZ-1｜Durvalumab 合併化療主要分析", "url": "https://pubmed.ncbi.nlm.nih.gov/38319896/" }, { "title": "TOPAZ-1｜更新整體生存分析", "url": "https://pubmed.ncbi.nlm.nih.gov/38823398/" }, { "title": "FDA｜Pembrolizumab 合併化療用於膽道癌", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-biliary-tract-cancer" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard-en.html", "title": "Claude Starts Running Experiments: AI Enters the Physical Lab", "language": "en", "datePublished": "2026-09-03", "dateModified": "2026-09-03", "summary": "Anthropic's Model Hardware Standard research preview gives AI agents a shared interface for microscopes, liquid handlers, robots and laser-control systems. The proof-of-concept results are important, but they do not mean autonomous laboratories are already mature.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Anthropic | Previewing the Model Hardware Standard", "url": "https://www.anthropic.com/news/model-hardware-standard-research-preview" }, { "title": "Anthropic | Expanding our support for scientists", "url": "https://www.anthropic.com/news/expanding-support-for-scientists" }, { "title": "Anthropic | Claude Science, an AI workbench for scientists, is now available", "url": "https://www.anthropic.com/news/claude-science-ai-workbench" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard.html", "title": "Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了", "language": "zh-Hant", "datePublished": "2026-09-03", "dateModified": "2026-09-03", "summary": "Anthropic 公開模型硬體標準 MHS 研究預覽，讓 AI 代理透過共通介面讀取與操作顯微鏡、移液工作站、機械手臂與雷射控制系統；這是概念驗證，不是無人實驗室已成熟。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.html", "title": "A New Drug Launched. Seven Months Later, the Company Sought Liquidation", "language": "en", "datePublished": "2026-09-02", "dateModified": "2026-09-02", "summary": "FDA approval does not erase business risk. Iterum, Karyopharm and Theravance show how revenue, cost, pipeline and capital clocks can begin running at the same time after a drug reaches the market.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Iterum | Third-quarter 2025 financial results", "url": "https://ir.iterumtx.com/press-releases/detail/159/iterum-therapeutics-reports-third-quarter-2025-financial" }, { "title": "Iterum | Liquidation application and provisional liquidation", "url": "https://www.sec.gov/Archives/edgar/data/1659323/000119312526127785/itrm-20260327.htm" }, { "title": "Iterum | Announcement following the court liquidation order", "url": "https://content.bsx.com/CompanyDocuments/1099939718/Iterum%20-%20BSX%20Announcement%20-%201%20June%202026.pdf" }, { "title": "Karyopharm | Second-quarter 2026 financial results", "url": "https://investors.karyopharm.com/2026-08-13-Karyopharm-Reports-Second-Quarter-2026-Financial-Results-and-Highlights-Continued-Progress-Toward-Myelofibrosis-sNDA-Submission" }, { "title": "Karyopharm | Phase 3 SENTRY results", "url": "https://investors.karyopharm.com/2026-06-02-Karyopharm-to-Present-Results-from-Phase-3-SENTRY-Trial-of-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-in-Late-Breaking-Oral-Presentation-at-ASCO-2026-with-Simultaneous-Publication-in-the-Journal-of-Clinical-Oncology" }, { "title": "Karyopharm | Myelofibrosis filing pathway", "url": "https://investors.karyopharm.com/2026-07-30-Karyopharm-Plans-to-Submit-sNDA-for-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-Under-Accelerated-Approval-Pathway" }, { "title": "Theravance | Phase 3 CYPRESS and restructuring", "url": "https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-reports-phase-3-cypress-study-did-not-meet" }, { "title": "Theravance | Second-quarter 2026 financial results and pending acquisition", "url": "https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-second-quarter-2026-financial" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html", "title": "新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後", "language": "zh-Hant", "datePublished": "2026-09-02", "dateModified": "2026-09-02", "summary": "ORLYNVAH 上市第一季只有 40 萬美元淨產品收入，同季銷售、一般與管理費約 650 萬美元；約七個月後，Iterum 聲請清盤。Karyopharm 與 Theravance 的情況不同，卻共同顯示新藥核准後，收入、成本、管線與資本四座時鐘會同時啟動。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery-en.html", "title": "Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here", "language": "en", "datePublished": "2026-09-01", "dateModified": "2026-09-01", "summary": "GenBio AI's AIDO Cell attempts to connect DNA, RNA, proteins and cell phenotypes through a shared state that supports sequential perturbations. The company says it matched or exceeded specialist models on 24 of 31 internal metrics, but the preview covers only K-562 and Hep-G2 cells, and novel predictions still require physical experiments, external replication and blinded testing.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "GenBio AI | AIDO Cell technical overview", "url": "https://genbio.ai/aido-cell-simulator/" }, { "title": "GenBio AI | Company team", "url": "https://genbio.ai/our-team/" }, { "title": "Xaira Therapeutics | X-Cell announcement", "url": "https://www.xaira.com/news/xaira-therapeutics-launches-x-cell-its-first-virtual-cell-model-trained-on-the-largest-ever-genome-wide-perturbation-dataset-x-atlas-pisces" }, { "title": "U.S. FDA | General Considerations for the Use of New Approach Methodologies in Drug Development", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-use-new-approach-methodologies-drug-development" }, { "title": "U.S. FDA | Frequently Asked Questions: Developing Potential Cellular and Gene Therapy Products", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products" }, { "title": "Nobel Prize | David Baker — Facts", "url": "https://www.nobelprize.org/prizes/chemistry/2024/baker/facts/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html", "title": "新藥能先在電腦裡試？「虛擬細胞」來了！", "language": "zh-Hant", "datePublished": "2026-09-01", "dateModified": "2026-09-01", "summary": "GenBio AI 的 AIDO Cell 嘗試用共享狀態串起 DNA、RNA、蛋白質與細胞表型，並連續模擬基因、藥物與抗藥性擾動。公司基準顯示 31 項指標中有 24 項追平或超越專用模型，但目前只有 K-562、Hep-G2 兩種原型細胞，新預測仍待實體實驗、外部重現與盲測。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "GenBio AI｜AIDO Cell 官方技術說明", "url": "https://genbio.ai/aido-cell-simulator/" }, { "title": "GenBio AI｜官方團隊頁", "url": "https://genbio.ai/our-team/" }, { "title": "Xaira Therapeutics｜X-Cell 官方發布", "url": "https://www.xaira.com/news/xaira-therapeutics-launches-x-cell-its-first-virtual-cell-model-trained-on-the-largest-ever-genome-wide-perturbation-dataset-x-atlas-pisces" }, { "title": "FDA｜新方法學草案", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-considerations-use-new-approach-methodologies-drug-development" }, { "title": "FDA｜細胞與基因治療常見問題最終指引", "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products" }, { "title": "Nobel Prize｜David Baker", "url": "https://www.nobelprize.org/prizes/chemistry/2024/baker/facts/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift-en.html", "title": "GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue?", "language": "en", "datePublished": "2026-08-31", "dateModified": "2026-08-31", "summary": "A U.S. household transaction study found that grocery spending fell 5.3% on average six months after GLP-1 adoption and 8.2% among higher-income households. Some luxury hotels are already testing smaller portions, protein-forward menus, zero-proof drinks and wellness services. The strategic question is whether hospitality operators can translate lower food volume into better service, pricing and repeat demand.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Forbes Travel Guide | How GLP-1s Are Reshaping Luxury Hospitality", "url": "https://www.forbes.com/sites/forbestravelguide/2026/07/15/how-glp-1s-are-reshaping-luxury-hospitality/" }, { "title": "Journal of Marketing Research | The No-Hunger Games", "url": "https://journals.sagepub.com/doi/10.1177/00222437251412834" }, { "title": "U.S. FDA | Wegovy 2025 Prescribing Information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s023lbl.pdf" }, { "title": "JAMA Psychiatry | Once-Weekly Semaglutide in Adults With Alcohol Use Disorder", "url": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811" }, { "title": "The Obesity Society and partner organizations | Nutritional Priorities to Support GLP-1 Therapy", "url": "https://www.obesity.org/wp-content/uploads/2025/06/Joint_Nutritional-Priorities-to-Support-GLP-1-Therapy-for-Obesity.pdf" }, { "title": "PwC | 2026 GLP-1 Consumer Trends", "url": "https://www.pwc.com/us/en/industries/consumer-markets/library/glp-1-consumer-trends.html" }, { "title": "Hilton Head Health | GLP-1 Support Experience", "url": "https://www.hhhealth.com/glp-1-support-experience/" }, { "title": "Four Seasons Los Angeles | Immortelle", "url": "https://www.fourseasons.com/losangeles/landing-pages/property/immortelle/" }, { "title": "Nestlé USA | Vital Pursuit", "url": "https://www.nestleusa.com/media/pressreleases/vital-pursuit-glp-1" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift.html", "title": "減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？", "language": "zh-Hant", "datePublished": "2026-08-31", "dateModified": "2026-08-31", "summary": "美國家戶交易研究顯示，採用 GLP-1 六個月後，雜貨支出平均下降 5.3%，高收入家庭下降 8.2%；部分高端飯店也開始測試小份餐、高蛋白、無酒精飲品與健康陪伴服務。真正的商業題目，不是客人吃少了多少，而是飯店能否把食物的量重新翻譯成服務、價格與回購。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Forbes Travel Guide｜How GLP-1s Are Reshaping Luxury Hospitality", "url": "https://www.forbes.com/sites/forbestravelguide/2026/07/15/how-glp-1s-are-reshaping-luxury-hospitality/" }, { "title": "Journal of Marketing Research｜The No-Hunger Games", "url": "https://journals.sagepub.com/doi/10.1177/00222437251412834" }, { "title": "美國 FDA｜Wegovy 2025 年核准仿單", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s023lbl.pdf" }, { "title": "JAMA Psychiatry｜Once-Weekly Semaglutide in Adults With Alcohol Use Disorder", "url": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811" }, { "title": "The Obesity Society 等四組織｜GLP-1 治療期間的營養優先事項", "url": "https://www.obesity.org/wp-content/uploads/2025/06/Joint_Nutritional-Priorities-to-Support-GLP-1-Therapy-for-Obesity.pdf" }, { "title": "PwC｜2026 GLP-1 Consumer Trends", "url": "https://www.pwc.com/us/en/industries/consumer-markets/library/glp-1-consumer-trends.html" }, { "title": "Hilton Head Health｜GLP-1 Support Experience", "url": "https://www.hhhealth.com/glp-1-support-experience/" }, { "title": "Four Seasons Los Angeles｜Immortelle", "url": "https://www.fourseasons.com/losangeles/landing-pages/property/immortelle/" }, { "title": "Nestlé USA｜Vital Pursuit", "url": "https://www.nestleusa.com/media/pressreleases/vital-pursuit-glp-1" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.html", "title": "Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight", "language": "en", "datePublished": "2026-08-30", "dateModified": "2026-08-30", "summary": "Avexitide reduced the combined rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo in Amylyx's Phase 3 LUCIDITY trial, sending the shares up about 64% in one session. This analysis examines the GLP-1 mechanism in post-bariatric hypoglycemia, the evidence still missing from the topline release, Amylyx's $35.1 million asset acquisition, its $500.2 million financing and the regulatory and commercial gates ahead.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Amylyx | Positive topline results from Phase 3 LUCIDITY", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-positive-topline-results-0" }, { "title": "Amylyx | Acquisition of the Phase 3-ready avexitide asset", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-acquisition-phase-3-ready-glp-1" }, { "title": "Amylyx | Formal intention to remove RELYVRIO and corporate restructuring", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-formal-intention-remove" }, { "title": "Amylyx | Historical stock-price lookup", "url": "https://investors.amylyx.com/stock-information/historical-price-lookup" }, { "title": "Amylyx | Pricing of the upsized approximately $500.2 million offering", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-pricing-upsized-500-million" }, { "title": "MBX Biosciences | Imapextide Phase 2 update", "url": "https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-provides-obesity-portfolio-update-including" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html", "title": "減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！", "language": "zh-Hant", "datePublished": "2026-08-30", "dateModified": "2026-08-30", "summary": "Amylyx 的 avexitide 在 LUCIDITY 三期試驗中，讓第二級與第三級低血糖事件合併發生率較安慰劑降低 55%，帶動股價單日上漲約 64%。本文拆解 PBH 的 GLP-1 機制、三期證據、3,510 萬美元資產收購、5 億美元募資，以及核准與商業化前仍須跨越的關卡。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Amylyx｜LUCIDITY 三期頂線結果", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-positive-topline-results-0" }, { "title": "Amylyx｜avexitide 資產收購", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-acquisition-phase-3-ready-glp-1" }, { "title": "Amylyx｜Relyvrio 撤市與重整", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-formal-intention-remove" }, { "title": "Amylyx｜歷史股價", "url": "https://investors.amylyx.com/stock-information/historical-price-lookup" }, { "title": "Amylyx｜5.002 億美元定價募資", "url": "https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-pricing-upsized-500-million" }, { "title": "MBX Biosciences｜imapextide 二期更新", "url": "https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-provides-obesity-portfolio-update-including" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on-en.html", "title": "Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval", "language": "en", "datePublished": "2026-08-29", "dateModified": "2026-08-29", "summary": "The FDA approved Revolution Medicines' RASONQUE 6.5 months ahead of schedule for a defined metastatic pancreatic adenocarcinoma population. This analysis examines the RASolute 302 survival data, the RAS(ON) mechanism, Revolution's eleven-year strategic pivot and the pricing, access, safety and global execution tests that begin after approval.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "FDA | Approval of daraxonrasib for metastatic pancreatic adenocarcinoma", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma" }, { "title": "FDA | First-in-class targeted therapy press announcement", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer" }, { "title": "Revolution Medicines | RASONQUE approval and RASolute 302 results", "url": "https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib" }, { "title": "Revolution Medicines | SEC filing disclosing wholesale acquisition cost", "url": "https://ir.revmed.com/node/13376/html" }, { "title": "Revolution Medicines | 2015 founding and Series A financing", "url": "https://ir.revmed.com/node/6491/pdf" }, { "title": "Revolution Medicines | Acquisition of Warp Drive Bio", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-acquires-warp-drive-bio-expand-drug/" }, { "title": "Revolution Medicines | 2019 financial filing and acquired-asset allocations", "url": "https://ir.revmed.com/node/6746/html" }, { "title": "Revolution Medicines / Sanofi | 2018 SHP2 partnership", "url": "https://ir.revmed.com/news-releases/news-release-details/sanofi-and-revolution-medicines-launch-global-partnership" }, { "title": "Revolution Medicines | Completion of the EQRx acquisition", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-completes-acquisition-eqrx" }, { "title": "Revolution Medicines | $2 billion Royalty Pharma financing agreement", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-enters-2-billion-flexible-funding-agreement" }, { "title": "Revolution Medicines | Second-quarter 2026 financial results", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-second-quarter-2026-financial" }, { "title": "Revolution Medicines / BeOne Medicines | RAS(ON) collaboration in parts of Asia", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on.html", "title": "胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥", "language": "zh-Hant", "datePublished": "2026-08-29", "dateModified": "2026-08-29", "summary": "FDA 提前 6.5 個月核准 Revolution Medicines 的 RASONQUE，用於特定轉移性胰臟腺癌成人。本文拆解 RASolute 302 的生存數據、RAS(ON) 技術、Revolution 十一年轉向史，以及藥證之後的定價、給付、安全性與全球商業化考驗。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv-en.html", "title": "A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million", "language": "en", "datePublished": "2026-08-28", "dateModified": "2026-08-28", "summary": "Zealand Pharma sold rusfertide-related milestones and a 1% global net-sales royalty for up to $100 million, not control of the drug itself. The transaction clarifies how Zealand, Protagonist and Takeda hold very different economics—and what rusfertide could mean for PharmaEssentia's BESREMi.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Zealand Pharma | August 12 royalty transaction", "url": "https://www.globenewswire.com/news-release/2026/08/12/3344048/0/en/zealand-pharma-enters-into-a-usd-100-million-royalty-purchase-and-sale-agreement-with-royalty-pharma-for-the-economics-related-to-rusfertide.html" }, { "title": "Zealand Pharma | First-half 2026 financial results", "url": "https://www.globenewswire.com/news-release/2026/08/13/3344209/0/en/zealand-pharma-announces-financial-results-for-the-first-half-of-2026.html" }, { "title": "Takeda / Protagonist | FDA priority-review announcement", "url": "https://www.takeda.com/newsroom/newsreleases/2026/nda-rusfertide/" }, { "title": "Protagonist Therapeutics | First-quarter 2026 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1377121/000110465926055661/ptgx-20260331x10q.htm" }, { "title": "VERIFY Phase 3 primary abstract", "url": "https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA3" }, { "title": "Takeda / Protagonist | 52-week data", "url": "https://www.takeda.com/newsroom/newsreleases/2025/ash-rusfertide/" }, { "title": "BESREMi | Latest FDA label", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761166s010lbl.pdf" }, { "title": "PharmaEssentia | BESREMi Pen approval", "url": "https://us.pharmaessentia.com/pharmaessentia-announces-fda-approval-and-u-s-launch-of-besremi-pen-ropeginterferon-alfa-2b-njft-for-polycythemia-vera/" }, { "title": "PharmaEssentia | FDA target date for the BESREMi ET application", "url": "https://us.pharmaessentia.com/fda-confirms-a-pdufa-goal-date-of-august-30-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b-njft-in-essential-thrombocythemia-et/" }, { "title": "PharmaEssentia | Long-term BESREMi molecular-response data", "url": "https://www.pharmaessentia.com/news/20251119" }, { "title": "Protagonist Therapeutics | First-quarter 2026 earnings exhibit", "url": "https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv.html", "title": "藥華藥迎新對手？1 億美元賣分潤", "language": "zh-Hant", "datePublished": "2026-08-28", "dateModified": "2026-08-28", "summary": "Zealand Pharma 以總對價 1 億美元出售 rusfertide 的里程碑與 1% 全球淨銷售權利金，交易不是出售藥物控制權。本文拆解 Zealand、Protagonist 與武田的不同經濟位置，並分析 rusfertide 對藥華藥 BESREMi 的競爭、互補與治療分層。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Zealand Pharma｜8 月 12 日交易公告", "url": "https://www.globenewswire.com/news-release/2026/08/12/3344048/0/en/zealand-pharma-enters-into-a-usd-100-million-royalty-purchase-and-sale-agreement-with-royalty-pharma-for-the-economics-related-to-rusfertide.html" }, { "title": "Zealand Pharma｜2026 上半年財報", "url": "https://www.globenewswire.com/news-release/2026/08/13/3344209/0/en/zealand-pharma-announces-financial-results-for-the-first-half-of-2026.html" }, { "title": "Takeda／Protagonist｜FDA 優先審查公告", "url": "https://www.takeda.com/newsroom/newsreleases/2026/nda-rusfertide/" }, { "title": "Protagonist｜2026 第一季 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1377121/000110465926055661/ptgx-20260331x10q.htm" }, { "title": "VERIFY 第三期原始摘要", "url": "https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA3" }, { "title": "Takeda／Protagonist｜52 週資料", "url": "https://www.takeda.com/newsroom/newsreleases/2025/ash-rusfertide/" }, { "title": "BESREMi 最新 FDA 標籤", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761166s010lbl.pdf" }, { "title": "藥華藥｜BESREMi Pen 核准公告", "url": "https://us.pharmaessentia.com/pharmaessentia-announces-fda-approval-and-u-s-launch-of-besremi-pen-ropeginterferon-alfa-2b-njft-for-polycythemia-vera/" }, { "title": "藥華藥｜BESREMi 擴張 ET 的 PDUFA 公告", "url": "https://us.pharmaessentia.com/fda-confirms-a-pdufa-goal-date-of-august-30-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b-njft-in-essential-thrombocythemia-et/" }, { "title": "藥華藥｜BESREMi 長期分子反應資料公告", "url": "https://www.pharmaessentia.com/news/20251119" }, { "title": "Protagonist｜2026 第一季財報附件", "url": "https://www.sec.gov/Archives/edgar/data/1377121/000110465926055629/tm2613550d1_ex99-1.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels-en.html", "title": "DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet", "language": "en", "datePublished": "2026-08-27", "dateModified": "2026-08-27", "summary": "Twist Bioscience is seeing rapid growth in AI-enabled drug-discovery orders and DSPS revenue, but demand growth, unit value and industry moat are not the same thing. The scarce asset may be the full wet-lab system that converts massive sequence volumes into proteins, functional data and model feedback.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Twist Bioscience | Fiscal Third Quarter 2026 Financial Results", "url": "https://investors.twistbioscience.com/static-files/09275eee-f3b8-45a6-b39c-4201339dbc8f" }, { "title": "Twist Bioscience | Fiscal 2026 Q3 Financial Results Presentation", "url": "https://investors.twistbioscience.com/static-files/f4d8b908-ec67-4c0a-9b16-29271fda205a" }, { "title": "Twist Bioscience | Investor Day 2026", "url": "https://investors.twistbioscience.com/static-files/b091befc-c055-44c7-a7ce-9becedaa4607" }, { "title": "Twist Bioscience | Complex Genes offering expansion", "url": "https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-expands-clonal-genes-offering-include-long-and/" }, { "title": "Twist Bioscience | Bispecific antibody discovery licensing agreement", "url": "https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-expands-antibody-discovery-offering-bispecific/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels.html", "title": "DNA 不是 AI 製藥的輝達，至少現在還不是", "language": "zh-Hant", "datePublished": "2026-08-27", "dateModified": "2026-08-27", "summary": "Twist Bioscience 的 AI 輔助藥物發現訂單與 DSPS 營收快速成長，但需求增加、單位價值與產業壁壘不是同一件事。真正稀缺的，可能不是單一 DNA 合成步驟，而是能把海量序列轉成蛋白質、功能數據並回饋模型的整座濕實驗工廠。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Twist Bioscience｜Fiscal Third Quarter 2026 Financial Results", "url": "https://investors.twistbioscience.com/static-files/09275eee-f3b8-45a6-b39c-4201339dbc8f" }, { "title": "Twist Bioscience｜Fiscal 2026 Q3 Financial Results Presentation", "url": "https://investors.twistbioscience.com/static-files/f4d8b908-ec67-4c0a-9b16-29271fda205a" }, { "title": "Twist Bioscience｜Investor Day 2026", "url": "https://investors.twistbioscience.com/static-files/b091befc-c055-44c7-a7ce-9becedaa4607" }, { "title": "Twist Bioscience｜Complex Genes offering expansion", "url": "https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-expands-clonal-genes-offering-include-long-and/" }, { "title": "Twist Bioscience｜Bispecific antibody discovery licensing agreement", "url": "https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-expands-antibody-discovery-offering-bispecific/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9-en.html", "title": "Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses?", "language": "en", "datePublished": "2026-08-26", "dateModified": "2026-08-26", "summary": "Lipfendra is the first FDA-approved oral PCSK9 inhibitor, lowering LDL-C by 56% and 59% in two Phase 3 trials. Oral dosing opens a major market, but cardiovascular outcomes, fasting adherence, payer access and Taiwan approval will decide whether it expands the category or displaces injections.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "FDA | Novel Drug Approvals for 2026", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026" }, { "title": "FDA | Lipfendra approval letter, NDA 220848", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf" }, { "title": "FDA | First Oral PCSK9 Inhibitor", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol" }, { "title": "Lipfendra | FDA-approved prescribing information", "url": "https://www.merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_pi.pdf" }, { "title": "Merck | FDA approval announcement", "url": "https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/" }, { "title": "Merck | Q2 2026 earnings release (SEC 8-K Exhibit 99.1)", "url": "https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm" }, { "title": "CORALreef Lipids | NCT05952856", "url": "https://clinicaltrials.gov/study/NCT05952856" }, { "title": "CORALreef HeFH | NCT05952869", "url": "https://clinicaltrials.gov/study/NCT05952869" }, { "title": "CORALreef Outcomes | NCT06008756", "url": "https://clinicaltrials.gov/study/NCT06008756" }, { "title": "Novartis | Q2 2026 results", "url": "https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed" }, { "title": "ACC/AHA | 2026 guideline on dyslipidemia", "url": "https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia" }, { "title": "Taiwan NHIA | Expanded reimbursement for injectable PCSK9 therapies", "url": "https://www.nhi.gov.tw/ch/cp-18857-f1abb-3255-1.html" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html", "title": "默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？", "language": "zh-Hant", "datePublished": "2026-08-26", "dateModified": "2026-08-26", "summary": "FDA 核准首款每日口服 PCSK9 抑制劑 Lipfendra，兩項第三期試驗在第 24 週降低 LDL-C 56% 與 59%。但口服不等於針劑退場：心血管硬終點、每日空腹依從性、保險准入與台灣核准，才會決定市場如何重切。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "FDA｜2026 Novel Drug Approvals", "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026" }, { "title": "FDA｜Lipfendra 核准函（NDA 220848）", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf" }, { "title": "FDA｜First Oral PCSK9 Inhibitor", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol" }, { "title": "Lipfendra｜FDA-approved prescribing information", "url": "https://www.merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_pi.pdf" }, { "title": "默沙東｜Lipfendra FDA 核准公告", "url": "https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/" }, { "title": "默沙東｜2026 年第二季財報（SEC 8-K Exhibit 99.1）", "url": "https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm" }, { "title": "CORALreef Lipids｜NCT05952856", "url": "https://clinicaltrials.gov/study/NCT05952856" }, { "title": "CORALreef HeFH｜NCT05952869", "url": "https://clinicaltrials.gov/study/NCT05952869" }, { "title": "CORALreef Outcomes｜NCT06008756", "url": "https://clinicaltrials.gov/study/NCT06008756" }, { "title": "Novartis｜2026 年第二季財報", "url": "https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed" }, { "title": "ACC／AHA｜2026 血脂異常指引", "url": "https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia" }, { "title": "衛生福利部中央健康保險署｜PCSK9 注射型降脂藥給付放寬", "url": "https://www.nhi.gov.tw/ch/cp-18857-f1abb-3255-1.html" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en.html", "title": "The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD?", "language": "en", "datePublished": "2026-08-25", "dateModified": "2026-08-25", "summary": "Big Pharma is paying for incremental efficacy around established therapies. ABT-301 has completed Phase 1; the CRC triplet's efficacy, sustainable dosing, durability and biomarker readouts will determine whether it can become a Combination Layer and open substantive partnering opportunities.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Revolution Medicines | Q2 2026 financial results and daraxonrasib regulatory progress", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-second-quarter-2026-financial/" }, { "title": "BeOne Medicines | 2025 interim report: global R&D and clinical-operations infrastructure", "url": "https://hkexir.beonemedicines.com/filings-financials/financial-reports" }, { "title": "PharmaCube / Shenlan View | Why a $40 billion biotech chose BeOne", "url": "https://www.pharmcube.com/newsLibrary/detail?id=64606a10cbd6fad153f9505ed7f5f446" }, { "title": "BeOne Medicines x Revolution Medicines | Clinical Development and Regional Commercialization Collaboration", "url": "https://sseir.beonemedicines.com/en/news/beone-medicines-and-revolution-medicines-announce-clinical-development-and-regional-commercialization-collaboration/0a35a8d0-de94-4e43-a54c-c08af0e2e7ad" }, { "title": "Revolution Medicines x Summit Therapeutics | RAS(ON) inhibitors + ivonescimab combination", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-summit-therapeutics-enter-clinical/" }, { "title": "GSK x Summit Therapeutics | Ivonescimab + B7-H3 ADC combination", "url": "https://www.businesswire.com/news/home/20260112976441/en/Summit-Therapeutics-Announces-Clinical-Trial-Collaboration-with-GSK-to-Evaluate-Ivonescimab-in-Combination-with-GSKs-B7-H3-Antibody-Drug-Conjugate-ADC" }, { "title": "Takeda x Innovent | Global oncology collaboration", "url": "https://www.takeda.com/newsroom/newsreleases/2025/closing-partnership-innovent/" }, { "title": "Pfizer x Innovent | Global strategic oncology collaboration", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic" }, { "title": "Astellas x Vir Biotechnology | VIR-5500 global collaboration", "url": "https://newsroom.astellas.com/2026-02-24-astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-r-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer" }, { "title": "ABT-301 First-in-Human Phase 1", "url": "https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e15137" }, { "title": "ABT-301 + Tislelizumab + Bevacizumab Phase 1/2 | NCT07244705", "url": "https://clinicaltrials.gov/study/NCT07244705" }, { "title": "CAPability-01 | HDAC + PD-1 + VEGF in MSS/pMMR mCRC", "url": "https://www.nature.com/articles/s41591-024-02813-1" }, { "title": "Laboratory of Veterinary Surgery, The University of Tokyo | Research output", "url": "https://www.vm.a.u-tokyo.ac.jp/geka/Results.html" }, { "title": "NCI Comparative Oncology Program", "url": "https://dctd.cancer.gov/research/research-areas/comparative-oncology" }, { "title": "Anbogen Biotech x The University of Tokyo | Collaborative Research Announcement", "url": "https://money.udn.com/money/story/5612/9710272" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html", "title": "主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？", "language": "zh-Hant", "datePublished": "2026-08-25", "dateModified": "2026-08-25", "summary": "大藥廠正為主藥旁的增量療效付費。安邦ABT-301已完成Phase I，接下來由CRC三聯的療效、劑量持續性、耐久性與biomarker決定其能否走向Combination Layer與大型藥廠合作。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Revolution Medicines｜2026年第二季財務與daraxonrasib監管進度", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-second-quarter-2026-financial/" }, { "title": "BeOne Medicines｜2025年中期報告：全球研發與臨床營運體系", "url": "https://hkexir.beonemedicines.com/filings-financials/financial-reports" }, { "title": "醫藥魔方／深藍觀｜400億美元市值Biotech，為什麼選擇百濟？", "url": "https://www.pharmcube.com/newsLibrary/detail?id=64606a10cbd6fad153f9505ed7f5f446" }, { "title": "BeOne Medicines × Revolution Medicines｜Clinical Development and Regional Commercialization Collaboration", "url": "https://sseir.beonemedicines.com/en/news/beone-medicines-and-revolution-medicines-announce-clinical-development-and-regional-commercialization-collaboration/0a35a8d0-de94-4e43-a54c-c08af0e2e7ad" }, { "title": "Revolution Medicines × Summit Therapeutics｜RAS(ON) inhibitors與ivonescimab聯用", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-summit-therapeutics-enter-clinical/" }, { "title": "GSK × Summit Therapeutics｜Ivonescimab與B7-H3 ADC聯用", "url": "https://www.businesswire.com/news/home/20260112976441/en/Summit-Therapeutics-Announces-Clinical-Trial-Collaboration-with-GSK-to-Evaluate-Ivonescimab-in-Combination-with-GSKs-B7-H3-Antibody-Drug-Conjugate-ADC" }, { "title": "Takeda × Innovent｜全球腫瘤合作", "url": "https://www.takeda.com/newsroom/newsreleases/2025/closing-partnership-innovent/" }, { "title": "Pfizer × Innovent｜全球策略腫瘤合作", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic" }, { "title": "Astellas × Vir Biotechnology｜VIR-5500全球合作", "url": "https://newsroom.astellas.com/2026-02-24-astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-r-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer" }, { "title": "ABT-301 First-in-Human Phase I", "url": "https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e15137" }, { "title": "ABT-301＋Tislelizumab＋Bevacizumab Phase I/II｜NCT07244705", "url": "https://clinicaltrials.gov/study/NCT07244705" }, { "title": "CAPability-01｜HDAC＋PD-1＋VEGF於MSS／pMMR mCRC", "url": "https://www.nature.com/articles/s41591-024-02813-1" }, { "title": "東京大學獸醫外科學實驗室｜研究成果", "url": "https://www.vm.a.u-tokyo.ac.jp/geka/Results.html" }, { "title": "NCI Comparative Oncology Program", "url": "https://dctd.cancer.gov/research/research-areas/comparative-oncology" }, { "title": "安邦生技 × 東京大學 Collaborative Research Announcement", "url": "https://money.udn.com/money/story/5612/9710272" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.html", "title": "Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business", "language": "en", "datePublished": "2026-08-24", "dateModified": "2026-08-24", "summary": "The $7 billion Curium-Lantheus rumor covered in June became a definitive agreement on August 3: $102.50 in cash plus up to $12.00 per share in CVRs, for total consideration of up to $8 billion. The strategic prize is an integrated chain spanning isotopes, manufacturing, distribution, diagnostics, therapy and U.S. hospital access.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Facebook | Original Drugnews long-form post, August 24, 2026", "url": "https://www.facebook.com/61568446257142/posts/122183498798614875" }, { "title": "Lantheus | Curium Announces Definitive Agreement to Merge with Lantheus, August 3, 2026", "url": "https://investor.lantheus.com/node/17091" }, { "title": "Curium | How we work: manufacturing and distribution network", "url": "https://www.curiumpharma.com/about/how-we-work/" }, { "title": "ClinicalTrials.gov | ECLIPSE phase 3 study, NCT05204927", "url": "https://clinicaltrials.gov/study/NCT05204927" }, { "title": "Lantheus | FDA Approval of PYLARIFY TruVu, March 6, 2026", "url": "https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-fda-approval-pylarify-truvutm-piflufolastat-f" }, { "title": "Lantheus | 2025 shareholder materials: Neuraceq and commercial portfolio", "url": "https://investor.lantheus.com/static-files/65cb003c-d33a-441c-b1f7-c6ea7768da2a" }, { "title": "Novartis | Full-year 2025 results and Pluvicto sales", "url": "https://www.novartis.com/news/media-releases/novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-pipeline-2025" }, { "title": "Eli Lilly | Lilly Completes Acquisition of POINT Biopharma", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma" }, { "title": "Taiwan GMS | Company profile and nuclear-medicine manufacturing and distribution", "url": "https://www.gmstw.com.tw/about.php" }, { "title": "Taiwan FDA | Approved AI and machine-learning medical devices", "url": "https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f639083041331900606&type=1" }, { "title": "EBM Technologies | PACS, RIS, DICOM and AI medical-imaging services", "url": "https://www.ebmtech.com/tw/services" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html", "title": "核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額", "language": "zh-Hant", "datePublished": "2026-08-24", "dateModified": "2026-08-24", "summary": "6 月官網追蹤的 Curium–Lantheus 70 億美元收購傳聞，已在 8 月 3 日推進為最終合併協議：每股 102.50 美元現金加最高 12 美元 CVR，總交易價值最高約 80 億美元。真正被整合的是核素、製造、配送、診斷、治療與美國院端網絡。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Facebook｜藥時事原始公開長文，2026-08-24", "url": "https://www.facebook.com/61568446257142/posts/122183498798614875" }, { "title": "Lantheus｜Curium Announces Definitive Agreement to Merge with Lantheus, 2026-08-03", "url": "https://investor.lantheus.com/node/17091" }, { "title": "Curium｜How we work：全球製造與配送網絡", "url": "https://www.curiumpharma.com/about/how-we-work/" }, { "title": "ClinicalTrials.gov｜ECLIPSE Phase 3, NCT05204927", "url": "https://clinicaltrials.gov/study/NCT05204927" }, { "title": "Lantheus｜FDA Approval of PYLARIFY TruVu, 2026-03-06", "url": "https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-fda-approval-pylarify-truvutm-piflufolastat-f" }, { "title": "Lantheus｜2025 shareholder materials：Neuraceq 與產品組合", "url": "https://investor.lantheus.com/static-files/65cb003c-d33a-441c-b1f7-c6ea7768da2a" }, { "title": "Novartis｜Full-year 2025 results：Pluvicto sales", "url": "https://www.novartis.com/news/media-releases/novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-pipeline-2025" }, { "title": "Eli Lilly｜Lilly Completes Acquisition of POINT Biopharma", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma" }, { "title": "臺灣新吉美碩｜公司簡介與核醫藥品製造配送", "url": "https://www.gmstw.com.tw/about.php" }, { "title": "TFDA｜AI／機器學習醫療器材許可證資料", "url": "https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f639083041331900606&type=1" }, { "title": "商之器｜PACS、RIS、DICOM 與 AI 醫療影像服務", "url": "https://www.ebmtech.com/tw/services" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html", "title": "Who Could Be Big Pharma's Next Major Biotech Acquisition?", "language": "en", "datePublished": "2026-08-23", "dateModified": "2026-08-23", "summary": "Biopharma acquisition capital in 2026 is clustering around a narrow window: human risk has started to fall, but strategic value is not yet fully priced. Alkermes, Dyne, First Tracks, Legend and Sail illustrate five ways a biotech can enter that window, while Taiwan's Pharmosa Biopharm and Belite Bio show how late-stage assets can speak the same global language.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Novartis: Successful completion of the Avidity Biosciences acquisition", "url": "https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy" }, { "title": "Gilead Sciences: Completion of the Arcellx acquisition", "url": "https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel" }, { "title": "Eli Lilly: Agreement to acquire Centessa Pharmaceuticals", "url": "https://investor.lilly.com/node/54066" }, { "title": "Eli Lilly: Agreement to acquire AtaiBeckley", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant" }, { "title": "argenx: Agreement to acquire Forte Biosciences and add FB102", "url": "https://argenx.com/news/2026/press-release-3333257.html" }, { "title": "Alkermes: Initiation of the Phase 3 Brilliance studies", "url": "https://investor.alkermes.com/node/23196/pdf" }, { "title": "Alkermes: Detailed positive results from the Phase 2 Vibrance-2 study", "url": "https://investor.alkermes.com/news-releases/news-release-details/alkermes-presents-detailed-positive-results-vibrance-2-phase-2/" }, { "title": "Dyne Therapeutics: FDA accepts the z-rostudirsen BLA and grants Priority Review", "url": "https://www.dyne-tx.com/fda-accepts-bla-for-z-rostudirsen/" }, { "title": "First Tracks Biotherapeutics: Second-quarter 2026 pipeline update", "url": "https://ir.firsttracksbio.com/news-releases/news-release-details/first-tracks-biotherapeutics-announces-second-quarter-2026" }, { "title": "First Tracks Biotherapeutics: ANB033 program overview", "url": "https://www.firsttracksbio.com/our-pipeline/anb033/overview/" }, { "title": "Legend Biotech: First-quarter 2026 results and Carvykti sales", "url": "https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-reports-first-quarter-2026-results-and-recent/" }, { "title": "Legend Biotech: Preliminary Phase 1 proof of concept for LB2501", "url": "https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-establishes-clinical-proof-concept-lb2501/" }, { "title": "Johnson & Johnson: Strategic collaboration with Sail Biomedicines", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-Collaboration-with-Sail-Biomedicines-to-Advance-in-vivo-CAR-T-Programs-and-Transform-Autoimmune-Disease-Through-Immune-Reset/default.aspx" }, { "title": "ClinicalTrials.gov: Re-Spire Phase 3 study of L606 in PH-ILD, NCT07285655", "url": "https://clinicaltrials.gov/study/NCT07285655" }, { "title": "Belite Bio: Positive topline results from the Phase 3 DRAGON trial", "url": "https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite" }, { "title": "Belite Bio: Completion of the rolling NDA submission for tinlarebant", "url": "https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html", "title": "Biotech 下一筆重磅併購，會落在誰身上？", "language": "zh-Hant", "datePublished": "2026-08-23", "dateModified": "2026-08-23", "summary": "2026 年的生技併購資金，正集中到臨床風險開始下降、商業價值尚未完全定價的公司。從 Alkermes、Dyne、First Tracks、Legend 到 Sail，再回看國邑與仁新，真正值得追的是人體概念驗證、平台外延、商業化距離與買方策略契合度。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Novartis｜Successfully completes acquisition of Avidity Biosciences", "url": "https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy" }, { "title": "Gilead｜Completes acquisition of Arcellx ahead of potential commercial launch of anito-cel", "url": "https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel" }, { "title": "Eli Lilly｜Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders", "url": "https://investor.lilly.com/node/54066" }, { "title": "Eli Lilly｜Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant" }, { "title": "argenx｜argenx to acquire Forte Biosciences, adding anti-CD122 antibody FB102", "url": "https://argenx.com/news/2026/press-release-3333257.html" }, { "title": "Alkermes｜Initiation of Phase 3 Brilliance studies evaluating alixorexton", "url": "https://investor.alkermes.com/node/23196/pdf" }, { "title": "Alkermes｜Detailed positive Vibrance-2 Phase 2 results", "url": "https://investor.alkermes.com/news-releases/news-release-details/alkermes-presents-detailed-positive-results-vibrance-2-phase-2/" }, { "title": "Dyne Therapeutics｜FDA accepts BLA for z-rostudirsen and grants Priority Review", "url": "https://www.dyne-tx.com/fda-accepts-bla-for-z-rostudirsen/" }, { "title": "First Tracks Biotherapeutics｜Second-quarter 2026 pipeline update", "url": "https://ir.firsttracksbio.com/news-releases/news-release-details/first-tracks-biotherapeutics-announces-second-quarter-2026" }, { "title": "First Tracks Biotherapeutics｜ANB033 overview", "url": "https://www.firsttracksbio.com/our-pipeline/anb033/overview/" }, { "title": "Legend Biotech｜First-quarter 2026 results and Carvykti sales", "url": "https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-reports-first-quarter-2026-results-and-recent/" }, { "title": "Legend Biotech｜LB2501 in vivo CD19/CD20 CAR-T Phase 1 data", "url": "https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-establishes-clinical-proof-concept-lb2501/" }, { "title": "Johnson & Johnson｜Strategic collaboration with Sail Biomedicines", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-Collaboration-with-Sail-Biomedicines-to-Advance-in-vivo-CAR-T-Programs-and-Transform-Autoimmune-Disease-Through-Immune-Reset/default.aspx" }, { "title": "ClinicalTrials.gov｜Re-Spire Phase 3 study of L606 in PH-ILD, NCT07285655", "url": "https://clinicaltrials.gov/study/NCT07285655" }, { "title": "Belite Bio｜Positive topline results from the Phase 3 DRAGON trial", "url": "https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite" }, { "title": "Belite Bio｜Completion of tinlarebant NDA rolling submission", "url": "https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.html", "title": "BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality", "language": "en", "datePublished": "2026-08-22", "dateModified": "2026-08-22", "summary": "BeOne is taking regional rights to four RAS(ON) programs, opening two candidate combination routes and funding one global registrational Phase 3. The strategic asset is not the sum of four drugs, but the optionality to decide where capital and development speed matter most.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Revolution Medicines: clinical development and regional commercialization collaboration announcement, August 10, 2026", "url": "https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical" }, { "title": "BeOne Medicines: clinical development and regional commercialization collaboration announcement, August 10, 2026", "url": "https://ir.beonemedicines.com/news/BeOne-Medicines-and-Revolution-Medicines-Announce-Clinical-Development-and-Regional-Commercialization-Collaboration/0a35a8d0-de94-4e43-a54c-c08af0e2e7ad" }, { "title": "SEC: BeOne Medicines first-quarter 2026 Form 10-Q cover data", "url": "https://www.sec.gov/Archives/edgar/data/1651308/000162828026030867/R1.htm" }, { "title": "BeOne Medicines: Hong Kong investor site in Traditional Chinese", "url": "https://hkexir.beonemedicines.com/zh-hant" }, { "title": "Revolution Medicines: clinical development pipeline", "url": "https://www.revmed.com/pipeline/" }, { "title": "Revolution Medicines: FDA accepts daraxonrasib NDA, July 22, 2026", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/" }, { "title": "Revolution Medicines: RASolute 305 global Phase 3 begins treating patients, June 23, 2026", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-begins-treating-patients-rasolute-305-phase/" }, { "title": "ClinicalTrials.gov: elironrasib and daraxonrasib Phase 1b/2, NCT06128551", "url": "https://clinicaltrials.gov/study/NCT06128551" }, { "title": "Revolution Medicines: first patient dosed with RMC-5127, January 29, 2026", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-clinical-trial/" }, { "title": "ClinicalTrials.gov: RMC-5127 Phase 1/1b, NCT07349537", "url": "https://clinicaltrials.gov/study/NCT07349537" }, { "title": "BeOne Medicines: oncology pipeline", "url": "https://beonemedicines.com/science/pipeline/" }, { "title": "BeOne Medicines: global clinical development pipeline", "url": "https://beonemedicines.com/wp-content/uploads/2026/02/Clinical-Pipeline_2026-February.pdf" }, { "title": "ClinicalTrials.gov: BGB-58067, NCT06589596", "url": "https://clinicaltrials.gov/study/NCT06589596" }, { "title": "ClinicalTrials.gov: BG-T187, NCT06598800", "url": "https://clinicaltrials.gov/study/NCT06598800" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html", "title": "百濟神州一口氣押上 4 款 RAS 新藥", "language": "zh-Hant", "datePublished": "2026-08-22", "dateModified": "2026-08-22", "summary": "百濟神州一次接進四款成熟度不同的 RAS(ON) 資產、兩條候選聯用路線與一項全球註冊三期。真正值得追的不是四藥相加，而是區域權利、開發分工與選擇權如何替雙方搶時間。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Revolution Medicines：雙方臨床開發與區域商業化合作公告（2026-08-10）", "url": "https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical" }, { "title": "BeOne Medicines：雙方臨床開發與區域商業化合作公告（2026-08-10）", "url": "https://ir.beonemedicines.com/news/BeOne-Medicines-and-Revolution-Medicines-Announce-Clinical-Development-and-Regional-Commercialization-Collaboration/0a35a8d0-de94-4e43-a54c-c08af0e2e7ad" }, { "title": "SEC：BeOne Medicines 2026 年第一季 Form 10-Q 封面資料", "url": "https://www.sec.gov/Archives/edgar/data/1651308/000162828026030867/R1.htm" }, { "title": "BeOne Medicines：香港投資人繁中官網", "url": "https://hkexir.beonemedicines.com/zh-hant" }, { "title": "Revolution Medicines：臨床開發管線", "url": "https://www.revmed.com/pipeline/" }, { "title": "Revolution Medicines：FDA 受理 daraxonrasib NDA（2026-07-22）", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/" }, { "title": "Revolution Medicines：RASolute 305 全球三期開始治療患者（2026-06-23）", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-begins-treating-patients-rasolute-305-phase/" }, { "title": "ClinicalTrials.gov：elironrasib／daraxonrasib Phase 1b/2，NCT06128551", "url": "https://clinicaltrials.gov/study/NCT06128551" }, { "title": "Revolution Medicines：RMC-5127 首位患者給藥（2026-01-29）", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-clinical-trial/" }, { "title": "ClinicalTrials.gov：RMC-5127 Phase 1/1b，NCT07349537", "url": "https://clinicaltrials.gov/study/NCT07349537" }, { "title": "BeOne Medicines：腫瘤管線", "url": "https://beonemedicines.com/science/pipeline/" }, { "title": "BeOne Medicines：全球臨床開發管線", "url": "https://beonemedicines.com/wp-content/uploads/2026/02/Clinical-Pipeline_2026-February.pdf" }, { "title": "ClinicalTrials.gov：BGB-58067，NCT06589596", "url": "https://clinicaltrials.gov/study/NCT06589596" }, { "title": "ClinicalTrials.gov：BG-T187，NCT06598800", "url": "https://clinicaltrials.gov/study/NCT06598800" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html", "title": "Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test", "language": "en", "datePublished": "2026-08-21", "dateModified": "2026-08-21", "summary": "Positive topline results from INTerpath-001 sent Moderna shares up 176.97% in one session. The deeper valuation question is whether patient-specific design, manufacturing, release and clinical delivery can become a scalable platform.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Nasdaq: MRNA market data", "url": "https://api.nasdaq.com/api/quote/MRNA/info?assetclass=stocks" }, { "title": "Moderna: prespecified interim topline results from Phase 3 INTerpath-001", "url": "https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma" }, { "title": "Merck: INTerpath-001 met RFS and DMFS endpoints", "url": "https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/" }, { "title": "ClinicalTrials.gov: INTerpath-001, NCT05933577", "url": "https://clinicaltrials.gov/study/NCT05933577" }, { "title": "Merck and Moderna: five-year Phase 2 KEYNOTE-942 follow-up", "url": "https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/" }, { "title": "Moderna 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm" }, { "title": "Merck 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html", "title": "再見癌症？癌症疫苗來了！莫德納單日暴漲176.97%", "language": "zh-Hant", "datePublished": "2026-08-21", "dateModified": "2026-08-21", "summary": "INTerpath-001 第三期頂線結果讓莫德納股價單日上漲 176.97%。真正被重新估價的，不只是一款黑色素瘤療法，而是個人化設計、製造、質控與臨床交付能否成為可擴張的平台。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Nasdaq：MRNA 行情資料", "url": "https://api.nasdaq.com/api/quote/MRNA/info?assetclass=stocks" }, { "title": "Moderna：INTerpath-001 第三期預設期中頂線結果", "url": "https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma" }, { "title": "Merck：INTerpath-001 第三期 RFS 與 DMFS 結果公告", "url": "https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/" }, { "title": "ClinicalTrials.gov：INTerpath-001，NCT05933577", "url": "https://clinicaltrials.gov/study/NCT05933577" }, { "title": "Merck／Moderna：KEYNOTE-942 第二期五年追蹤", "url": "https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/" }, { "title": "Moderna 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm" }, { "title": "Merck 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html", "title": "NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion", "language": "en", "datePublished": "2026-08-20", "dateModified": "2026-08-20", "summary": "BMS is preparing to deploy what NVIDIA's published specifications imply is a 576-GPU Rubin system, while Lilly and NVIDIA plan to commit up to $1 billion over five years. The real contest is whether proprietary data, wet-lab execution and clinical evidence can become one learning loop.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Bristol Myers Squibb: building an NVIDIA Vera Rubin AI factory", "url": "https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-to-Build-the-Most-Powerful-AI-Factory-in-Life-Sciences-with-NVIDIA/default.aspx" }, { "title": "NVIDIA: BMS to deploy eight DGX Vera Rubin NVL72 systems", "url": "https://blogs.nvidia.com/blog/bristol-myers-squibb-building-life-science-industrys-most-advanced-ai-factory-on-nvidia-vera-rubin/" }, { "title": "NVIDIA: DGX Vera Rubin NVL72 specifications", "url": "https://www.nvidia.com/en-us/data-center/dgx-vera-rubin-nvl72/" }, { "title": "Bristol Myers Squibb: Claude Enterprise rollout to more than 30,000 employees", "url": "https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Strategic-Agreement-with-Anthropic-to-Position-Claude-Enterprise-as-the-Shared-Intelligence-Platform-Across-Its-Global-Operations/default.aspx" }, { "title": "Schrödinger: Bunsen early access for molecular discovery", "url": "https://ir.schrodinger.com/press-releases/news-details/2026/Schrdinger-Introduces-Bunsen-an-AI-Co-Scientist-for-Molecular-Discovery/default.aspx" }, { "title": "Eli Lilly: five-year NVIDIA co-innovation laboratory commitment of up to $1 billion", "url": "https://investor.lilly.com/news-releases/news-release-details/nvidia-and-lilly-announce-co-innovation-ai-lab-reinvent-drug" }, { "title": "Roche: addition of 2,176 Blackwell GPUs", "url": "https://www.roche.com/media/releases/med-cor-2026-03-16" }, { "title": "Merck & Co.: multiyear Google Cloud collaboration of up to $1 billion", "url": "https://www.merck.com/news/merck-and-google-cloud-partner-to-accelerate-agentic-ai-enterprise-transformation/" }, { "title": "Novo Nordisk: strategic collaboration with OpenAI", "url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916532" }, { "title": "Sanofi: equity investment in Owkin and a three-year research collaboration", "url": "https://www.sanofi.com/en/media-room/press-releases/2021/2021-11-18-06-30-00-2336966" }, { "title": "Nature Medicine: randomized Phase 2a study of rentosertib", "url": "https://www.nature.com/articles/s41591-025-03743-2" }, { "title": "ClinicalTrials.gov: rentosertib study NCT05938920", "url": "https://clinicaltrials.gov/study/NCT05938920" }, { "title": "MindRank: first participant dosed in the Chinese Phase 3 study of MDR-001", "url": "https://www.mindrank.ai/en/news/detail/155" }, { "title": "Drug Discovery Today: 2024 review of clinical success rates for AI-discovered drugs", "url": "https://pubmed.ncbi.nlm.nih.gov/38692505/" }, { "title": "NVIDIA: Vera Rubin production and Taiwan supply-chain partners", "url": "https://nvidianews.nvidia.com/news/vera-rubin-full-production-agentic-ai-factory" }, { "title": "NVIDIA: Taiwan's AI infrastructure ecosystem", "url": "https://blogs.nvidia.com/blog/taiwan-ecosystem-ai-infrastructure/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html", "title": "輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元", "language": "zh-Hant", "datePublished": "2026-08-20", "dateModified": "2026-08-20", "summary": "BMS 準備部署依 NVIDIA 規格推算共 576 顆 Rubin GPU，禮來與 NVIDIA 五年共同投入上限 10 億美元；真正的競爭不只在算力，而在能否把專有資料、濕實驗與臨床證據接成研發閉環。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Bristol Myers Squibb：建置 NVIDIA Vera Rubin AI factory", "url": "https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-to-Build-the-Most-Powerful-AI-Factory-in-Life-Sciences-with-NVIDIA/default.aspx" }, { "title": "NVIDIA：BMS 將部署 8 套 DGX Vera Rubin NVL72", "url": "https://blogs.nvidia.com/blog/bristol-myers-squibb-building-life-science-industrys-most-advanced-ai-factory-on-nvidia-vera-rubin/" }, { "title": "NVIDIA：DGX Vera Rubin NVL72 規格", "url": "https://www.nvidia.com/en-us/data-center/dgx-vera-rubin-nvl72/" }, { "title": "Bristol Myers Squibb：Claude Enterprise 導入逾 3 萬名員工", "url": "https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Strategic-Agreement-with-Anthropic-to-Position-Claude-Enterprise-as-the-Shared-Intelligence-Platform-Across-Its-Global-Operations/default.aspx" }, { "title": "Schrödinger：Bunsen 分子研發代理人開放早期使用", "url": "https://ir.schrodinger.com/press-releases/news-details/2026/Schrdinger-Introduces-Bunsen-an-AI-Co-Scientist-for-Molecular-Discovery/default.aspx" }, { "title": "Eli Lilly：與 NVIDIA 建立五年最高 10 億美元共同創新實驗室", "url": "https://investor.lilly.com/news-releases/news-release-details/nvidia-and-lilly-announce-co-innovation-ai-lab-reinvent-drug" }, { "title": "Roche：新增 2,176 顆 Blackwell GPU", "url": "https://www.roche.com/media/releases/med-cor-2026-03-16" }, { "title": "Merck & Co.：與 Google Cloud 建立多年最高 10 億美元合作", "url": "https://www.merck.com/news/merck-and-google-cloud-partner-to-accelerate-agentic-ai-enterprise-transformation/" }, { "title": "Novo Nordisk：與 OpenAI 建立策略合作", "url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916532" }, { "title": "Sanofi：投資 Owkin 並建立三年研究合作", "url": "https://www.sanofi.com/en/media-room/press-releases/2021/2021-11-18-06-30-00-2336966" }, { "title": "Nature Medicine：rentosertib IIa 期隨機對照研究", "url": "https://www.nature.com/articles/s41591-025-03743-2" }, { "title": "ClinicalTrials.gov：rentosertib NCT05938920", "url": "https://clinicaltrials.gov/study/NCT05938920" }, { "title": "MindRank：MDR-001 中國三期首位受試者給藥", "url": "https://www.mindrank.ai/en/news/detail/155" }, { "title": "Drug Discovery Today：AI-discovered drugs 臨床成功率回顧", "url": "https://pubmed.ncbi.nlm.nih.gov/38692505/" }, { "title": "NVIDIA：Vera Rubin 量產與台灣供應鏈夥伴", "url": "https://nvidianews.nvidia.com/news/vera-rubin-full-production-agentic-ai-factory" }, { "title": "NVIDIA：台灣 AI 基礎設施生態系", "url": "https://blogs.nvidia.com/blog/taiwan-ecosystem-ai-infrastructure/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html", "title": "Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King?", "language": "en", "datePublished": "2026-08-19", "dateModified": "2026-08-19", "summary": "Skyrizi generated $5.505 billion in Q2 2026, only $74 million below Humira's historic quarterly peak. The real succession test spans efficacy, treatment burden, multi-indication reach and access.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "AbbVie second-quarter 2026 financial results", "url": "https://news.abbvie.com/2026-07-31-AbbVie-Reports-Second-Quarter-2026-Financial-Results" }, { "title": "AbbVie first-quarter 2026 financial results", "url": "https://news.abbvie.com/2026-04-29-AbbVie-Reports-First-Quarter-2026-Financial-Results" }, { "title": "AbbVie full-year and fourth-quarter 2022 financial results", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2022-financial" }, { "title": "Skyrizi U.S. prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s044lbl.pdf" }, { "title": "ICOTYDE U.S. prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf" }, { "title": "Johnson & Johnson announcement of FDA approval for ICOTYDE", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/FDA-approval-of-ICOTYDE-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide/default.aspx" }, { "title": "U.S. adult psoriasis prevalence study", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/" }, { "title": "Cosentyx U.S. prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s098lbl.pdf" }, { "title": "AbbVie completes acquisition of Nimble Therapeutics", "url": "https://news.abbvie.com/2025-01-23-AbbVie-Completes-Acquisition-of-Nimble-Therapeutics" }, { "title": "AbbVie June 2026 immunology pipeline presentation filed with the SEC", "url": "https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/tm2618365d1_ex99-2.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html", "title": "55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？", "language": "zh-Hant", "datePublished": "2026-08-19", "dateModified": "2026-08-19", "summary": "Skyrizi 2026 年第二季收入達 55.05 億美元，距 Humira 的歷史單季高點只差 7,400 萬美元；真正的接班考驗，是療效、治療負擔、多適應症與支付能力能否一起延續。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "AbbVie 2026 年第二季財報", "url": "https://news.abbvie.com/2026-07-31-AbbVie-Reports-Second-Quarter-2026-Financial-Results" }, { "title": "AbbVie 2026 年第一季財報", "url": "https://news.abbvie.com/2026-04-29-AbbVie-Reports-First-Quarter-2026-Financial-Results" }, { "title": "AbbVie 2022 年第四季與全年財報", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2022-financial" }, { "title": "Skyrizi 美國 FDA 核准標籤", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s044lbl.pdf" }, { "title": "ICOTYDE 美國 FDA 核准標籤", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf" }, { "title": "Johnson & Johnson ICOTYDE 核准公告", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/FDA-approval-of-ICOTYDE-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide/default.aspx" }, { "title": "美國成人乾癬盛行率原始研究", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/" }, { "title": "Cosentyx 美國 FDA 核准標籤", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s098lbl.pdf" }, { "title": "AbbVie 完成收購 Nimble Therapeutics", "url": "https://news.abbvie.com/2025-01-23-AbbVie-Completes-Acquisition-of-Nimble-Therapeutics" }, { "title": "AbbVie 2026 年 6 月免疫管線簡報（SEC 附件）", "url": "https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/tm2618365d1_ex99-2.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html", "title": "Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King?", "language": "en", "datePublished": "2026-08-18", "dateModified": "2026-08-18", "summary": "Tirzepatide has allowed Eli Lilly to dominate both diabetes and obesity, but revenue concentration, pricing pressure and the next product relay are the investment questions that matter now.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Eli Lilly 2026 Q2 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm" }, { "title": "Eli Lilly 2026 Q2 sales and earnings press release", "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm" }, { "title": "FDA approval announcement for Foundayo", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program" }, { "title": "Foundayo prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf" }, { "title": "NEJM SURMOUNT-5 tirzepatide versus semaglutide", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2416394" }, { "title": "Lilly Zepbound versus Wegovy SURMOUNT-5 release", "url": "https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy" }, { "title": "Lilly retatrutide TRIUMPH-1 Phase 3 topline release", "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html" }, { "title": "Novo Nordisk 2026 Q2 results", "url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916590" }, { "title": "Lilly acquisition and infectious-disease portfolio releases", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease" }, { "title": "Lilly Indiana manufacturing investment", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-commits-additional-45-billion-across-indiana-manufacturing" }, { "title": "Caliway CBL-514 and tirzepatide combination trial announcement", "url": "https://www.caliwaybiopharma.com/news-detail/Caliway-Submits-IND-for-Cbl-514-Combination-Therapy-Phase-2/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html", "title": "一季狂賣 230 億美元，禮來卻急著買下一個藥王", "language": "zh-Hant", "datePublished": "2026-08-18", "dateModified": "2026-08-18", "summary": "Tirzepatide 讓禮來同時吃下糖尿病與減重兩個大市場，但收入集中、價格壓力與下一代產品接班，才是市場真正該看的投資問題。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Eli Lilly 2026 Q2 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm" }, { "title": "Eli Lilly 2026 Q2 sales and earnings press release", "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm" }, { "title": "FDA approval announcement for Foundayo", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program" }, { "title": "Foundayo prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf" }, { "title": "NEJM SURMOUNT-5 tirzepatide versus semaglutide", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2416394" }, { "title": "Lilly Zepbound versus Wegovy SURMOUNT-5 release", "url": "https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy" }, { "title": "Lilly retatrutide TRIUMPH-1 Phase 3 topline release", "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html" }, { "title": "Novo Nordisk 2026 Q2 results", "url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916590" }, { "title": "Lilly acquisition and infectious-disease portfolio releases", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease" }, { "title": "Lilly Indiana manufacturing investment", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-commits-additional-45-billion-across-indiana-manufacturing" }, { "title": "Caliway CBL-514 and tirzepatide combination trial announcement", "url": "https://www.caliwaybiopharma.com/news-detail/Caliway-Submits-IND-for-Cbl-514-Combination-Therapy-Phase-2/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html", "title": "Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business?", "language": "en", "datePublished": "2026-08-17", "dateModified": "2026-08-17", "summary": "Iovance's Amtagvi rebounded sharply in the second quarter, but the central question is no longer whether TIL therapy can work. It is whether a personalized cell therapy can become a reproducible, reimbursable and scalable medical service.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Iovance 2026 Q2 results press release", "url": "https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm" }, { "title": "Iovance 2026 Q2 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/iova-20260630x10q.htm" }, { "title": "Iovance 2026 Q1 results press release", "url": "https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_ex99-1.htm" }, { "title": "FDA Amtagvi product page", "url": "https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi" }, { "title": "FDA approval announcement for Amtagvi", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-to-treat-patients-with-unresectable-or-metastatic-melanoma" }, { "title": "Amtagvi prescribing information", "url": "https://www.fda.gov/media/176417/download" }, { "title": "FDA Summary Basis for Regulatory Action", "url": "https://www.fda.gov/media/176951/download" }, { "title": "ClinicalTrials.gov NCT05727904", "url": "https://clinicaltrials.gov/study/NCT05727904" }, { "title": "ClinicalTrials.gov NCT02360579", "url": "https://clinicaltrials.gov/study/NCT02360579" }, { "title": "TPEx emerging stock disclosure for Timing Pharma", "url": "https://wwwov.tpex.org.tw/storage/eb_data/11412/11400105781.html" }, { "title": "Timing Pharma cell therapy services", "url": "https://www.timing-pharmacy.com/service" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html", "title": "營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？", "language": "zh-Hant", "datePublished": "2026-08-17", "dateModified": "2026-08-17", "summary": "Iovance 的 Amtagvi 第二季營收明顯反彈，但真正要驗證的不是 TIL 是否有療效，而是個人化細胞療法能否被做成可複製、可支付、可放大的醫療服務。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Iovance 2026 Q2 results press release", "url": "https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm" }, { "title": "Iovance 2026 Q2 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/iova-20260630x10q.htm" }, { "title": "Iovance 2026 Q1 results press release", "url": "https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_ex99-1.htm" }, { "title": "FDA Amtagvi product page", "url": "https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi" }, { "title": "FDA approval announcement for Amtagvi", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-to-treat-patients-with-unresectable-or-metastatic-melanoma" }, { "title": "Amtagvi prescribing information", "url": "https://www.fda.gov/media/176417/download" }, { "title": "FDA Summary Basis for Regulatory Action", "url": "https://www.fda.gov/media/176951/download" }, { "title": "ClinicalTrials.gov NCT05727904", "url": "https://clinicaltrials.gov/study/NCT05727904" }, { "title": "ClinicalTrials.gov NCT02360579", "url": "https://clinicaltrials.gov/study/NCT02360579" }, { "title": "TPEx emerging stock disclosure for Timing Pharma", "url": "https://wwwov.tpex.org.tw/storage/eb_data/11412/11400105781.html" }, { "title": "Timing Pharma cell therapy services", "url": "https://www.timing-pharmacy.com/service" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html", "title": "Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses?", "language": "en", "datePublished": "2026-08-16", "dateModified": "2026-08-16", "summary": "Pfizer, Roche and Amgen are pruning obesity programs that lack clear differentiation. The GLP-1 market has moved from a race to enter the clinic to a contest across efficacy, safety, convenience and commercial execution.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Fierce Biotech | Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout", "url": "https://www.fiercebiotech.com/biotech/pfizer-axes-ex-metsera-obesity-asset-and-gipr-prospect-quarterly-clearout" }, { "title": "Pfizer | Robust Phase 2b efficacy and favorable tolerability support monthly dosing for berobenatide", "url": "https://www.pfizer.com/news/press-release/press-release-detail/robust-phase-2b-efficacy-and-favorable-tolerability-support" }, { "title": "Reuters | Metsera shareholders vote for an acquisition by Pfizer valued at up to US$10 billion", "url": "https://www.investing.com/news/stock-market-news/metsera-shareholders-vote-for-10-billion-acquisition-by-pfizer-4355617" }, { "title": "Reuters | What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?", "url": "https://finance.yahoo.com/news/factbox-metsera-target-pfizers-novo-170136393.html" }, { "title": "Roche | Positive Phase 2 results for dual GLP-1/GIP receptor agonist CT-388", "url": "https://www.roche.com/media/releases/med-cor-2026-01-27" }, { "title": "BioSpace | Roche cans one Carmot obesity asset as another shows best-in-class potential", "url": "https://www.biospace.com/business/roche-cans-one-carmot-obesity-asset-as-another-shows-best-in-class-potential" }, { "title": "Amgen | Second-quarter 2026 financial results and pipeline update", "url": "https://www.amgen.com/newsroom/press-releases/2026/08/amgen-reports-second-quarter-2026-financial-results" }, { "title": "Terns Pharmaceuticals | Topline Phase 2 data from TERN-601 in obesity", "url": "https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2/" }, { "title": "The New England Journal of Medicine | Retatrutide for Obesity", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2301972" }, { "title": "Caliway Biopharmaceuticals | CBL-514 in combination with GLP-1R-based therapies at ADA 2026", "url": "https://www.caliwaybiopharma.com/en/news-detail/U-S-OI25-IND-CBL-514-ADA/" }, { "title": "Center Laboratories / ANYA Biopharm | ANY-002 oral GLP-1 receptor agonist", "url": "https://www.centerlab.com.tw/en/industrial/company/21" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html", "title": "百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？", "language": "zh-Hant", "datePublished": "2026-08-16", "dateModified": "2026-08-16", "summary": "Pfizer、Roche 與 Amgen 同步清理缺乏差異化的肥胖症管線，顯示 GLP-1 下半場的門檻已從「有藥可做」升高為療效、安全、便利性與商業化能力的全面競爭。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Fierce Biotech｜Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout", "url": "https://www.fiercebiotech.com/biotech/pfizer-axes-ex-metsera-obesity-asset-and-gipr-prospect-quarterly-clearout" }, { "title": "Pfizer｜Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide", "url": "https://www.pfizer.com/news/press-release/press-release-detail/robust-phase-2b-efficacy-and-favorable-tolerability-support" }, { "title": "Reuters｜Metsera shareholders vote for up to $10 billion acquisition by Pfizer", "url": "https://www.investing.com/news/stock-market-news/metsera-shareholders-vote-for-10-billion-acquisition-by-pfizer-4355617" }, { "title": "Reuters｜What is Metsera, the target in Pfizer’s and Novo Nordisk’s bidding war?", "url": "https://finance.yahoo.com/news/factbox-metsera-target-pfizers-novo-170136393.html" }, { "title": "Roche｜Positive Phase II results for dual GLP-1/GIP receptor agonist CT-388", "url": "https://www.roche.com/media/releases/med-cor-2026-01-27" }, { "title": "BioSpace｜Roche cans one Carmot obesity asset as another shows best-in-class potential", "url": "https://www.biospace.com/business/roche-cans-one-carmot-obesity-asset-as-another-shows-best-in-class-potential" }, { "title": "Amgen｜Second-quarter 2026 financial results and pipeline update", "url": "https://www.amgen.com/newsroom/press-releases/2026/08/amgen-reports-second-quarter-2026-financial-results" }, { "title": "Terns Pharmaceuticals｜Topline Phase 2 data from TERN-601 in obesity", "url": "https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2/" }, { "title": "The New England Journal of Medicine｜Retatrutide for Obesity", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2301972" }, { "title": "Caliway Biopharmaceuticals｜CBL-514 in combination with GLP-1R-based therapies at ADA 2026", "url": "https://www.caliwaybiopharma.com/en/news-detail/U-S-OI25-IND-CBL-514-ADA/" }, { "title": "Centerlab / ANYA Biopharm｜ANY-002 oral GLP-1 receptor agonist", "url": "https://www.centerlab.com.tw/en/industrial/company/21" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html", "title": "GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall", "language": "en", "datePublished": "2026-08-15", "dateModified": "2026-08-15", "summary": "After GSK's roughly US$2 billion acquisition of BELLUS Health, CALM-1 met its endpoint but CALM-2 did not reproduce the result. The divergence shows why Phase 2 promise, patient experience and reproducibility must move together.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "GSK, CALM-1 and CALM-2 Phase 3 update, 17 July 2026", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials/" }, { "title": "GSK, agreement to acquire BELLUS Health, 18 April 2023", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-bellus-health/" }, { "title": "GSK, completion of the BELLUS Health acquisition, 28 June 2023", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-bellus-health/" }, { "title": "SOOTHE original peer-reviewed Phase 2b paper, NCT04678206", "url": "https://academic.oup.com/ajrccm/article/211/6/1038/8513749" }, { "title": "ClinicalTrials.gov: SOOTHE, NCT04678206", "url": "https://clinicaltrials.gov/study/NCT04678206" }, { "title": "GSK, J.P. Morgan Healthcare Conference transcript", "url": "https://www.gsk.com/media/tsvlrat3/jp-morgan-healthcare-conference-transcript.pdf" }, { "title": "ClinicalTrials.gov: CALM-1, NCT05599191", "url": "https://clinicaltrials.gov/study/NCT05599191" }, { "title": "ClinicalTrials.gov: CALM-2, NCT05600777", "url": "https://clinicaltrials.gov/study/NCT05600777" }, { "title": "ClinicalTrials.gov: BALANCE, NCT07519395", "url": "https://clinicaltrials.gov/study/NCT07519395" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html", "title": "GSK 砸 20 億美元買止咳新藥，三期卻翻車！", "language": "zh-Hant", "datePublished": "2026-08-15", "dateModified": "2026-08-15", "summary": "GSK 約 20 億美元收購 BELLUS Health 後，camlipixant 的 CALM-1 達標、CALM-2 卻未能複製。這場第三期落差揭示：二期訊號、患者感受與可重現性必須一起過關。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.html", "title": "This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body", "language": "en", "datePublished": "2026-08-13", "dateModified": "2026-08-13", "summary": "Oligonucleotide therapeutics are moving from sequence design to extrahepatic delivery. Intelligene is using EV and LNP platforms to target the lung and airways, testing whether RNA medicines can truly reach disease sites beyond the liver.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Alnylam, Inceptive sign up to $2 billion AI drug discovery deal | Reuters", "url": "https://www.reuters.com/legal/litigation/alnylam-inceptive-sign-up-2-billion-ai-drug-discovery-deal-2026-06-03/" }, { "title": "The Leading RNAi Therapeutics Company | Alnylam", "url": "https://www.alnylam.com/" }, { "title": "Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B | GSK", "url": "https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/" }, { "title": "Intelligene — Core Technology", "url": "https://www.intelli-gene.com/en/research" }, { "title": "Intelligene — News and Media", "url": "https://www.intelli-gene.com/en/news" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html", "title": "這家台灣Biotech正在打造人體內奈米火箭", "language": "zh-Hant", "datePublished": "2026-08-13", "dateModified": "2026-08-13", "summary": "小核酸藥物的競爭正從 RNA 序列設計走向肝外遞送；智新生技以 EV 與 LNP 平台切入肺部與呼吸道，挑戰小核酸下半場最值錢的問題：能否真正抵達病灶。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Alnylam, Inceptive sign up to $2 billion AI drug discovery deal | Reuters", "url": "https://www.reuters.com/legal/litigation/alnylam-inceptive-sign-up-2-billion-ai-drug-discovery-deal-2026-06-03/" }, { "title": "The Leading RNAi Therapeutics Company | Alnylam", "url": "https://www.alnylam.com/" }, { "title": "Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B | GSK", "url": "https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/" }, { "title": "核心技術 - Intelligene Inc. | Innovate the cures of tomorrow.", "url": "https://www.intelli-gene.com/en/research" }, { "title": "媒體發表 - Intelligene Inc. | Innovate the cures of tomorrow.", "url": "https://www.intelli-gene.com/en/news" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html", "title": "Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk", "language": "en", "datePublished": "2026-08-13", "dateModified": "2026-08-13", "summary": "ZEUS showed the central translational risk in cardiovascular drug development: ziltivekimab suppressed the IL-6 pathway, but the 6,300-patient outcomes trial did not reduce three-point MACE.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Novo Nordisk ZEUS headline results", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916587" }, { "title": "ZEUS study registration", "url": "https://clinicaltrials.gov/study/NCT05021835" }, { "title": "RESCUE phase 2 trial", "url": "https://pubmed.ncbi.nlm.nih.gov/34015342/" }, { "title": "ILLUMINATE", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa0706628" }, { "title": "PROMINENT", "url": "https://pubmed.ncbi.nlm.nih.gov/36342113/" }, { "title": "STABILITY", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1315878" }, { "title": "VISTA-16", "url": "https://pubmed.ncbi.nlm.nih.gov/24247616/" }, { "title": "NORVIT", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa055227" }, { "title": "CANTOS", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1707914" }, { "title": "LoDoCo2", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2021372" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html", "title": "諾和諾德大三期慘敗！6,300 人的教科書級教訓", "language": "zh-Hant", "datePublished": "2026-08-13", "dateModified": "2026-08-13", "summary": "ZEUS 超過 6,300 人卻交出 HR 0.99：ziltivekimab 壓低 free IL-6 與 hsCRP，卻沒有證明能降低三點 MACE。這不是抗發炎假說死亡，而是 biomarker 不能替患者硬終點預支成功。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Novo Nordisk，ZEUS 第三期結果", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916587" }, { "title": "ZEUS 登錄", "url": "https://clinicaltrials.gov/study/NCT05021835" }, { "title": "RESCUE", "url": "https://pubmed.ncbi.nlm.nih.gov/34015342/" }, { "title": "ILLUMINATE", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa0706628" }, { "title": "PROMINENT", "url": "https://pubmed.ncbi.nlm.nih.gov/36342113/" }, { "title": "STABILITY", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1315878" }, { "title": "VISTA-16", "url": "https://pubmed.ncbi.nlm.nih.gov/24247616/" }, { "title": "NORVIT", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa055227" }, { "title": "CANTOS", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1707914" }, { "title": "LoDoCo2", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2021372" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd-en.html", "title": "Can $1.2 Billion Help AI Double the Pace of Drug R&D?", "language": "en", "datePublished": "2026-08-12", "dateModified": "2026-08-12", "summary": "The Bio Genesis Mission is an attempt to connect supercomputing, biomedical data, AI agents, automated laboratories, clinical networks, and regulation into one R&D loop. Its real test is whether governed data and reproducible experiments can reach patients faster.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "NIH - Bio Genesis Mission", "url": "https://www.nih.gov/bio-genesismission" }, { "title": "NIH Director - Statement on the Launch of the Bio Genesis Mission", "url": "https://www.nih.gov/about-nih/nih-director/statements/statement-launch-bio-genesis-mission-nihs-component-national-genesis-mission" }, { "title": "The White House - More Than $5 Billion for the Genesis Mission", "url": "https://www.whitehouse.gov/releases/2026/07/45502/" }, { "title": "Executive Order 14363 - Launching the Genesis Mission", "url": "https://www.federalregister.gov/documents/2025/11/28/2025-21665/launching-the-genesis-mission" }, { "title": "DOE - First Genesis Mission Projects Selected", "url": "https://www.energy.gov/articles/secretary-energy-chris-wright-announces-first-genesis-mission-projects-selected-accelerate" }, { "title": "DOE - More Than $800 Million in Partner Commitments", "url": "https://www.energy.gov/undersecretaryforscience/articles/us-department-energy-announces-more-800-million-partner" }, { "title": "HHS - HHS Joins the Genesis Mission", "url": "https://www.hhs.gov/press-room/hhs-joins-genesis-mission-ai-chronic-disease-research.html" }, { "title": "DOE - Genesis Mission Collaboration", "url": "https://www.energy.gov/undersecretaryforscience/genesis-mission/genesis-mission-collaboration" }, { "title": "TWSE Market Insights - AetherAI", "url": "https://www.twse.com.tw/market_insights/zh/detail/8a8216d69dbea9fd019e25ffea930207" }, { "title": "AetherAI - Our Service", "url": "https://www.aetherai.com/our-service" }, { "title": "AetherAI - About", "url": "https://www.aetherai.com/zh/about" }, { "title": "TWSE Market Insights - Genomics BioSci & Tech", "url": "https://www.twse.com.tw/market_insights/zh/detail/8a8216d69dbea9fd019dd856ecae00a6" }, { "title": "Genomics BioSci & Tech - Multi-Omics Services", "url": "https://www.genomics.com.tw/tw/product/product0?cate=cate1" }, { "title": "Genomics BioSci & Tech - CRDMO Services", "url": "https://www.genomics.com.tw/tw/product/product8?cate=cate3" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd.html", "title": "美國砸 12 億美元，想用 AI 把新藥研發快一倍！", "language": "zh-Hant", "datePublished": "2026-08-12", "dateModified": "2026-08-12", "summary": "美國以 Bio Genesis Mission 串起超算、生醫資料、AI 代理、自動化實驗、臨床與監管能力；真正的成敗不在模型口號，而在資料治理、實驗重現與患者轉譯能否形成閉環。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "NIH — Bio Genesis Mission", "url": "https://www.nih.gov/bio-genesismission" }, { "title": "NIH Director — Statement on the Launch of the Bio Genesis Mission", "url": "https://www.nih.gov/about-nih/nih-director/statements/statement-launch-bio-genesis-mission-nihs-component-national-genesis-mission" }, { "title": "The White House — More Than $5 Billion for the Genesis Mission", "url": "https://www.whitehouse.gov/releases/2026/07/45502/" }, { "title": "Executive Order 14363 — Launching the Genesis Mission", "url": "https://www.federalregister.gov/documents/2025/11/28/2025-21665/launching-the-genesis-mission" }, { "title": "DOE — First Genesis Mission Projects Selected", "url": "https://www.energy.gov/articles/secretary-energy-chris-wright-announces-first-genesis-mission-projects-selected-accelerate" }, { "title": "DOE — More Than $800 Million in Partner Commitments", "url": "https://www.energy.gov/undersecretaryforscience/articles/us-department-energy-announces-more-800-million-partner" }, { "title": "HHS — HHS Joins the Genesis Mission", "url": "https://www.hhs.gov/press-room/hhs-joins-genesis-mission-ai-chronic-disease-research.html" }, { "title": "DOE — Genesis Mission Collaboration", "url": "https://www.energy.gov/undersecretaryforscience/genesis-mission/genesis-mission-collaboration" }, { "title": "TWSE Market Insights — 雲象科技", "url": "https://www.twse.com.tw/market_insights/zh/detail/8a8216d69dbea9fd019e25ffea930207" }, { "title": "雲象科技 — Our Service", "url": "https://www.aetherai.com/our-service" }, { "title": "雲象科技 — About", "url": "https://www.aetherai.com/zh/about" }, { "title": "TWSE Market Insights — 基米", "url": "https://www.twse.com.tw/market_insights/zh/detail/8a8216d69dbea9fd019dd856ecae00a6" }, { "title": "基米 — 多體學服務", "url": "https://www.genomics.com.tw/tw/product/product0?cate=cate1" }, { "title": "基米 — CRDMO 服務", "url": "https://www.genomics.com.tw/tw/product/product8?cate=cate3" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html", "title": "After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone", "language": "en", "datePublished": "2026-08-11", "dateModified": "2026-08-11", "summary": "Chidamide has brought HDAC inhibition back into solid-tumor development. ABT-301 must now show that a wider therapeutic window, triplet combinability, and human immune-mechanism data can support a next-generation combination backbone.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "HUYABIO International Delivers Significant Landmark Phase 3 Results in Advanced Melanoma", "url": "https://huyabio.com/huyabio-international-delivers-significant-landmark-phase-3-results-in-advanced-melanoma/" }, { "title": "Combined anti-PD-1, histone deacetylase inhibitor and anti-VEGF treatment in MSS/pMMR colorectal cancer (Nature Medicine, CAPability-01)", "url": "https://www.nature.com/articles/s41591-024-02813-1" }, { "title": "Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor in patients with advanced solid tumors (JCO 2023 abstract e15137)", "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e15137" }, { "title": "Imofinostat - NCI Drug Dictionary", "url": "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imofinostat" }, { "title": "Anbogen Therapeutics - ABT-301 clinical and AACR updates", "url": "https://anbogen.com/en/news/cCCcD7dA6dcf" }, { "title": "ClinicalTrials.gov: ABT-301 + Tislelizumab + Bevacizumab in pMMR/non-MSI-H colorectal cancer", "url": "https://clinicaltrials.gov/study/NCT07244705" }, { "title": "Chipscreen Biosciences - Chidamide/Tucidinostat development history", "url": "https://www.chipscreen.com/en/news/company-news/1178.html" }, { "title": "Phase II randomized trial of first-line pembrolizumab and vorinostat in metastatic NSCLC: final results", "url": "https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9125" }, { "title": "Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial", "url": "https://www.nature.com/articles/s43018-025-01004-2" }, { "title": "Anbogen Therapeutics Pre-TPEx Investor Presentation (2026)", "url": "https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf" }, { "title": "Credence Research: Global Checkpoint Inhibitor Refractory Cancer Drugs Market", "url": "https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market" }, { "title": "Pancreatic Cancer Market Size and Forecase 2026-2035 (Research Nester)", "url": "https://www.researchnester.com/reports/pancreatic-cancer-market/5299" }, { "title": "Brain Cancer Market Trends for 2026 (Towards Healthcare)", "url": "https://www.towardshealthcare.com/insights/brain-cancer-market-sizing" }, { "title": "Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer", "url": "https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html", "title": "20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹", "language": "zh-Hant", "datePublished": "2026-08-11", "dateModified": "2026-08-11", "summary": "Chidamide以pMMR大腸癌44% ORR與黑色素瘤第三期PFS達標，重新降低HDAC抑制劑的類別風險；安邦ABT-301接下來必須用治療窗口、三聯可組合性與人體免疫機轉，證明資產差異。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "HUYABIO International Delivers Significant Landmark Phase 3 Results in Advanced Melanoma", "url": "https://huyabio.com/huyabio-international-delivers-significant-landmark-phase-3-results-in-advanced-melanoma/" }, { "title": "Combined anti-PD-1, histone deacetylase inhibitor and anti-VEGF treatment in MSS/pMMR colorectal cancer (Nature Medicine, CAPability-01)", "url": "https://www.nature.com/articles/s41591-024-02813-1" }, { "title": "Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor in patients with advanced solid tumors (JCO 2023 abstract e15137)", "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e15137" }, { "title": "Imofinostat - NCI Drug Dictionary", "url": "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imofinostat" }, { "title": "Anbogen Therapeutics - ABT-301 clinical and AACR updates", "url": "https://anbogen.com/en/news/cCCcD7dA6dcf" }, { "title": "ClinicalTrials.gov: ABT-301 + Tislelizumab + Bevacizumab in pMMR/non-MSI-H colorectal cancer", "url": "https://clinicaltrials.gov/study/NCT07244705" }, { "title": "Chipscreen Biosciences - Chidamide/Tucidinostat development history", "url": "https://www.chipscreen.com/en/news/company-news/1178.html" }, { "title": "Phase II randomized trial of first-line pembrolizumab and vorinostat in metastatic NSCLC: final results", "url": "https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9125" }, { "title": "Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial", "url": "https://www.nature.com/articles/s43018-025-01004-2" }, { "title": "安邦興櫃前法說會簡報 (2026)", "url": "https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf" }, { "title": "Credence Research: Global Checkpoint Inhibitor Refractory Cancer Drugs Market", "url": "https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market" }, { "title": "Pancreatic Cancer Market Size and Forecase 2026-2035 (Research Nester)", "url": "https://www.researchnester.com/reports/pancreatic-cancer-market/5299" }, { "title": "Brain Cancer Market Trends for 2026 (Towards Healthcare)", "url": "https://www.towardshealthcare.com/insights/brain-cancer-market-sizing" }, { "title": "Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer", "url": "https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.html", "title": "$130 Billion in Six Months: Big Pharma Is Buying Time", "language": "en", "datePublished": "2026-08-10", "dateModified": "2026-08-10", "summary": "Biopharma M&A reached approximately $130 billion in the first half of 2026 as buyers favored late-stage and near-launch assets. This is not a broad biotech bull market; it is Big Pharma using cash and contingent deal structures to buy measurable development time before the patent cliff.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "BioSpace, H1 2026 M&A count and methodology", "url": "https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend" }, { "title": "IQVIA, Biopharma M&A: Mid-year 2026 update", "url": "https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update" }, { "title": "PwC, US Deals 2026 midyear outlook", "url": "https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html" }, { "title": "Merck/Terns transaction agreement", "url": "https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/" }, { "title": "Merck completion of Terns acquisition", "url": "https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/" }, { "title": "AbbVie/Apogee transaction announcement", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology" }, { "title": "Gilead completion of Arcellx acquisition", "url": "https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel" }, { "title": "Gilead completion of Tubulis acquisition", "url": "https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx" }, { "title": "GSK/Nuvalent transaction agreement", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/" }, { "title": "GSK completion of Nuvalent acquisition", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/" }, { "title": "Sun Pharma/Organon definitive agreement", "url": "https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html", "title": "禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！", "language": "zh-Hant", "datePublished": "2026-08-10", "dateModified": "2026-08-10", "summary": "2026 年上半年生技製藥併購總額約 1,300 億美元，買家偏向臨床後期與接近上市的資產。這一輪不是全面牛市，而是大藥廠在專利懸崖前，用交易結構與現金購買可計算的開發時間。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "BioSpace, H1 2026 M&A count and methodology", "url": "https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend" }, { "title": "IQVIA, Biopharma M&A: Mid-year 2026 update", "url": "https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update" }, { "title": "PwC, US Deals 2026 midyear outlook", "url": "https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html" }, { "title": "Merck／Terns transaction agreement", "url": "https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/" }, { "title": "Merck completion of Terns acquisition", "url": "https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/" }, { "title": "AbbVie／Apogee transaction announcement", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology" }, { "title": "Gilead completion of Arcellx acquisition", "url": "https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel" }, { "title": "Gilead completion of Tubulis acquisition", "url": "https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx" }, { "title": "GSK／Nuvalent transaction agreement", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/" }, { "title": "GSK completion of Nuvalent acquisition", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/" }, { "title": "Sun Pharma／Organon definitive agreement", "url": "https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.html", "title": "J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables?", "language": "en", "datePublished": "2026-08-09", "dateModified": "2026-08-09", "summary": "ICOTYDE logged more than 18,000 prescriptions in its first full quarter. The oral IL-23R peptide has earned entry into the high-efficacy psoriasis market, but durable value still depends on paid fills, persistence, payer quality, safety, and additional indications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "FDA ICOTYDE label", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf" }, { "title": "FDA multidisciplinary review", "url": "https://www.fda.gov/media/192646/download" }, { "title": "J&J FDA approval release", "url": "https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide" }, { "title": "J&J 2025 PASI 90 maintenance results", "url": "https://www.investor.jnj.com/investor-news/news-details/2025/Icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-reinforcing-promise-of-novel-targeted-oral-peptide-for-treatment-of-plaque-psoriasis/default.aspx" }, { "title": "J&J one-year results", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/ICOTYDE-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-oncedaily-pill-for-plaque-psoriasis/default.aspx" }, { "title": "J&J second-quarter 2026 results", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx" }, { "title": "J&J second-quarter 2026 earnings call transcript", "url": "https://s203.q4cdn.com/636242992/files/doc_financials/2026/q2/JNJ-USQ_Transcript_2026-07-15.pdf" }, { "title": "J&J development pipeline", "url": "https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html", "title": "嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？", "language": "zh-Hant", "datePublished": "2026-08-09", "dateModified": "2026-08-09", "summary": "ICOTYDE 上市後第一個完整季度累積逾 18,000 張處方。口服 IL-23R 胜肽已取得進入高療效市場的資格，真正的商業答案仍取決於續方、支付品質、長期留存與多適應症。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "FDA ICOTYDE label", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf" }, { "title": "FDA multidisciplinary review", "url": "https://www.fda.gov/media/192646/download" }, { "title": "J&J FDA approval release", "url": "https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide" }, { "title": "J&J 2025 PASI 90 維持資料", "url": "https://www.investor.jnj.com/investor-news/news-details/2025/Icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-reinforcing-promise-of-novel-targeted-oral-peptide-for-treatment-of-plaque-psoriasis/default.aspx" }, { "title": "J&J one-year results", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/ICOTYDE-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-oncedaily-pill-for-plaque-psoriasis/default.aspx" }, { "title": "J&J 2026 Q2 results", "url": "https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx" }, { "title": "J&J 2026 Q2 earnings call transcript", "url": "https://s203.q4cdn.com/636242992/files/doc_financials/2026/q2/JNJ-USQ_Transcript_2026-07-15.pdf" }, { "title": "J&J development pipeline", "url": "https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling-en.html", "title": "Why These Four Biotechs Can Afford Not to Sell", "language": "en", "datePublished": "2026-08-08", "dateModified": "2026-08-08", "summary": "argenx, Insmed, Incyte, and Revolution Medicines show why biotech independence depends on product evidence, cash generation, a second growth curve, global execution, and financing without surrendering control.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "argenx FY2025 results", "url": "https://argenx.com/news/2026/press-release-3245199" }, { "title": "argenx 2025 Annual Report", "url": "https://reports.argenx.com/2025/" }, { "title": "argenx H1 and Q2 2026 results", "url": "https://argenx.com/news/2026/press-release-3331862.html" }, { "title": "Insmed FY2025 results", "url": "https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm" }, { "title": "Insmed Q2 2026 results", "url": "https://investor.insmed.com/2026-08-06-Insmed-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed SEC filings", "url": "https://investor.insmed.com/financial-information/sec-filings" }, { "title": "Incyte FY2025 results", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2025-financial" }, { "title": "Incyte 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm" }, { "title": "Incyte Q1 2026 results", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides" }, { "title": "Revolution Medicines RASolute 302 detailed results", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-asco-plenary-presentation" }, { "title": "Revolution Medicines EMA phased review release", "url": "https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution" }, { "title": "FDA accepts the daraxonrasib NDA for review", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/" }, { "title": "Revolution Medicines Q1 2026 results", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-first-quarter-2026-financial/" }, { "title": "Revolution Medicines Q1 2026 Form 10-Q", "url": "https://ir.revmed.com/static-files/e7a99744-380a-4fa9-93b6-2fb71793c8ee" }, { "title": "Revolution Medicines April 2026 offering 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1628171/000119312526159289/d95226d8k.htm" }, { "title": "Royalty Pharma and Revolution Medicines funding agreement", "url": "https://www.royaltypharma.com/news/royalty-pharma-and-revolution-medicines-enter-into-funding-agreements-for-up-to-2-billion/" }, { "title": "Royalty Pharma 2026-04-13 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html", "title": "不賣給大藥廠，4 家生技公司憑什麼自己做大？", "language": "zh-Hant", "datePublished": "2026-08-08", "dateModified": "2026-08-08", "summary": "argenx、Insmed、Incyte 與 Revolution Medicines 選擇保留獨立經營權。真正的不賣資格，來自產品證據、現金引擎、第二曲線、全球執行與不交出控制權也能取得資金的能力。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "argenx FY2025 財務結果", "url": "https://argenx.com/news/2026/press-release-3245199" }, { "title": "argenx 2026 H1／Q2 財務結果", "url": "https://argenx.com/news/2026/press-release-3331862.html" }, { "title": "Insmed FY2025 財務結果", "url": "https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed 2026 Q2 財務結果", "url": "https://investor.insmed.com/2026-08-06-Insmed-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed SEC filings", "url": "https://investor.insmed.com/financial-information/sec-filings" }, { "title": "Incyte FY2025 財務結果", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2025-financial" }, { "title": "Incyte 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm" }, { "title": "Incyte 2026 Q1 財務結果", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides" }, { "title": "Revolution Medicines RASolute 302 第三期結果", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-asco-plenary-presentation" }, { "title": "Revolution Medicines EMA phased review 公告", "url": "https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution" }, { "title": "FDA 接受 daraxonrasib NDA 審查公告", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-new-drug-application-daraxonrasib-accepted/" }, { "title": "Revolution Medicines 2026 Q1 財務結果", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-first-quarter-2026-financial/" }, { "title": "Revolution Medicines 2026 Q1 Form 10-Q", "url": "https://ir.revmed.com/static-files/e7a99744-380a-4fa9-93b6-2fb71793c8ee" }, { "title": "Revolution Medicines 2026 年 4 月融資 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1628171/000119312526159289/d95226d8k.htm" }, { "title": "Royalty Pharma 與 Revolution Medicines 融資協議", "url": "https://www.royaltypharma.com/news/royalty-pharma-and-revolution-medicines-enter-into-funding-agreements-for-up-to-2-billion/" }, { "title": "Royalty Pharma 2026-04-13 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition-en.html", "title": "$2.2 Billion for the Next Autoimmune Blockbuster?", "language": "en", "datePublished": "2026-08-07", "dateModified": "2026-08-07", "summary": "argenx plans to pay $2.2 billion in cash for Forte and its early anti-CD122 antibody FB102. The real test is not one Phase 1b p-value, but whether VYVGART's product success reflects a development engine the company can repeat.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "argenx, “argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline,” July 27, 2026", "url": "https://argenx.com/news/2026/press-release-3333257.html" }, { "title": "Forte Biosciences, Form 8-K and merger agreement, July 27, 2026", "url": "https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm" }, { "title": "argenx, first-half 2026 financial results and second-quarter business update", "url": "https://argenx.com/news/2026/press-release-3331862.html" }, { "title": "Forte Biosciences, FB102 Phase 1b celiac disease results", "url": "https://www.fortebiorx.com/investor-relations/news/news-details/2025/Forte-Biosciences-Announces-Positive-Data-in-FB102-Celiac-Disease-Phase-1B-Study/default.aspx" }, { "title": "Forte Biosciences, FB102 Phase 1b vitiligo results", "url": "https://www.fortebiorx.com/investor-relations/news/news-details/2026/FB102-Achieves-Statistically-Significant-Improvement-in-Vitiligo-at-Week-24-After-Completion-of-12-Week-Treatment-Period/default.aspx" }, { "title": "ClinicalTrials.gov, celiac disease Phase 2, NCT06982963", "url": "https://clinicaltrials.gov/study/NCT06982963" }, { "title": "ClinicalTrials.gov, vitiligo Phase 1, NCT06905873", "url": "https://clinicaltrials.gov/study/NCT06905873" }, { "title": "argenx and Zai Lab, Greater China collaboration for efgartigimod", "url": "https://argenx.com/news/2021/argenx-and-zai-lab-announce-strategic-collaboration-efgartigimod-greater-china" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html", "title": "22 億美元，買下一個自體免疫藥王？", "language": "zh-Hant", "datePublished": "2026-08-07", "dateModified": "2026-08-07", "summary": "argenx 擬以 22 億美元現金收購 Forte，把早期抗 CD122 抗體 FB102 納入管線。真正的考題不是一組一期 p 值，而是 VYVGART 的單品成功能否被複製成可重複的公司能力。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "argenx.com", "url": "https://argenx.com/news/2026/press-release-3333257.html" }, { "title": "sec.gov", "url": "https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm" }, { "title": "argenx.com", "url": "https://argenx.com/news/2026/press-release-3331862.html" }, { "title": "fortebiorx.com", "url": "https://www.fortebiorx.com/investor-relations/news/news-details/2025/Forte-Biosciences-Announces-Positive-Data-in-FB102-Celiac-Disease-Phase-1B-Study/default.aspx" }, { "title": "fortebiorx.com", "url": "https://www.fortebiorx.com/investor-relations/news/news-details/2026/FB102-Achieves-Statistically-Significant-Improvement-in-Vitiligo-at-Week-24-After-Completion-of-12-Week-Treatment-Period/default.aspx" }, { "title": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT06982963" }, { "title": "clinicaltrials.gov", "url": "https://clinicaltrials.gov/study/NCT06905873" }, { "title": "argenx.com", "url": "https://argenx.com/news/2021/argenx-and-zai-lab-announce-strategic-collaboration-efgartigimod-greater-china" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html", "title": "Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster", "language": "en", "datePublished": "2026-08-06", "dateModified": "2026-08-06", "summary": "Lilly has placed a $40 million bet on next-generation hair-loss drugs. With roughly 80 million U.S. patients still constrained by two legacy therapies, AH-001's Phase 2 data could become the next global asset-revaluation trigger.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Veradermics | S-1: U.S. pattern hair-loss population, treatment penetration, satisfaction, and market estimates", "url": "https://www.sec.gov/Archives/edgar/data/1827635/000162828026001651/veradermicsincs-1.htm" }, { "title": "Veradermics | Positive topline results from VDPHL01 Study 302 (April 27, 2026)", "url": "https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/exhibit991-8xk.htm" }, { "title": "Investor's Business Daily | One-day market reaction following Study 302", "url": "https://www.investors.com/news/technology/veradermics-ipo-stock-oral-rogaine/" }, { "title": "Eli Lilly | Olumiant (baricitinib) for severe alopecia areata", "url": "https://olumiant.lilly.com/alopecia-areata" }, { "title": "Veradermics | IPO prospectus: Lilly indication of interest (non-binding)", "url": "https://www.sec.gov/Archives/edgar/data/1827635/000162828026005505/veradermicsinc424b4.htm" }, { "title": "Absci | Prospectus supplement: $40 million share allocation to Eli Lilly", "url": "https://investors.absci.com/static-files/5d70b681-4b5b-4830-9578-3a0e8473b3f4" }, { "title": "Absci | ABS-201 for androgenetic alopecia / HEADLINE Phase 1/2a", "url": "https://www.absci.com/abs-201-case-study/" }, { "title": "ClinicalTrials.gov | AH-001 Phase 1, NCT06927960", "url": "https://clinicaltrials.gov/study/NCT06927960" }, { "title": "AnHorn Medicines | AH-001 completes U.S. Phase 1 (October 30, 2025)", "url": "https://www.anhornmed.com/zh-hant/news/ai-design-ah001-protein-degrader-phase1-complete/" }, { "title": "AnHorn Medicines | AH-008 receives FDA IND clearance and CDE Index Case designation", "url": "https://www.anhornmed.com/news/ah008-ind-cipn/" }, { "title": "Kintor Pharmaceutical | KX-826 Phase 3 met the primary endpoint", "url": "https://en.kintor.com.cn/news_details/22.html" }, { "title": "Kintor Pharmaceutical | GT20029 China Phase 2 met the primary endpoint", "url": "https://en.kintor.com.cn/news_details/1803365125008502784.html" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html", "title": "投資人請注意，下一個減肥藥級別賽道來了！", "language": "zh-Hant", "datePublished": "2026-08-06", "dateModified": "2026-08-06", "summary": "禮來用 4,000 萬美元卡位掉髮新藥；當美國約 8,000 萬名患者仍受限於兩款老藥，安宏 AH-001 的二期數據可能成為下一次全球資產重估關鍵。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Veradermics｜S-1：美國型態性落髮患者、治療滲透率、滿意度與市場估算", "url": "https://www.sec.gov/Archives/edgar/data/1827635/000162828026001651/veradermicsincs-1.htm" }, { "title": "Veradermics｜Study 302 Phase 2/3 正向頂線資料（2026-04-27）", "url": "https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/exhibit991-8xk.htm" }, { "title": "Investor's Business Daily｜Study 302 公布後股價單日反應", "url": "https://www.investors.com/news/technology/veradermics-ipo-stock-oral-rogaine/" }, { "title": "Eli Lilly｜Olumiant（baricitinib）嚴重圓禿適應症", "url": "https://olumiant.lilly.com/alopecia-areata" }, { "title": "Veradermics｜IPO Prospectus：禮來認購意向（非具約束力）", "url": "https://www.sec.gov/Archives/edgar/data/1827635/000162828026005505/veradermicsinc424b4.htm" }, { "title": "Absci｜Prospectus Supplement：4,000 萬美元股份配置給 Eli Lilly", "url": "https://investors.absci.com/static-files/5d70b681-4b5b-4830-9578-3a0e8473b3f4" }, { "title": "Absci｜ABS-201 for Androgenetic Alopecia／HEADLINE Phase 1/2a", "url": "https://www.absci.com/abs-201-case-study/" }, { "title": "ClinicalTrials.gov｜AH-001 Phase I，NCT06927960", "url": "https://clinicaltrials.gov/study/NCT06927960" }, { "title": "AnHorn Medicines｜AH-001 完成美國 Phase I（2025-10-30）", "url": "https://www.anhornmed.com/zh-hant/news/ai-design-ah001-protein-degrader-phase1-complete/" }, { "title": "AnHorn Medicines｜AH-008 取得 FDA IND clearance 與 CDE Index Case designation", "url": "https://www.anhornmed.com/news/ah008-ind-cipn/" }, { "title": "Kintor Pharmaceutical｜KX-826 Phase III 達主要終點", "url": "https://en.kintor.com.cn/news_details/22.html" }, { "title": "Kintor Pharmaceutical｜GT20029 中國 Phase II 達主要終點", "url": "https://en.kintor.com.cn/news_details/1803365125008502784.html" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html", "title": "More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%?", "language": "en", "datePublished": "2026-08-05", "dateModified": "2026-08-05", "summary": "Amvuttra surpassed $1 billion in quarterly sales, yet Alnylam cut its TTR guidance and lost 28% in one day. The reset was not about RNAi technology failing; it was about pent-up demand normalizing, revenue concentration and the timing gap before a second commercial pillar arrives.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Alnylam, 2026 Q2 financial results and full-year guidance update", "url": "https://investors.alnylam.com/press-release?id=29986" }, { "title": "Alnylam, 2026 Q2 Form 10-Q", "url": "https://alnylampharmaceuticalsinc.gcs-web.com/static-files/df2ac46c-f252-4864-97e7-02db276e70db" }, { "title": "U.S. Food and Drug Administration, Amvuttra (vutrisiran) prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215515s006lbl.pdf" }, { "title": "Ionis, CARDIO-TTRansform topline results", "url": "https://ir.ionis.com/node/34896" }, { "title": "U.S. Food and Drug Administration, Attruby approval announcement", "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis" }, { "title": "ClinicalTrials.gov, TRITON-CM (NCT07052903)", "url": "https://clinicaltrials.gov/study/NCT07052903" }, { "title": "Nasdaq, ALNY historical trading data", "url": "https://www.nasdaq.com/market-activity/stocks/alny/historical" }, { "title": "Oneness Biotech, SNS851 Phase 1 and co-development announcement", "url": "https://onenessbio.com/en/a-phase-1-clinical-trial-of-sns851-has-been-approved-by-australia-hrec-and-acknowledged-by-australia-tga/" }, { "title": "Microbio, SNS851 co-development announcement", "url": "https://www.twmicrobio.com/tw/%E9%87%8D%E5%A4%A7%E8%A8%8A%E6%81%AF-17/" }, { "title": "Genomics, short-chain nucleic acid and siRNA API capabilities (2024 annual report)", "url": "https://www.genomics.com.tw/upload/2025_09_11/2_202509111525141hcglwe9Y0.pdf" }, { "title": "Taipei Exchange, IntelliGene (7832) company overview and RNAi/delivery research and development", "url": "https://www.tpex.org.tw/storage/emerging_register/2025/04/1745477059_14400_CH_7832.pdf" }, { "title": "IntelliGene, core technologies and IG-001/IG-002", "url": "https://www.intelli-gene.com/tech" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html", "title": "一季賣破 10 億，Alnylam 為何崩 28%？", "language": "zh-Hant", "datePublished": "2026-08-05", "dateModified": "2026-08-05", "summary": "Amvuttra 單季銷售突破 10 億美元，Alnylam 卻下修 TTR 指引並重挫 28%。真正被重估的不是 RNAi 技術，而是積壓需求退潮、收入集中與下一個商業支柱的時間差。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Alnylam｜2026 Q2 財務結果與全年指引更新", "url": "https://investors.alnylam.com/press-release?id=29986" }, { "title": "Alnylam｜2026 Q2 Form 10-Q", "url": "https://alnylampharmaceuticalsinc.gcs-web.com/static-files/df2ac46c-f252-4864-97e7-02db276e70db" }, { "title": "FDA｜Amvuttra（vutrisiran）處方標籤", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215515s006lbl.pdf" }, { "title": "Ionis｜CARDIO-TTRansform topline 結果", "url": "https://ir.ionis.com/node/34896" }, { "title": "FDA｜Attruby 核准公告", "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis" }, { "title": "ClinicalTrials.gov｜TRITON-CM（NCT07052903）", "url": "https://clinicaltrials.gov/study/NCT07052903" }, { "title": "Nasdaq｜ALNY 歷史交易資料", "url": "https://www.nasdaq.com/market-activity/stocks/alny/historical" }, { "title": "合一｜SNS851 一期與共同開發公告", "url": "https://onenessbio.com/en/a-phase-1-clinical-trial-of-sns851-has-been-approved-by-australia-hrec-and-acknowledged-by-australia-tga/" }, { "title": "中天｜SNS851 共同開發公告", "url": "https://www.twmicrobio.com/tw/%E9%87%8D%E5%A4%A7%E8%A8%8A%E6%81%AF-17/" }, { "title": "基米｜短鏈核酸與 siRNA API 能力（2024 年報）", "url": "https://www.genomics.com.tw/upload/2025_09_11/2_202509111525141hcglwe9Y0.pdf" }, { "title": "櫃買中心｜智新生技（7832）公司概況與 RNAi／遞送研發", "url": "https://www.tpex.org.tw/storage/emerging_register/2025/04/1745477059_14400_CH_7832.pdf" }, { "title": "智新生技｜核心技術與 IG-001／IG-002", "url": "https://www.intelli-gene.com/tech" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks-en.html", "title": "A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking", "language": "en", "datePublished": "2026-08-04", "dateModified": "2026-08-04", "summary": "AstraZeneca and BMS reportedly explored a combination with a combined market value approaching $400 billion. There is no announced transaction. The real questions are AstraZeneca's 2030 growth target, BMS's Eliquis and Opdivo exclusivity timeline, oncology-pipeline overlap, antitrust and whether integration can actually buy time.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Financial Times | AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up", "url": "https://www.ft.com/content/e9027253-e13c-460a-a4b1-f9047e5a6ca7" }, { "title": "Reuters | AstraZeneca shares fall on Bristol Myers Squibb merger talks", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-shares-fall-bristol-myers-squibb-merger-talks-2026-08-03/" }, { "title": "AstraZeneca | 2025 Form 20-F", "url": "https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm" }, { "title": "AstraZeneca | $80 billion revenue ambition for 2030", "url": "https://news.cision.com/astrazeneca/r/astrazeneca-to-deliver--80bn-revenue-by-2030%2Cc3984754" }, { "title": "Bristol Myers Squibb | 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm" }, { "title": "Bristol Myers Squibb | Second-quarter 2026 financial results", "url": "https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2026/default.aspx" }, { "title": "Federal Trade Commission | Final order in the BMS-Celgene transaction", "url": "https://www.ftc.gov/news-events/news/press-releases/2020/01/ftc-approves-final-order-requiring-bristol-myers-squibb-company-celgene-corporation-divest-psoriasis" }, { "title": "ClinicalTrials.gov | NCT07100080", "url": "https://clinicaltrials.gov/study/NCT07100080" }, { "title": "ClinicalTrials.gov | NCT07431281", "url": "https://clinicaltrials.gov/study/NCT07431281" }, { "title": "ClinicalTrials.gov | NCT03298451", "url": "https://clinicaltrials.gov/study/NCT03298451" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html", "title": "超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！", "language": "zh-Hant", "datePublished": "2026-08-04", "dateModified": "2026-08-04", "summary": "Financial Times 報導 AstraZeneca 與 BMS 曾探討結合，合計市值接近 4,000 億美元。這不是已簽交易；真正的產業問題是 2030 成長、Eliquis／Opdivo 獨占期、腫瘤管線重疊、反壟斷與整合能否買到時間。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Financial Times｜AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up", "url": "https://www.ft.com/content/e9027253-e13c-460a-a4b1-f9047e5a6ca7" }, { "title": "Reuters｜AstraZeneca shares fall on Bristol Myers Squibb merger talks", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-shares-fall-bristol-myers-squibb-merger-talks-2026-08-03/" }, { "title": "AstraZeneca｜2025 Form 20-F", "url": "https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm" }, { "title": "AstraZeneca｜2030 年 800 億美元營收目標", "url": "https://news.cision.com/astrazeneca/r/astrazeneca-to-deliver--80bn-revenue-by-2030%2Cc3984754" }, { "title": "Bristol Myers Squibb｜2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm" }, { "title": "Bristol Myers Squibb｜2026 年第二季財報", "url": "https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2026/default.aspx" }, { "title": "FTC｜BMS／Celgene 最終命令", "url": "https://www.ftc.gov/news-events/news/press-releases/2020/01/ftc-approves-final-order-requiring-bristol-myers-squibb-company-celgene-corporation-divest-psoriasis" }, { "title": "ClinicalTrials.gov｜NCT07100080", "url": "https://clinicaltrials.gov/study/NCT07100080" }, { "title": "ClinicalTrials.gov｜NCT07431281", "url": "https://clinicaltrials.gov/study/NCT07431281" }, { "title": "ClinicalTrials.gov｜NCT03298451", "url": "https://clinicaltrials.gov/study/NCT03298451" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3-en.html", "title": "Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint", "language": "en", "datePublished": "2026-08-03", "dateModified": "2026-08-03", "summary": "CELIA missed its prespecified dose-response primary endpoint, yet the lowest dose produced a 0.54-point CDR-SB difference, or 26% slowing, while CSF total tau and tau PET moved in the expected direction. That is enough to justify Phase 3 planning, but not enough to declare tau a validated second disease-modifying pathway.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "AAIC 2026 official program, London, July 12–15, 2026:", "url": "https://aaic.alz.org/program/schedule.asp" }, { "title": "ClinicalTrials.gov, CELIA, NCT05399888:", "url": "https://clinicaltrials.gov/study/NCT05399888" }, { "title": "Biogen, complete CELIA Phase 2 data:", "url": "https://investors.biogen.com/node/30826" }, { "title": "Ionis, diranersen and CELIA announcement:", "url": "https://ir.ionis.com/node/34616" }, { "title": "Alzheimer's Association, 2026 drug-development pipeline overview:", "url": "https://www.alz.org/news/2026/alzheimers-disease-drug-development-pipeline-is-growing" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3.html", "title": "Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？", "language": "zh-Hant", "datePublished": "2026-08-03", "dateModified": "2026-08-03", "summary": "CELIA 未達預設劑量反應主要終點，最低劑量卻在 CDR-SB 看到 26% 惡化減緩，CSF total tau 與 Tau PET 也同向下降。這些訊號足以讓 Biogen 與 Ionis 規劃三期，還不足以宣布 Tau 已成為第二條獲確認的疾病修飾路線。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "AAIC 2026 官方日程（London，2026/7/12–7/15）", "url": "https://aaic.alz.org/program/schedule.asp" }, { "title": "ClinicalTrials.gov，CELIA（NCT05399888）", "url": "https://clinicaltrials.gov/study/NCT05399888" }, { "title": "Biogen，CELIA Phase 2 完整資料", "url": "https://investors.biogen.com/node/30826" }, { "title": "Ionis，diranersen／CELIA 公告", "url": "https://ir.ionis.com/node/34616" }, { "title": "Alzheimer's Association，2026 藥物研發管線總覽", "url": "https://www.alz.org/news/2026/alzheimers-disease-drug-development-pipeline-is-growing" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.html", "title": "Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors", "language": "en", "datePublished": "2026-08-02", "dateModified": "2026-08-02", "summary": "Q32 Bio nearly doubled after a 33-patient, single-arm Phase 2a readout. The investable questions are whether efficacy survives randomization, whether responses persist after treatment stops, and whether a larger safety database can support a differentiated place beside JAK inhibitors.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Q32 Bio, SIGNAL-AA Part B Week 36 topline results:", "url": "https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-positive-36-week-topline-results-part-b-signal" }, { "title": "ClinicalTrials.gov, SIGNAL-AA (NCT06018428):", "url": "https://clinicaltrials.gov/study/NCT06018428" }, { "title": "Q32 Bio, pricing of the $200 million public offering:", "url": "https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-pricing-200-million-public-offering-common/" }, { "title": "Q32 Bio SEC filing:", "url": "https://ir.q32bio.com/node/10981/html" }, { "title": "AbbVie, FDA submission for upadacitinib in severe alopecia areata:", "url": "https://news.abbvie.com/2026-04-28-AbbVie-Submits-Application-to-FDA-for-Upadacitinib-RINVOQ-R-for-Adults-and-Adolescents-with-Severe-Alopecia-Areata" }, { "title": "Nektar, 52-week REZOLVE-AA results and development stage:", "url": "https://ir.nektar.com/news-releases/news-release-details/52-week-topline-results-16-week-blinded-treatment-extension" }, { "title": "Nasdaq, QTTB historical prices:", "url": "https://www.nasdaq.com/market-activity/stocks/qttb/historical" } ] }, { "url": "https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html", "title": "鬼剃頭新藥，先別封神", "language": "zh-Hant", "datePublished": "2026-08-02", "dateModified": "2026-08-02", "summary": "33 人、單臂、開放標籤的 Phase 2a 資料讓 Q32 Bio 股價近乎翻倍；真正的問題是療效能否重現、停藥後能否維持，以及安全性是否足以改變 JAK 抑制劑的臨床位置。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Q32 Bio，SIGNAL-AA Part B 36 週頂線結果", "url": "https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-positive-36-week-topline-results-part-b-signal" }, { "title": "ClinicalTrials.gov，SIGNAL-AA（NCT06018428）", "url": "https://clinicaltrials.gov/study/NCT06018428" }, { "title": "Q32 Bio，2 億美元公開發行定價", "url": "https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-pricing-200-million-public-offering-common/" }, { "title": "Q32 Bio SEC filing", "url": "https://ir.q32bio.com/node/10981/html" }, { "title": "AbbVie，upadacitinib 斑禿適應症 FDA 申請", "url": "https://news.abbvie.com/2026-04-28-AbbVie-Submits-Application-to-FDA-for-Upadacitinib-RINVOQ-R-for-Adults-and-Adolescents-with-Severe-Alopecia-Areata" }, { "title": "Nektar，REZOLVE-AA 52 週資料與開發期別", "url": "https://ir.nektar.com/news-releases/news-release-details/52-week-topline-results-16-week-blinded-treatment-extension" }, { "title": "Nasdaq，QTTB 歷史價格", "url": "https://www.nasdaq.com/market-activity/stocks/qttb/historical" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html", "title": "AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy", "language": "en", "datePublished": "2026-07-31", "dateModified": "2026-07-31", "summary": "Can a small molecule from Taiwan extend the $30 billion PD-1 ecosystem into the 95% of metastatic colorectal cancer patients still beyond immunotherapy’s reach?", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Starlink | Technology", "url": "https://starlink.com/technology" }, { "title": "Merck | 2025 Form 10-K", "url": "https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf" }, { "title": "BeOne Medicines | 2025 Full-Year Results", "url": "https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/exhibit991-q42025earningsr.htm" }, { "title": "AnBogen Therapeutics | ABT-301 Triple Therapy Phase 1/2 Study", "url": "https://anbogen.com/en/news/cCCcD7dA6dcf" }, { "title": "Nature Medicine / PubMed | Triple Therapy in MSS/pMMR Metastatic Colorectal Cancer", "url": "https://pubmed.ncbi.nlm.nih.gov/38438735/" }, { "title": "AnBogen Therapeutics | 2026 AACR ABT-301 Research", "url": "https://anbogen.com/en/news/E6B4eB8309E6" }, { "title": "Credence Research | Global Checkpoint Inhibitor-Refractory Cancer Drugs Market", "url": "https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market" }, { "title": "AnBogen Therapeutics | Innovation Pipeline: ABT-500 Series, ABT-501, ABT-502, and ABT-505", "url": "https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html", "title": "安邦生技：免疫治療的「星鏈計畫」", "language": "zh-Hant", "datePublished": "2026-07-31", "dateModified": "2026-07-31", "summary": "一顆台灣小分子，有機會把三百億美元級PD-1藥王送進九成五患者仍無法受益的治療盲區嗎？", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Starlink｜Technology", "url": "https://starlink.com/technology" }, { "title": "Merck｜2025 Form 10-K", "url": "https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf" }, { "title": "BeOne Medicines｜2025 Full-Year Results", "url": "https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/exhibit991-q42025earningsr.htm" }, { "title": "安邦生技｜ABT-301三聯療法Phase 1/2試驗", "url": "https://anbogen.com/en/news/cCCcD7dA6dcf" }, { "title": "Nature Medicine／PubMed｜MSS／pMMR大腸直腸癌三聯療法研究", "url": "https://pubmed.ncbi.nlm.nih.gov/38438735/" }, { "title": "安邦生技｜2026 AACR ABT-301 Research", "url": "https://anbogen.com/en/news/E6B4eB8309E6" }, { "title": "Credence Research: Global Checkpoint Inhibitor Refractory Cancer Drugs Market", "url": "https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market" }, { "title": "安邦生技｜創新研發：ABT-500系列、ABT-501、ABT-502與ABT-505", "url": "https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html", "title": "After Xtandi: Can Astellas Build an Oncology Platform?", "language": "en", "datePublished": "2026-07-30", "dateModified": "2026-07-30", "summary": "Xtandi still dominates Astellas oncology sales. The real test is whether Padcev, Vyloy and the next CLDN18.2 assets can become a repeatable post-LOE platform.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Astellas FY2025 Financial Results Presentation", "url": "https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_pre_en.pdf" }, { "title": "Astellas FY2025 Supplementary Materials", "url": "https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_sup_en.pdf" }, { "title": "Astellas/Pfizer: US approval of perioperative Padcev plus Keytruda in MIBC, July 13, 2026", "url": "https://newsroom.astellas.com/2026-07-13-us-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility" }, { "title": "FDA: 2025 perioperative approval of Padcev plus Keytruda in MIBC", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer" }, { "title": "FDA: Vyloy approval and SPOTLIGHT/GLOW summary", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma" }, { "title": "Astellas/Evopoint: XNW27011 licensing announcement", "url": "https://newsroom.astellas.com/2025-05-30-CLDN18-2-XNW27011" }, { "title": "ClinicalTrials.gov: phase 3 AZD0901 study in second-line or later gastric/GEJ cancer, NCT06346392", "url": "https://clinicaltrials.gov/study/NCT06346392" }, { "title": "Innovent: phase 3 primary endpoint and China NDA acceptance for IBI343, June 4, 2026", "url": "https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=601" }, { "title": "FDA: Xospata approval", "url": "https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutation" }, { "title": "Astellas CSP2026 Presentation", "url": "https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/Investors-Meeting/astellas_csp2026_presentation_20260526_en.pdf" }, { "title": "Astellas 2026 JPM Healthcare Conference Script", "url": "https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/Investors-Meeting/44th_Annual_JPM_Healthcare_Conference_meeting_script_Astellas.pdf" }, { "title": "ScinoPharm Taiwan: commercial API portfolio", "url": "https://www.scinopharm.com/tw/products-detail/commercialAPI/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html", "title": "Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門", "language": "zh-Hant", "datePublished": "2026-07-30", "dateModified": "2026-07-30", "summary": "Xtandi 仍主導安斯泰來腫瘤收入；Padcev、Vyloy 與下一代 CLDN18.2 資產能否在 LOE 後形成可重複的產品平台，才是下一段考題。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.html", "title": "Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events?", "language": "en", "datePublished": "2026-07-29", "dateModified": "2026-07-29", "summary": "Pelacarsen can substantially lower Lp(a), but HORIZON must show whether biomarker reduction on top of standard care translates into fewer cardiovascular deaths, myocardial infarctions, strokes and urgent revascularizations.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "ClinicalTrials.gov | NCT04023552, Lp(a) HORIZON", "url": "https://clinicaltrials.gov/study/NCT04023552" }, { "title": "Novartis | Q1 2026 investor presentation", "url": "https://www.novartis.com/sites/novartis_com/files/q1-2026-investor-presentation.pdf" }, { "title": "Ionis | First-quarter 2026 financial results", "url": "https://ir.ionis.com/news-releases/news-release-details/ionis-reports-first-quarter-2026-financial-results-and" }, { "title": "American Heart Journal | HORIZON design and rationale, PMID 40185318", "url": "https://pubmed.ncbi.nlm.nih.gov/40185318/" }, { "title": "New England Journal of Medicine | Pelacarsen phase 2, PMID 31893580", "url": "https://pubmed.ncbi.nlm.nih.gov/31893580/" }, { "title": "ClinicalTrials.gov | OCEAN(a)-Outcomes, NCT05581303", "url": "https://clinicaltrials.gov/study/NCT05581303" }, { "title": "ClinicalTrials.gov | ACCLAIM-Lp(a), NCT06292013", "url": "https://clinicaltrials.gov/study/NCT06292013" }, { "title": "ClinicalTrials.gov | MOVE-Lp(a), NCT07157774", "url": "https://clinicaltrials.gov/study/NCT07157774" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html", "title": "HORIZON：Lp(a) 降了，心梗會少嗎？", "language": "zh-Hant", "datePublished": "2026-07-29", "dateModified": "2026-07-29", "summary": "Pelacarsen 已證明能大幅降低 Lp(a)，但 HORIZON 真正要回答的是：在標準治療之上，生物標記下降能否轉成更少的心血管死亡、心肌梗塞、中風與緊急再血管化。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "ClinicalTrials.gov, NCT04023552", "url": "https://clinicaltrials.gov/study/NCT04023552" }, { "title": "Novartis Q1 2026 investor presentation", "url": "https://www.novartis.com/sites/novartis_com/files/q1-2026-investor-presentation.pdf" }, { "title": "Ionis Q1 2026 financial results", "url": "https://ir.ionis.com/news-releases/news-release-details/ionis-reports-first-quarter-2026-financial-results-and" }, { "title": "HORIZON design and rationale, PMID 40185318", "url": "https://pubmed.ncbi.nlm.nih.gov/40185318/" }, { "title": "Pelacarsen phase 2, PMID 31893580", "url": "https://pubmed.ncbi.nlm.nih.gov/31893580/" }, { "title": "OCEAN(a)-Outcomes, NCT05581303", "url": "https://clinicaltrials.gov/study/NCT05581303" }, { "title": "ACCLAIM-Lp(a), NCT06292013", "url": "https://clinicaltrials.gov/study/NCT06292013" }, { "title": "MOVE-Lp(a), NCT07157774", "url": "https://clinicaltrials.gov/study/NCT07157774" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability-en.html", "title": "T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability", "language": "en", "datePublished": "2026-07-28", "dateModified": "2026-07-28", "summary": "PD-1 blockade, CAR-T and T-cell engagers ultimately depend on T cells that can expand, renew and persist. This analysis connects exhaustion biology, product engineering and clinical evidence to the next competitive threshold in immunotherapy.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Blank et al., Defining T cell exhaustion, Nature Reviews Immunology, 2019:", "url": "https://www.nature.com/articles/s41577-019-0221-9" }, { "title": "Im et al., Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy, Nature, 2016:", "url": "https://www.nature.com/articles/nature19330" }, { "title": "Pauken et al., Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade, Science, 2016:", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5484795/" }, { "title": "Long et al., 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nature Medicine, 2015:", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4458184/" }, { "title": "Haber et al., Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning, Scientific Reports 11, 14397, 2021:", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8277787/" }, { "title": "Philipp et al., T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals, Blood, 2022:", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10652962/" }, { "title": "Pell Biomedical, PL001 product page:", "url": "https://www.pellbmt.com/service_info.asp?id=1081" }, { "title": "Taiwan Stock Exchange, Newly listed company: Pell Biomedical (6949):", "url": "https://www.twse.com.tw/market_insights/zh/detail/ff8080818d397607018e11bd8c380277" }, { "title": "ClinicalTrials.gov, NCT05326243, PL001 Phase I/II:", "url": "https://clinicaltrials.gov/study/NCT05326243" }, { "title": "Shine-On Biomedical, SOA101 product page:", "url": "https://www.shineon-bio.com/products2_detail/5" }, { "title": "ClinicalTrials.gov, NCT07055594, SOA101 Phase I/IIa:", "url": "https://clinicaltrials.gov/study/NCT07055594" }, { "title": "Ever Supreme, CAR001 Phase IIa initiation update:", "url": "https://www.ever-supreme.com.tw/news_detail/39" }, { "title": "ClinicalTrials.gov, NCT06150885, CAR001 Phase I/II:", "url": "https://clinicaltrials.gov/study/NCT06150885" }, { "title": "AP Biosciences, AP203 product page:", "url": "https://www.apbioinc.com/en/pipeline-detail1.htm" }, { "title": "ClinicalTrials.gov, NCT05473156, AP203 Phase I/II:", "url": "https://clinicaltrials.gov/study/NCT05473156" }, { "title": "AcePodiA, ACE1831 Phase I completion update:", "url": "https://www.acepodia.com/tw/newsroom-detail/ACE1831_CSR/" }, { "title": "Fraietta et al., Determinants of response and resistance to CD19 CAR T cell therapy of chronic lymphocytic leukemia, Nature Medicine, 2018:", "url": "https://pubmed.ncbi.nlm.nih.gov/29713085/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability.html", "title": "T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後", "language": "zh-Hant", "datePublished": "2026-07-28", "dateModified": "2026-07-28", "summary": "PD-1、CAR-T 與 TCE 最後都仰賴可增殖、可補充且能持久的 T 細胞戰力。本文從耗竭分化、產品工程與臨床資料，拆解免疫治療下半場的真正競爭門檻。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Blank et al., Defining T cell exhaustion, Nature Reviews Immunology, 2019", "url": "https://www.nature.com/articles/s41577-019-0221-9" }, { "title": "Im et al., Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy, Nature, 2016", "url": "https://www.nature.com/articles/nature19330" }, { "title": "Pauken et al., Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade, Science, 2016", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5484795/" }, { "title": "Long et al., 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nature Medicine, 2015", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4458184/" }, { "title": "Haber et al., Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning, Scientific Reports 11, 14397, 2021", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8277787/" }, { "title": "Philipp et al., T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals, Blood, 2022", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10652962/" }, { "title": "沛爾生醫 PL001 產品頁", "url": "https://www.pellbmt.com/service_info.asp?id=1081" }, { "title": "臺灣證券交易所，新上市公司：沛爾生醫（6949）", "url": "https://www.twse.com.tw/market_insights/zh/detail/ff8080818d397607018e11bd8c380277" }, { "title": "ClinicalTrials.gov，NCT05326243，PL001 Phase 1/2", "url": "https://clinicaltrials.gov/study/NCT05326243" }, { "title": "聖安生醫，SOA101 產品頁", "url": "https://www.shineon-bio.com/products2_detail/5" }, { "title": "ClinicalTrials.gov，NCT07055594，SOA101 Phase 1/2", "url": "https://clinicaltrials.gov/study/NCT07055594" }, { "title": "長聖，CAR001 啟動 Phase IIa 公告", "url": "https://www.ever-supreme.com.tw/news_detail/39" }, { "title": "ClinicalTrials.gov，NCT06150885，CAR001 Phase 1/2", "url": "https://clinicaltrials.gov/study/NCT06150885" }, { "title": "圓祥生技，AP203 產品頁", "url": "https://www.apbioinc.com/en/pipeline-detail1.htm" }, { "title": "ClinicalTrials.gov，NCT05473156，AP203 Phase 1/2", "url": "https://clinicaltrials.gov/study/NCT05473156" }, { "title": "育世博，ACE1831 血液癌症第一期結案公告", "url": "https://www.acepodia.com/tw/newsroom-detail/ACE1831_CSR/" }, { "title": "Fraietta et al., Determinants of response and resistance to CD19 CAR T cell therapy of chronic lymphocytic leukemia, Nature Medicine, 2018", "url": "https://pubmed.ncbi.nlm.nih.gov/29713085/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html", "title": "$130 Billion in Six Months: Big Pharma Is Buying Time", "language": "en", "datePublished": "2026-07-27", "dateModified": "2026-07-27", "summary": "Biopharma M&A accelerated in the first half of 2026, but BioSpace's 52 deals and IQVIA's 42 deals cannot be combined. The deeper story is that patent cliffs are pushing Big Pharma to pay for measurable clinical time.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "BioSpace | H1 2026 M&A count and methodology", "url": "https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend" }, { "title": "IQVIA | Biopharma M&A: Mid-year 2026 update", "url": "https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update" }, { "title": "PwC | US Deals 2026 midyear outlook", "url": "https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html" }, { "title": "Merck and Terns | Transaction agreement", "url": "https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/" }, { "title": "Merck | Completion of Terns acquisition", "url": "https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/" }, { "title": "AbbVie and Apogee | Transaction announcement", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology" }, { "title": "Gilead | Completion of Arcellx acquisition", "url": "https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel" }, { "title": "Gilead | Completion of Tubulis acquisition", "url": "https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx" }, { "title": "GSK and Nuvalent | Transaction agreement", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/" }, { "title": "GSK | Completion of Nuvalent acquisition", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/" }, { "title": "Organon and Sun Pharma | Definitive agreement", "url": "https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html", "title": "半年千億，買的是時間", "language": "zh-Hant", "datePublished": "2026-07-27", "dateModified": "2026-07-27", "summary": "2026 上半年生醫併購轉熱，但 BioSpace 的 52 筆與 IQVIA 的 42 筆不能硬拼。真正的主線，是專利懸崖迫使大藥廠用現金購買可計算的臨床時間。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "BioSpace｜H1 2026 M&A count and methodology", "url": "https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend" }, { "title": "IQVIA｜Biopharma M&A: Mid-year 2026 update", "url": "https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update" }, { "title": "PwC｜US Deals 2026 midyear outlook", "url": "https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html" }, { "title": "Merck／Terns｜Transaction agreement", "url": "https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/" }, { "title": "Merck｜Completion of Terns acquisition", "url": "https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/" }, { "title": "AbbVie／Apogee｜Transaction announcement", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology" }, { "title": "Gilead｜Completion of Arcellx acquisition", "url": "https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel" }, { "title": "Gilead｜Completion of Tubulis acquisition", "url": "https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx" }, { "title": "GSK／Nuvalent｜Transaction agreement", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/" }, { "title": "GSK｜Completion of Nuvalent acquisition", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/" }, { "title": "Sun Pharma／Organon｜Definitive agreement", "url": "https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.html", "title": "Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle", "language": "en", "datePublished": "2026-07-25", "dateModified": "2026-07-25", "summary": "Roche generated CHF 47.669 billion in pharmaceutical sales in 2025, with Ocrevus, Hemlibra, and Vabysmo already accounting for roughly one-third of the total. The number that matters is not simply 19 potential new molecules, but whether giredestrant, fenebrutinib, obesity, Alzheimer's, and protein-degradation assets can inherit Roche's existing clinical, diagnostic, and commercial infrastructure on time.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Roche | Full-year results 2025", "url": "https://www.roche.com/media/releases/med-cor-2026-01-29" }, { "title": "Roche | FDA grants priority review to giredestrant in early breast cancer", "url": "https://www.roche.com/media/releases/med-cor-2026-06-02" }, { "title": "Roche | FDA accepts giredestrant application in advanced breast cancer", "url": "https://www.roche.com/media/releases/med-cor-2026-02-20" }, { "title": "Roche | Third pivotal fenebrutinib phase 3 study meets primary endpoint", "url": "https://www.roche.com/investors/updates/inv-update-2026-03-02" }, { "title": "Roche | Complete phase 3 efficacy and safety data for fenebrutinib", "url": "https://www.roche.com/media/releases/med-cor-2026-04-21c" }, { "title": "Roche | Agreement with Nurix for bexobrutideg", "url": "https://www.roche.com/investors/updates/inv-update-2026-06-08" }, { "title": "Roche | Petrelintide transaction terms", "url": "https://www.roche.com/media/releases/med-cor-2025-03-12" }, { "title": "Roche | Petrelintide phase 2 results", "url": "https://www.roche.com/media/releases/med-cor-2026-03-05" }, { "title": "Roche | 2026 ADA obesity pipeline update", "url": "https://www.roche.com/investors/updates/inv-update-2026-06-01" }, { "title": "Roche | 2026 AAIC Alzheimer's and diagnostics update", "url": "https://www.roche.com/investors/updates/inv-update-2026-07-07" }, { "title": "Roche | Pharma Day 2025 pipeline and pre-2030 launch potential", "url": "https://assets.roche.com/f/176343/x/059c686d27/20250922_pharma-day-2025_vf_online.pdf" }, { "title": "Roche | Pharmaceutical pipeline", "url": "https://www.roche.com/solutions/pipeline" }, { "title": "BRIM Biotechnology | Company and research model", "url": "https://www.brimbiotech.com/en/" }, { "title": "BRIM Biotechnology | Development milestones", "url": "https://www.brimbiotech.com/about-us/milestone" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html", "title": "羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？", "language": "zh-Hant", "datePublished": "2026-07-25", "dateModified": "2026-07-25", "summary": "羅氏 2025 年製藥銷售 476.69 億瑞士法郎，Ocrevus、Hemlibra 與 Vabysmo 已撐起約三分之一收入。真正值得追的不是 19 個新分子的總數，而是 giredestrant、fenebrutinib、減重、阿茲海默症與蛋白質降解資產能否沿既有臨床、診斷與商業通路準時接棒。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Roche｜2025 年全年業績", "url": "https://www.roche.com/media/releases/med-cor-2026-01-29" }, { "title": "Roche｜Giredestrant 早期乳癌 NDA 獲 FDA 優先審查", "url": "https://www.roche.com/media/releases/med-cor-2026-06-02" }, { "title": "Roche｜Giredestrant 晚期乳癌 NDA 獲 FDA 受理", "url": "https://www.roche.com/media/releases/med-cor-2026-02-20" }, { "title": "Roche｜Fenebrutinib 第三個關鍵三期達主要終點", "url": "https://www.roche.com/investors/updates/inv-update-2026-03-02" }, { "title": "Roche｜Fenebrutinib 四月完整三期與安全性資料", "url": "https://www.roche.com/media/releases/med-cor-2026-04-21c" }, { "title": "Roche｜與 Nurix 合作開發 Bexobrutideg", "url": "https://www.roche.com/investors/updates/inv-update-2026-06-08" }, { "title": "Roche｜Petrelintide 合作交易條件", "url": "https://www.roche.com/media/releases/med-cor-2025-03-12" }, { "title": "Roche｜Petrelintide 二期結果", "url": "https://www.roche.com/media/releases/med-cor-2026-03-05" }, { "title": "Roche｜2026 ADA 減重管線更新", "url": "https://www.roche.com/investors/updates/inv-update-2026-06-01" }, { "title": "Roche｜2026 AAIC 阿茲海默症藥品與診斷更新", "url": "https://www.roche.com/investors/updates/inv-update-2026-07-07" }, { "title": "Roche｜2025 Pharma Day 管線與 2030 上市潛力", "url": "https://assets.roche.com/f/176343/x/059c686d27/20250922_pharma-day-2025_vf_online.pdf" }, { "title": "Roche｜藥品研發管線", "url": "https://www.roche.com/solutions/pipeline" }, { "title": "全福生技｜公司與研發模式", "url": "https://www.brimbiotech.com/en/" }, { "title": "全福生技｜研發里程碑", "url": "https://www.brimbiotech.com/about-us/milestone" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines-en.html", "title": "When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma", "language": "en", "datePublished": "2026-07-24", "dateModified": "2026-07-24", "summary": "An acquisition is not the only successful outcome for a biotech. Using argenx, Insmed, Incyte, and Revolution Medicines as four operating snapshots, this analysis tests product evidence, cash generation, a second growth curve, global execution, and financing options—and shows what retaining control really costs.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "argenx FY2025 results", "url": "https://argenx.com/news/2026/press-release-3245199" }, { "title": "argenx 2025 Annual Report", "url": "https://reports.argenx.com/2025/" }, { "title": "argenx Q1 2026 results", "url": "https://argenx.com/news/2026/press-release-3289577" }, { "title": "Insmed FY2025 results", "url": "https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm" }, { "title": "Insmed Q1 2026 results", "url": "https://investor.insmed.com/2026-05-07-Insmed-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed Q1 2026 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1104506/000110450626000032/insm-20260331.htm" }, { "title": "Incyte FY2025 results", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2025-financial" }, { "title": "Incyte 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm" }, { "title": "Incyte Q1 2026 results", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides" }, { "title": "Revolution Medicines RASolute 302 detailed results", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-asco-plenary-presentation" }, { "title": "Revolution Medicines EMA phased review release", "url": "https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution" }, { "title": "Revolution Medicines Q1 2026 results", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-first-quarter-2026-financial/" }, { "title": "Revolution Medicines Q1 2026 Form 10-Q", "url": "https://ir.revmed.com/static-files/e7a99744-380a-4fa9-93b6-2fb71793c8ee" }, { "title": "Revolution Medicines April 2026 offering 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1628171/000119312526159289/d95226d8k.htm" }, { "title": "Revolution Medicines transaction 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/d838043d8k.htm" }, { "title": "Royalty Pharma and Revolution Medicines funding agreement", "url": "https://www.royaltypharma.com/news/royalty-pharma-and-revolution-medicines-enter-into-funding-agreements-for-up-to-2-billion/" }, { "title": "Royalty Pharma 2026-04-13 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines.html", "title": "Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma", "language": "zh-Hant", "datePublished": "2026-07-24", "dateModified": "2026-07-24", "summary": "被收購不是 Biotech 唯一的成功終點。本文以 argenx、Insmed、Incyte 與 Revolution Medicines 為四個截面，檢驗產品證據、現金引擎、第二曲線、全球執行與融資選項，並拆解保留控制權的真實成本。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "argenx FY2025 results", "url": "https://argenx.com/news/2026/press-release-3245199" }, { "title": "argenx 2025 Annual Report", "url": "https://reports.argenx.com/2025/" }, { "title": "argenx Q1 2026 results", "url": "https://argenx.com/news/2026/press-release-3289577" }, { "title": "Insmed FY2025 results", "url": "https://investor.insmed.com/2026-02-19-Insmed-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/insm-20251231.htm" }, { "title": "Insmed Q1 2026 results", "url": "https://investor.insmed.com/2026-05-07-Insmed-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update" }, { "title": "Insmed Q1 2026 Form 10-Q", "url": "https://www.sec.gov/Archives/edgar/data/1104506/000110450626000032/insm-20260331.htm" }, { "title": "Incyte FY2025 results", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-fourth-quarter-and-full-year-2025-financial" }, { "title": "Incyte 2025 Form 10-K", "url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm" }, { "title": "Incyte Q1 2026 results", "url": "https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides" }, { "title": "Revolution Medicines RASolute 302 detailed results", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-asco-plenary-presentation" }, { "title": "Revolution Medicines EMA phased review release", "url": "https://ir.revmed.com/news-releases/news-release-details/european-medicines-agency-expedites-assessment-revolution" }, { "title": "Revolution Medicines Q1 2026 results", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-first-quarter-2026-financial/" }, { "title": "Revolution Medicines Q1 2026 Form 10-Q", "url": "https://ir.revmed.com/static-files/e7a99744-380a-4fa9-93b6-2fb71793c8ee" }, { "title": "Revolution Medicines April 2026 offering 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1628171/000119312526159289/d95226d8k.htm" }, { "title": "Revolution Medicines transaction 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/d838043d8k.htm" }, { "title": "Royalty Pharma and Revolution Medicines funding agreement", "url": "https://www.royaltypharma.com/news/royalty-pharma-and-revolution-medicines-enter-into-funding-agreements-for-up-to-2-billion/" }, { "title": "Royalty Pharma 2026-04-13 8-K", "url": "https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals-en.html", "title": "SpaceX Goes to Orbit. Is the Money in the Crystals?", "language": "en", "datePublished": "2026-07-24", "dateModified": "2026-07-24", "summary": "SpaceX is making low-Earth-orbit round trips more routine, but rockets do not discover drugs. From Keytruda crystallization and SpaceMD to Varda, UK regulation, and a Taiwan mission, this analysis asks whether microgravity-enabled manufacturing can pass the tests of repetition, scale-up, and regulation.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Redwire/SpaceMD", "url": "https://ir.rdw.com/news-events/press-releases/detail/235/former-merck-and-nasa-leaders-bring-strategic-expertise-to" }, { "title": "NASA/SpaceX CRS-34", "url": "https://www.nasa.gov/missions/station/iss-research/nasas-spacex-crs-34-dragon-returns-packed-with-space-station-science/" }, { "title": "NASA June 17, 2026 Dragon splashdown log", "url": "https://www.nasa.gov/blogs/spacestation/2026/06/17/spacex-dragon-splashes-down-in-pacific-completes-cargo-mission/" }, { "title": "npj Microgravity: pembrolizumab crystallization in microgravity", "url": "https://www.nature.com/articles/s41526-019-0090-3" }, { "title": "NASA: Space Station Research Informs New FDA-Approved Cancer Therapy", "url": "https://www.nasa.gov/missions/station/iss-research/space-station-research-informs-new-fda-approved-cancer-therapy/" }, { "title": "FDA: Keytruda Qlex", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection" }, { "title": "Varda Space Industries mission platform", "url": "https://www.varda.com/platform" }, { "title": "npj Microgravity: Varda ritonavir Form III", "url": "https://www.nature.com/articles/s41526-026-00594-0" }, { "title": "UK government: regulatory pathway for space-manufactured drugs", "url": "https://www.gov.uk/government/news/uk-sets-out-world-leading-pathway-for-space-manufactured-drugs" }, { "title": "Space BD: NSRRC protein crystallization in space", "url": "https://www.space-bd.com/dam/include-content/PUBLIC/en/news_archive/storage/news20220303-001/pdf/20220520en-4.pdf" }, { "title": "HelioX Cosmos", "url": "https://www.helioxcosmos.com/about/ABOUT-US/" }, { "title": "Shanghai Institute of Materia Medica", "url": "https://simm.cas.cn/web/xwzx/kydt/202508/t20250801_7900455.html" }, { "title": "Chinese Academy of Sciences/SIMM English release", "url": "https://english.simm.cas.cn/News/Headline/202508/t20250829_1051693.html" }, { "title": "NASA: Commercial Space Stations", "url": "https://www.nasa.gov/humans-in-space/commercial-space/commercial-space-stations/" }, { "title": "MHRA: The Next Frontier—unlocking in-orbit manufacturing of medicines", "url": "https://medregs.blog.gov.uk/2026/06/25/the-next-frontier-unlocking-in-orbit-manufacturing-of-medicines/" }, { "title": "UK Space Agency Annual Report 2025–2026", "url": "https://www.gov.uk/government/publications/uk-space-agency-annual-report-and-accounts-2025-2026/uk-space-agency-annual-report-2025-2026" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals.html", "title": "SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金", "language": "zh-Hant", "datePublished": "2026-07-24", "dateModified": "2026-07-24", "summary": "SpaceX 讓低軌往返逐漸有了班次，但火箭不是新藥公司。本文從 Keytruda 結晶、SpaceMD、Varda、英國監管與台灣任務，拆解微重力製藥能否通過重複、放大與監管三道商業考驗。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Redwire／SpaceMD", "url": "https://ir.rdw.com/news-events/press-releases/detail/235/former-merck-and-nasa-leaders-bring-strategic-expertise-to" }, { "title": "NASA／SpaceX CRS-34", "url": "https://www.nasa.gov/missions/station/iss-research/nasas-spacex-crs-34-dragon-returns-packed-with-space-station-science/" }, { "title": "NASA／2026-06-17 Dragon 濺落紀錄", "url": "https://www.nasa.gov/blogs/spacestation/2026/06/17/spacex-dragon-splashes-down-in-pacific-completes-cargo-mission/" }, { "title": "npj Microgravity／Pembrolizumab microgravity crystallization experimentation", "url": "https://www.nature.com/articles/s41526-019-0090-3" }, { "title": "NASA／Space Station Research Informs New FDA-Approved Cancer Therapy", "url": "https://www.nasa.gov/missions/station/iss-research/space-station-research-informs-new-fda-approved-cancer-therapy/" }, { "title": "FDA／Keytruda Qlex", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection" }, { "title": "Varda Space Industries／任務頁", "url": "https://www.varda.com/platform" }, { "title": "npj Microgravity／Varda ritonavir Form III", "url": "https://www.nature.com/articles/s41526-026-00594-0" }, { "title": "英國政府／太空製藥監管路線", "url": "https://www.gov.uk/government/news/uk-sets-out-world-leading-pathway-for-space-manufactured-drugs" }, { "title": "Space BD／NSRRC 太空蛋白質結晶", "url": "https://www.space-bd.com/dam/include-content/PUBLIC/en/news_archive/storage/news20220303-001/pdf/20220520en-4.pdf" }, { "title": "HelioX Cosmos", "url": "https://www.helioxcosmos.com/about/ABOUT-US/" }, { "title": "中國科學院上海藥物研究所", "url": "https://simm.cas.cn/web/xwzx/kydt/202508/t20250801_7900455.html" }, { "title": "Chinese Academy of Sciences／SIMM English release", "url": "https://english.simm.cas.cn/News/Headline/202508/t20250829_1051693.html" }, { "title": "NASA／Commercial Space Stations", "url": "https://www.nasa.gov/humans-in-space/commercial-space/commercial-space-stations/" }, { "title": "MHRA／The Next Frontier: unlocking in-orbit manufacturing of medicines", "url": "https://medregs.blog.gov.uk/2026/06/25/the-next-frontier-unlocking-in-orbit-manufacturing-of-medicines/" }, { "title": "UK Space Agency／Annual Report 2025–2026", "url": "https://www.gov.uk/government/publications/uk-space-agency-annual-report-and-accounts-2025-2026/uk-space-agency-annual-report-2025-2026" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.html", "title": "Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine", "language": "en", "datePublished": "2026-07-20", "dateModified": "2026-07-20", "summary": "Rezdiffra has opened the MASH market and built its commercialization infrastructure. Madrigal is now adding six Ribo siRNA programs and Arrowhead's ARO-PNPLA3 to create a cornerstone-plus-precision-combination treatment matrix.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Facebook | Original Drugnews post, July 20, 2026", "url": "https://www.facebook.com/61568446257142/posts/1371920785993874/" }, { "title": "FDA | FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease, March 14, 2024", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease" }, { "title": "New England Journal of Medicine | A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis, 2024", "url": "https://www.nejm.org/doi/10.1056/NEJMoa2309000" }, { "title": "Madrigal | 2025 Full-Year Financial Results, February 19, 2026", "url": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0" }, { "title": "Madrigal | 2026 First-Quarter Financial Results, May 6, 2026", "url": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-first-quarter-2026-financial" }, { "title": "Novo Nordisk | Wegovy Receives FDA Accelerated Approval for MASH, August 15, 2025", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916416" }, { "title": "Roche | Agreement to Acquire 89bio and Pegozafermin, September 18, 2025", "url": "https://www.roche.com/media/releases/med-cor-2025-09-18" }, { "title": "Madrigal | Exclusive Global License for Six Ribo siRNA Programs, February 11, 2026", "url": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensing" }, { "title": "Ribocure | Ribo and Madrigal Reach First Major MASH siRNA Milestone, July 2, 2026", "url": "https://ribocure.com/news/" }, { "title": "Madrigal | Global License for Arrowhead ARO-PNPLA3, May 5, 2026", "url": "https://ir.madrigalpharma.com/node/17406" }, { "title": "TaiwanJ Pharmaceuticals | Company History and Liver-Disease Pipeline", "url": "https://www.taiwanj.com/pages/page_history_en" }, { "title": "Sinew Pharma | SNP-630 MASH Program", "url": "https://www.sinewpharma.com/en/products-detail2-4.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html", "title": "聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒", "language": "zh-Hant", "datePublished": "2026-07-20", "dateModified": "2026-07-20", "summary": "Rezdiffra 已把 MASH 市場與商業化基礎設施打開；Madrigal 再以 Ribo 六條 siRNA 管線與 Arrowhead ARO-PNPLA3，建立基石藥加精準聯用矩陣。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Facebook｜藥時事原始貼文，2026-07-20", "url": "https://www.facebook.com/61568446257142/posts/1371920785993874/" }, { "title": "FDA｜FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease，2024-03-14", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease" }, { "title": "New England Journal of Medicine｜A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis，2024", "url": "https://www.nejm.org/doi/10.1056/NEJMoa2309000" }, { "title": "Madrigal｜2025 Full-Year Financial Results，2026-02-19", "url": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0" }, { "title": "Madrigal｜2026 First-Quarter Financial Results，2026-05-06", "url": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-first-quarter-2026-financial" }, { "title": "Novo Nordisk｜Wegovy Receives FDA Accelerated Approval for MASH，2025-08-15", "url": "https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916416" }, { "title": "Roche｜Agreement to Acquire 89bio and Pegozafermin，2025-09-18", "url": "https://www.roche.com/media/releases/med-cor-2025-09-18" }, { "title": "Madrigal｜Exclusive Global License for Six Ribo siRNA Programs，2026-02-11", "url": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensing" }, { "title": "Ribocure｜Ribo and Madrigal Reach First Major MASH siRNA Milestone，2026-07-02", "url": "https://ribocure.com/news/" }, { "title": "Madrigal｜Global License for Arrowhead ARO-PNPLA3，2026-05-05", "url": "https://ir.madrigalpharma.com/node/17406" }, { "title": "景凱生技｜Company History and Liver-Disease Pipeline", "url": "https://www.taiwanj.com/pages/page_history_en" }, { "title": "欣耀生醫｜SNP-630 MASH Program", "url": "https://www.sinewpharma.com/en/products-detail2-4.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift-en.html", "title": "Animal Studies Are Not Disappearing. Drug Development Rules Are Changing.", "language": "en", "datePublished": "2026-07-19", "dateModified": "2026-07-19", "summary": "China's CDE PIONEER program opens a regulatory pathway for new approach methodologies. The real test is whether human-relevant evidence becomes reproducible, validated and reusable.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "CDE public consultation and PIONEER materials:", "url": "https://www.cde.org.cn/" }, { "title": "U.S. FDA, New Approach Methodologies:", "url": "https://www.fda.gov/science-research/about-science-research-fda/new-approach-methodologies-nams" }, { "title": "European Medicines Agency, regulatory science and qualification:", "url": "https://www.ema.europa.eu/" }, { "title": "UK Government, replacing animal testing roadmap:", "url": "https://www.gov.uk/government/publications/replacing-animals-in-science-a-strategy-to-support-the-development-use-and-uptake-of-alternatives-to-animal-testing" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift.html", "title": "動物實驗不是消失，而是藥物研發規則開始換代", "language": "zh-Hant", "datePublished": "2026-07-19", "dateModified": "2026-07-19", "summary": "CDE 的 NAMs 先鋒計畫為藥企與方法開發者開出雙軌入口；真正的考題是可重複、可驗證且被監管接受的人體相關證據。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.html", "title": "When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing", "language": "en", "datePublished": "2026-07-18", "dateModified": "2026-07-18", "summary": "The opportunity for autoimmune ADCs is not to transplant oncology cytotoxins into immune cells. It is to deliver powerful glucocorticoids, small molecules, ASOs or siRNAs selectively to the cells that drive disease. LFD-200 offers an early human proof-of-mechanism signal for that thesis.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Original Drugnews article on Dcard", "url": "https://www.dcard.tw/@drugnews/post/261839370" }, { "title": "Lifordi Immunotherapeutics: LFD-200 technology", "url": "https://www.lifordi.com/technology/lfd-200/" }, { "title": "Lifordi: preliminary phase 1 LFD-200 data presented at EULAR 2026", "url": "https://www.biospace.com/press-releases/lifordi-immunotherapeutics-presents-phase-1-clinical-data-for-lfd-200-a-subcutaneous-glucocorticoid-antibody-drug-conjugate-at-eular-2026" }, { "title": "ClinicalTrials.gov: NCT07207954", "url": "https://clinicaltrials.gov/study/NCT07207954" }, { "title": "Yaseen et al.: review of antibody-drug conjugates in autoimmune disease, PMID 40186891", "url": "https://pubmed.ncbi.nlm.nih.gov/40186891/" }, { "title": "Zhou et al.: review of ADC applications beyond oncology, PMID 40843358", "url": "https://pubmed.ncbi.nlm.nih.gov/40843358/" }, { "title": "CD19 CAR-T in autoimmune disease, Nature Medicine 2026", "url": "https://www.nature.com/articles/s41591-025-04185-6" }, { "title": "CD19 CAR-T case series in autoimmune disease, PMID 38381673", "url": "https://pubmed.ncbi.nlm.nih.gov/38381673/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html", "title": "當 ADC 走進自體免疫：不是殺得更狠，而是調得更準", "language": "zh-Hant", "datePublished": "2026-07-18", "dateModified": "2026-07-18", "summary": "自體免疫 ADC 的價值不在把腫瘤細胞毒 payload 搬到免疫細胞，而在把 glucocorticoid、ASO、siRNA 等強效免疫調節作用定向送到真正需要干預的細胞；LFD-200 的早期人體訊號，是這條路第一次重要的機制驗證。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Drugnews Dcard 原文", "url": "https://www.dcard.tw/@drugnews/post/261839370" }, { "title": "Lifordi Immunotherapeutics：LFD-200 技術介紹", "url": "https://www.lifordi.com/technology/lfd-200/" }, { "title": "Lifordi：EULAR 2026 Phase 1 初步資料新聞稿", "url": "https://www.biospace.com/press-releases/lifordi-immunotherapeutics-presents-phase-1-clinical-data-for-lfd-200-a-subcutaneous-glucocorticoid-antibody-drug-conjugate-at-eular-2026" }, { "title": "ClinicalTrials.gov：NCT07207954", "url": "https://clinicaltrials.gov/study/NCT07207954" }, { "title": "Yaseen et al.：自體免疫疾病抗體藥物複合體綜述，PMID 40186891", "url": "https://pubmed.ncbi.nlm.nih.gov/40186891/" }, { "title": "Zhou et al.：ADC 在非腫瘤疾病的應用綜述，PMID 40843358", "url": "https://pubmed.ncbi.nlm.nih.gov/40843358/" }, { "title": "CD19 CAR-T 自體免疫疾病研究，Nature Medicine 2026", "url": "https://www.nature.com/articles/s41591-025-04185-6" }, { "title": "CD19 CAR-T 治療自體免疫疾病病例系列，PMID 38381673", "url": "https://pubmed.ncbi.nlm.nih.gov/38381673/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html", "title": "RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived", "language": "en", "datePublished": "2026-07-17", "dateModified": "2026-07-17", "summary": "Daraxonrasib has already raised the bar with phase 3 overall-survival data. Early zoldonrasib combinations now suggest that pancreatic cancer's RAS competition is shifting from single agents to treatment ecosystems.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Revolution Medicines | Phase 1/2 clinical data for zoldonrasib combination regimens, July 2, 2026", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-phase-12-clinical-data-zoldonrasib" }, { "title": "ClinicalTrials.gov | RASolute 302: daraxonrasib versus investigator's choice in previously treated metastatic PDAC (NCT06625320)", "url": "https://clinicaltrials.gov/study/NCT06625320" }, { "title": "Revolution Medicines | RASolute 302 ASCO plenary presentation and overall-survival results", "url": "https://ir.revmed.com/node/13046/pdf" }, { "title": "ClinicalTrials.gov | Zoldonrasib phase 1/1b study (NCT06040541)", "url": "https://clinicaltrials.gov/study/NCT06040541" }, { "title": "ClinicalTrials.gov | RASolute 305 first-line phase 3 study (NCT07621718)", "url": "https://clinicaltrials.gov/study/NCT07621718" }, { "title": "Revolution Medicines | First-quarter 2026 corporate and pipeline update", "url": "https://ir.revmed.com/node/12976/pdf" }, { "title": "ClinicalTrials.gov | MRTX1133 study in advanced solid tumors with KRAS G12D mutation (NCT05737706)", "url": "https://clinicaltrials.gov/study/NCT05737706" }, { "title": "ClinicalTrials.gov | LY4066434 study in KRAS-mutant solid tumors (NCT06607185)", "url": "https://clinicaltrials.gov/study/NCT06607185" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html", "title": "又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代", "language": "zh-Hant", "datePublished": "2026-07-17", "dateModified": "2026-07-17", "summary": "Daraxonrasib 已用第三期總生存期資料抬高胰臟癌 RAS 賽道門檻；zoldonrasib 與 pan-RAS 或化療的早期組合訊號，則把競爭從單藥推向治療生態系。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Revolution Medicines｜Phase 1/2 clinical data for zoldonrasib combination regimens, 2026-07-02", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-phase-12-clinical-data-zoldonrasib" }, { "title": "ClinicalTrials.gov｜RASolute 302: daraxonrasib versus investigator's choice in previously treated metastatic PDAC (NCT06625320)", "url": "https://clinicaltrials.gov/study/NCT06625320" }, { "title": "Revolution Medicines｜RASolute 302 ASCO plenary presentation and overall-survival results", "url": "https://ir.revmed.com/node/13046/pdf" }, { "title": "ClinicalTrials.gov｜Zoldonrasib phase 1/1b study (NCT06040541)", "url": "https://clinicaltrials.gov/study/NCT06040541" }, { "title": "ClinicalTrials.gov｜RASolute 305 first-line phase 3 study (NCT07621718)", "url": "https://clinicaltrials.gov/study/NCT07621718" }, { "title": "Revolution Medicines｜First-quarter 2026 corporate and pipeline update", "url": "https://ir.revmed.com/node/12976/pdf" }, { "title": "ClinicalTrials.gov｜MRTX1133 study in advanced solid tumors with KRAS G12D mutation (NCT05737706)", "url": "https://clinicaltrials.gov/study/NCT05737706" }, { "title": "ClinicalTrials.gov｜LY4066434 study in KRAS-mutant solid tumors (NCT06607185)", "url": "https://clinicaltrials.gov/study/NCT06607185" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html", "title": "Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype", "language": "en", "datePublished": "2026-07-16", "dateModified": "2026-07-16", "summary": "Vertex's roughly $10 billion deal for Crinetics captures a wider change in Big Pharma's acquisition taste: away from scale and fashionable platforms, toward niche leadership, technological step-changes and commercial visibility.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Vertex | Vertex to Acquire Crinetics Pharmaceuticals, July 6, 2026", "url": "https://news.vrtx.com/node/35161/pdf" }, { "title": "Organon | Sun Pharma signs Definitive Agreement to Acquire Organon, April 26, 2026", "url": "https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/" }, { "title": "Eli Lilly | Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders, March 31, 2026", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-centessa-pharmaceuticals-advance-treatments-sleep" }, { "title": "AbbVie | AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio, June 22, 2026", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology" }, { "title": "Novartis | Novartis agrees to acquire Avidity Biosciences, October 26, 2025", "url": "https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline" }, { "title": "Merck | Merck to Acquire Cidara Therapeutics, November 14, 2025", "url": "https://www.merck.com/news/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase-antiviral-agent/" }, { "title": "Pfizer | Phase 3 topline results for sigvotatug vedotin in previously treated metastatic non-squamous NSCLC, June 22, 2026", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-3-results-sigvotatug-vedotin" }, { "title": "FDA | Voluntary withdrawal of Oxbryta from the market due to safety concerns, September 26, 2024", "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due" }, { "title": "FDA | BESREMi prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761166s007lbl.pdf" }, { "title": "FDA | CAMCEVI prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211488s010lbl.pdf" }, { "title": "Indivior | Exclusive licensing agreement for Alar Pharmaceuticals' ALA-1000, October 11, 2023", "url": "https://www.indivior.com/latest/category/press-releases/2023/indivior-enters-an-exclusive-licensing-agreement-with-alar-pharmaceuticals" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html", "title": "百億美元併購新狂潮", "language": "zh-Hant", "datePublished": "2026-07-16", "dateModified": "2026-07-16", "summary": "Vertex 以約 100 億美元收購 Crinetics，映照 Big Pharma 併購審美的轉向：不再只買規模或熱門平台，而是買細分市場統治力、技術代差與商業確定性。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Vertex｜Vertex to Acquire Crinetics Pharmaceuticals, 2026-07-06", "url": "https://news.vrtx.com/node/35161/pdf" }, { "title": "Organon｜Sun Pharma signs Definitive Agreement to Acquire Organon, 2026-04-26", "url": "https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/" }, { "title": "Eli Lilly｜Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders, 2026-03-31", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-centessa-pharmaceuticals-advance-treatments-sleep" }, { "title": "AbbVie｜AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio, 2026-06-22", "url": "https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology" }, { "title": "Novartis｜Novartis agrees to acquire Avidity Biosciences, 2025-10-26", "url": "https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline" }, { "title": "Merck｜Merck to Acquire Cidara Therapeutics, 2025-11-14", "url": "https://www.merck.com/news/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase-antiviral-agent/" }, { "title": "Pfizer｜Phase 3 topline results for sigvotatug vedotin in previously treated metastatic non-squamous NSCLC, 2026-06-22", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-3-results-sigvotatug-vedotin" }, { "title": "FDA｜Voluntary withdrawal of Oxbryta from the market due to safety concerns, 2024-09-26", "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due" }, { "title": "FDA｜BESREMi prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761166s007lbl.pdf" }, { "title": "FDA｜CAMCEVI prescribing information", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211488s010lbl.pdf" }, { "title": "Indivior｜Exclusive licensing agreement for Alar Pharmaceuticals' ALA-1000, 2023-10-11", "url": "https://www.indivior.com/latest/category/press-releases/2023/indivior-enters-an-exclusive-licensing-agreement-with-alar-pharmaceuticals" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html", "title": "After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product", "language": "en", "datePublished": "2026-07-15", "dateModified": "2026-07-15", "summary": "The Nobel Prize illuminated Treg biology, but commercial value will depend on whether immune tolerance can become a releasable, trackable, scalable and reimbursable product, not on an unverified first-approval headline.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "NobelPrize.org｜The Nobel Prize in Physiology or Medicine 2025", "url": "https://www.nobelprize.org/prizes/medicine/2025/summary/" }, { "title": "Nektar Therapeutics｜Our Pipeline", "url": "https://www.nektar.com/our-pipeline/" }, { "title": "Sonoma Biotherapeutics｜Pipeline", "url": "https://sonomabio.com/platform-pipeline/pipeline/" }, { "title": "Quell Therapeutics｜Pipeline", "url": "https://www.quell-tx.com/pipeline" }, { "title": "Quell Therapeutics｜Technology Platform", "url": "https://www.quell-tx.com/science/" }, { "title": "Taiwan Bio Therapeutics｜TRK-001 Phase II study cleared to proceed in Taiwan", "url": "https://twbio-thera.com/tw/news/1/16" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html", "title": "諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品", "language": "zh-Hant", "datePublished": "2026-07-15", "dateModified": "2026-07-15", "summary": "諾貝爾獎照亮 Treg 科學，但產業價值要看免疫耐受能否被做成可放行、可追蹤、可定價、可複製的產品，而不是急著追逐未經核實的第一款獲批敘事。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "NobelPrize.org｜The Nobel Prize in Physiology or Medicine 2025", "url": "https://www.nobelprize.org/prizes/medicine/2025/summary/" }, { "title": "Nektar Therapeutics｜Our Pipeline", "url": "https://www.nektar.com/our-pipeline/" }, { "title": "Sonoma Biotherapeutics｜Pipeline", "url": "https://sonomabio.com/platform-pipeline/pipeline/" }, { "title": "Quell Therapeutics｜Pipeline", "url": "https://www.quell-tx.com/our-science/pipeline/" }, { "title": "Quell Therapeutics｜Technology Platform", "url": "https://www.quell-tx.com/our-science/technology-platform/" }, { "title": "台寶生醫｜TRK-001 取得衛福部原則同意執行第二期腎臟移植排斥預防臨床試驗", "url": "https://twbio-thera.com/tw/news/1/16" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html", "title": "The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class", "language": "en", "datePublished": "2026-07-14", "dateModified": "2026-07-14", "summary": "Novartis is paying up to $1.5 billion for Myricx. The strategic prize is not merely two ADC assets, but an NMT-inhibitor payload platform that could reopen the questions of therapeutic window, resistance and platform value.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Novartis｜Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload", "url": "https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients" }, { "title": "OBI Pharma｜Pipeline Overview", "url": "https://www.obipharma.com/what-we-do/pipeline-overview/" }, { "title": "OBI Pharma｜Obrion ADC Technology Platform", "url": "https://www.obipharma.com/what-we-do/technology-platform/" }, { "title": "Immunwork｜T-E Meds shortlisted for the World ADC Awards", "url": "https://immunwork.com/article_d.php?lang=tw&tb=4&id=1524" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html", "title": "ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload", "language": "zh-Hant", "datePublished": "2026-07-14", "dateModified": "2026-07-14", "summary": "諾華最高 15 億美元收購 Myricx，真正買下的不只是兩條 ADC 管線，而是可能改寫安全窗、耐藥與平台估值的新型 NMTi payload。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Novartis｜Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload", "url": "https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients" }, { "title": "OBI Pharma｜Pipeline Overview", "url": "https://www.obipharma.com/what-we-do/pipeline-overview/" }, { "title": "OBI Pharma｜Obrion ADC Technology Platform", "url": "https://www.obipharma.com/what-we-do/technology-platform/" }, { "title": "免疫功坊｜賀！諦醫生技入圍世界ADC獎，技術平台與產品獲國際肯定", "url": "https://immunwork.com/article_d.php?lang=tw&tb=4&id=1524" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html", "title": "Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena", "language": "en", "datePublished": "2026-07-13", "dateModified": "2026-07-13", "summary": "Anthropic's launch of Claude Science and its move into drug discovery show foundation-model companies shifting from research tools into real R&D workflows. AI drug discovery will ultimately be judged by experiments, clinical data and tradable assets.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Anthropic | Claude Science, an AI workbench for scientists:", "url": "https://www.anthropic.com/news/claude-science-ai-workbench" }, { "title": "The Verge | Anthropic is getting into drug development:", "url": "https://www.theverge.com/ai-artificial-intelligence/961311/anthropic-claude-science-ai-drug-development" }, { "title": "NVIDIA | NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI:", "url": "https://nvidianews.nvidia.com/news/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai" }, { "title": "Iambic | Iambic Announces Collaboration with Takeda:", "url": "https://www.iambic.ai/post/iambic-announces-collaboration-with-takeda" }, { "title": "AnHorn Medicines | AIMCADD technology platform:", "url": "https://www.anhornmed.com/our-technology/" }, { "title": "AnHorn Medicines | AI-Designed Drug AH-001 Complete U.S. Phase I Trial:", "url": "https://www.anhornmed.com/news/ai-design-ah001-protein-degrader-phase1-complete/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery.html", "title": "大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場", "language": "zh-Hant", "datePublished": "2026-07-13", "dateModified": "2026-07-13", "summary": "Anthropic 推出 Claude Science 並啟動藥物發現計畫，顯示大模型公司正從科研工具走向真實研發工作流；AI 製藥最終仍要用實驗、臨床資料與可交易資產證明價值。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Anthropic｜Claude Science, an AI workbench for scientists:", "url": "https://www.anthropic.com/news/claude-science-ai-workbench" }, { "title": "The Verge｜Anthropic is getting into drug development:", "url": "https://www.theverge.com/ai-artificial-intelligence/961311/anthropic-claude-science-ai-drug-development" }, { "title": "NVIDIA｜NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI:", "url": "https://nvidianews.nvidia.com/news/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai" }, { "title": "Iambic｜Iambic Announces Collaboration with Takeda:", "url": "https://www.iambic.ai/post/iambic-announces-collaboration-with-takeda" }, { "title": "AnHorn Medicines｜AIMCADD technology platform:", "url": "https://www.anhornmed.com/our-technology/" }, { "title": "AnHorn Medicines｜AI-Designed Drug AH-001 Complete U.S. Phase I Trial:", "url": "https://www.anhornmed.com/news/ai-design-ah001-protein-degrader-phase1-complete/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html", "title": "Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race", "language": "en", "datePublished": "2026-07-12", "dateModified": "2026-07-12", "summary": "Roche's divarasib beat first-generation KRAS G12C inhibitors in a head-to-head Phase III study, moving the RAS field from proving druggability to replacing earlier products with harder clinical evidence.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Roche | Divarasib shows superiority in head-to-head Phase III Krascendo 1:", "url": "https://www.roche.com/investors/updates/inv-update-2026-07-02" }, { "title": "New England Journal of Medicine / PubMed | Single-Agent Divarasib in Solid Tumors with a KRAS G12C Mutation:", "url": "https://pubmed.ncbi.nlm.nih.gov/37611121/" }, { "title": "ClinicalTrials.gov | NCT06497556, Krascendo 1:", "url": "https://clinicaltrials.gov/study/NCT06497556" }, { "title": "ClinicalTrials.gov | NCT04449874, GO42144 divarasib study:", "url": "https://clinicaltrials.gov/study/NCT04449874" }, { "title": "ClinicalTrials.gov | NCT06793215, Krascendo 2:", "url": "https://clinicaltrials.gov/study/NCT06793215" }, { "title": "National Cancer Institute | Divarasib drug dictionary:", "url": "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/divarasib" }, { "title": "PharmaEngine | Products and R&D:", "url": "https://www.pharmaengine.com/" }, { "title": "OBI Pharma | Pipeline and technology:", "url": "https://www.obipharma.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation.html", "title": "先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰", "language": "zh-Hant", "datePublished": "2026-07-12", "dateModified": "2026-07-12", "summary": "Roche 的 divarasib 在頭對頭三期試驗中擊敗第一代 KRAS G12C 抑制劑，代表 RAS 賽道已從證明可成藥，進入用臨床硬終點淘汰上一代產品的競爭。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Roche｜Divarasib shows superiority in head-to-head Phase III Krascendo 1:", "url": "https://www.roche.com/investors/updates/inv-update-2026-07-02" }, { "title": "New England Journal of Medicine / PubMed｜Single-Agent Divarasib in Solid Tumors with a KRAS G12C Mutation:", "url": "https://pubmed.ncbi.nlm.nih.gov/37611121/" }, { "title": "ClinicalTrials.gov｜NCT06497556, Krascendo 1:", "url": "https://clinicaltrials.gov/study/NCT06497556" }, { "title": "ClinicalTrials.gov｜NCT04449874, GO42144 divarasib study:", "url": "https://clinicaltrials.gov/study/NCT04449874" }, { "title": "ClinicalTrials.gov｜NCT06793215, Krascendo 2:", "url": "https://clinicaltrials.gov/study/NCT06793215" }, { "title": "National Cancer Institute｜Divarasib drug dictionary:", "url": "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/divarasib" }, { "title": "智擎生技｜產品與研發資料:", "url": "https://www.pharmaengine.com/" }, { "title": "OBI Pharma｜Pipeline and technology:", "url": "https://www.obipharma.com/" }, { "title": "更多完整長文與產業追蹤，會整理在藥時事官網", "url": "https://drugnews.com.tw/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html", "title": "Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job.", "language": "en", "datePublished": "2026-07-11", "dateModified": "2026-07-11", "summary": "Fasedienol's PALISADE-4 miss was not simply a failed Phase 3 headline. It exposed the core CNS drug-development problem: a beautiful mechanism and a real unmet need still have to survive subjective endpoints, placebo response, patient selection, and a commercial repositioning test.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Vistagen | PALISADE-4 Phase 3 topline and post-hoc data:", "url": "https://www.vistagen.com/news-releases/news-release-details/vistagen-announces-topline-and-post-hoc-data-palisade-4-phase-3" }, { "title": "Vistagen | Fasedienol / PH94B overview:", "url": "https://www.vistagen.com/pipeline/PH94B/overview" }, { "title": "ClinicalTrials.gov | NCT06615557 PALISADE-4:", "url": "https://clinicaltrials.gov/study/NCT06615557" }, { "title": "NIMH | Social Anxiety Disorder: What You Need to Know:", "url": "https://www.nimh.nih.gov/health/publications/social-anxiety-disorder-more-than-just-shyness" }, { "title": "SyneuRx | Research and CNS pipeline:", "url": "https://www.syneurx.com/research/" }, { "title": "Lumosa Therapeutics | Neuroscience pipeline:", "url": "https://www.lumosa.com.tw/tw/pipeline/list?id=neuroscience" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html", "title": "社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格", "language": "zh-Hant", "datePublished": "2026-07-11", "dateModified": "2026-07-11", "summary": "一款藥最迷人的時候，常常也是它最危險的時候：市場先愛上故事，臨床才慢慢追問證據。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Vistagen｜PALISADE-4 Phase 3 topline and post-hoc data:", "url": "https://www.vistagen.com/news-releases/news-release-details/vistagen-announces-topline-and-post-hoc-data-palisade-4-phase-3" }, { "title": "Vistagen｜Fasedienol / PH94B overview:", "url": "https://www.vistagen.com/pipeline/PH94B/overview" }, { "title": "ClinicalTrials.gov｜NCT06615557 PALISADE-4:", "url": "https://clinicaltrials.gov/study/NCT06615557" }, { "title": "NIMH｜Social Anxiety Disorder: What You Need to Know:", "url": "https://www.nimh.nih.gov/health/publications/social-anxiety-disorder-more-than-just-shyness" }, { "title": "SyneuRx｜Research and CNS pipeline:", "url": "https://www.syneurx.com/research/" }, { "title": "Lumosa Therapeutics｜Neuroscience pipeline:", "url": "https://www.lumosa.com.tw/tw/pipeline/list?id=neuroscience" }, { "title": "drugnews.com.tw", "url": "https://drugnews.com.tw/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html", "title": "Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy", "language": "en", "datePublished": "2026-07-10", "dateModified": "2026-07-10", "summary": "FDA identified no clinical efficacy or safety concerns that affected NASP's approvability. The setback centered on CMC controls and contract-manufacturing deficiencies, showing biotech investors why manufacturing credibility becomes part of asset value near launch.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Sobi receives Complete Response Letter from FDA for NASP, nanoencapsulated sirolimus plus pegadricase", "url": "https://www.sobi.com/en/press-releases/sobi-receives-complete-response-letter-fda-nasp-nanoencapsulated-sirolimus-plus-pegadricase-2465072" }, { "title": "DISSOLVE I, NCT04513366", "url": "https://clinicaltrials.gov/study/NCT04513366" }, { "title": "DISSOLVE II, NCT04596540", "url": "https://clinicaltrials.gov/study/NCT04596540" }, { "title": "COMPARE, NCT03905512", "url": "https://clinicaltrials.gov/study/NCT03905512" }, { "title": "AR882-301, NCT06846515", "url": "https://clinicaltrials.gov/study/NCT06846515" }, { "title": "AR882-302, NCT06439602", "url": "https://clinicaltrials.gov/study/NCT06439602" }, { "title": "KRYSTEXXA (pegloticase) injection label", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e566303-d93a-4130-b764-25749829aa95" }, { "title": "Active drug license dataset", "url": "https://data.gov.tw/dataset/9123" }, { "title": "Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor", "url": "https://pubmed.ncbi.nlm.nih.gov/41113711/" }, { "title": "Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs", "url": "https://pubmed.ncbi.nlm.nih.gov/40169562/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html", "title": "痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度", "language": "zh-Hant", "datePublished": "2026-07-10", "dateModified": "2026-07-10", "summary": "FDA 並未指出影響 NASP 核准可能性的臨床療效或安全性問題，真正要求補強的是 CMC 控制策略與委託製造設施缺失。這封 CRL 提醒投資人：越接近上市，製造可信度越是藥品價值的一部分。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Sobi receives Complete Response Letter from FDA for NASP, nanoencapsulated sirolimus plus pegadricase", "url": "https://www.sobi.com/en/press-releases/sobi-receives-complete-response-letter-fda-nasp-nanoencapsulated-sirolimus-plus-pegadricase-2465072" }, { "title": "DISSOLVE I, NCT04513366", "url": "https://clinicaltrials.gov/study/NCT04513366" }, { "title": "DISSOLVE II, NCT04596540", "url": "https://clinicaltrials.gov/study/NCT04596540" }, { "title": "COMPARE, NCT03905512", "url": "https://clinicaltrials.gov/study/NCT03905512" }, { "title": "AR882-301, NCT06846515", "url": "https://clinicaltrials.gov/study/NCT06846515" }, { "title": "AR882-302, NCT06439602", "url": "https://clinicaltrials.gov/study/NCT06439602" }, { "title": "KRYSTEXXA（pegloticase）injection label", "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e566303-d93a-4130-b764-25749829aa95" }, { "title": "未註銷藥品許可證資料集", "url": "https://data.gov.tw/dataset/9123" }, { "title": "Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor", "url": "https://pubmed.ncbi.nlm.nih.gov/41113711/" }, { "title": "Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs", "url": "https://pubmed.ncbi.nlm.nih.gov/40169562/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html", "title": "Why Has Japan Struggled to Build Global-Scale Biotech Companies?", "language": "en", "datePublished": "2026-07-09", "dateModified": "2026-07-09", "summary": "Japan has strong science, major pharmaceutical companies, and a large drug market. The harder question is why that foundation has not produced more global-scale biotech startups. The answer is not scientific weakness, but an ecosystem gap across assets, talent, capital, clinical execution, and exits.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Startup Development Five-year Plan", "url": "https://www.cas.go.jp/jp/seisaku/atarashii_sihonsyugi/pdf/sdfyplan2022en.pdf" }, { "title": "Japan country outputs", "url": "https://www.nature.com/nature-index/country-outputs/Japan" }, { "title": "AMED official website", "url": "https://www.amed.go.jp/en/" }, { "title": "Drug Trials Snapshot: Enhertu", "url": "https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-enhertu" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap.html", "title": "日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態", "language": "zh-Hant", "datePublished": "2026-07-09", "dateModified": "2026-07-09", "summary": "日本不是缺少科學，也不是缺少大藥廠，而是缺少把大學技術、人才、資本、臨床與 BD 串成全球級 Biotech 的連續生態。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Startup Development Five-year Plan", "url": "https://www.cas.go.jp/jp/seisaku/atarashii_sihonsyugi/pdf/sdfyplan2022en.pdf" }, { "title": "Japan country outputs", "url": "https://www.nature.com/nature-index/country-outputs/Japan" }, { "title": "AMED official website", "url": "https://www.amed.go.jp/en/" }, { "title": "Drug Trials Snapshot: Enhertu", "url": "https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-enhertu" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html", "title": "GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last", "language": "en", "datePublished": "2026-07-08", "dateModified": "2026-07-08", "summary": "GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial", "url": "https://www.nature.com/articles/s41591-022-01802-6" }, { "title": "Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial", "url": "https://www.nature.com/articles/s41591-022-01803-5" }, { "title": "Weight regain after cessation of medication for weight management: systematic review and meta-analysis", "url": "https://www.bmj.com/content/392/bmj-2025-085304" }, { "title": "FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease" }, { "title": "Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis", "url": "https://www.nejm.org/doi/10.1056/NEJMoa2401943" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "language": "zh-Hant", "datePublished": "2026-07-08", "dateModified": "2026-07-08", "summary": "GLP-1 競爭進入長期維持與聯用下半場，dorzagliatin 的價值不在取代減重藥，而是可能成為代謝治療的可持續底座。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial", "url": "https://www.nature.com/articles/s41591-022-01802-6" }, { "title": "Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial", "url": "https://www.nature.com/articles/s41591-022-01803-5" }, { "title": "Weight regain after cessation of medication for weight management: systematic review and meta-analysis", "url": "https://www.bmj.com/content/392/bmj-2025-085304" }, { "title": "FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease", "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease" }, { "title": "Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis", "url": "https://www.nejm.org/doi/10.1056/NEJMoa2401943" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html", "title": "Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot", "language": "en", "datePublished": "2026-07-07", "dateModified": "2026-07-07", "summary": "After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Pfizer Completes Acquisition of Seagen", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen" }, { "title": "Pfizer Completes Licensing Agreement with 3SBio", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio" }, { "title": "NCT06012435: SGN-B6A versus docetaxel in previously treated NSCLC", "url": "https://clinicaltrials.gov/study/NCT06012435" }, { "title": "NCT06758401: sigvotatug vedotin plus pembrolizumab in PD-L1 high NSCLC", "url": "https://clinicaltrials.gov/study/NCT06758401" }, { "title": "NCT07227298: PF-08634404 combination study in advanced cancers", "url": "https://clinicaltrials.gov/study/NCT07227298" }, { "title": "NCT07222566: PF-08634404 plus chemotherapy in NSCLC", "url": "https://clinicaltrials.gov/study/NCT07222566" }, { "title": "NCT07226999: PF-08634404 in extensive-stage small cell lung cancer", "url": "https://clinicaltrials.gov/study/NCT07226999" }, { "title": "NCT07421700: PF-08634404 plus enfortumab vedotin in urothelial cancer", "url": "https://clinicaltrials.gov/study/NCT07421700" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "language": "zh-Hant", "datePublished": "2026-07-07", "dateModified": "2026-07-07", "summary": "sigvotatug vedotin Phase III 單藥失利後，輝瑞的 430 億美元 Seagen ADC 賭局正轉向 3SBio PD-1/VEGF 雙抗與聯合療法底座。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Pfizer Completes Acquisition of Seagen", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen" }, { "title": "Pfizer Completes Licensing Agreement with 3SBio", "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-licensing-agreement-3sbio" }, { "title": "NCT06012435, SGN-B6A versus docetaxel in previously treated NSCLC", "url": "https://clinicaltrials.gov/study/NCT06012435" }, { "title": "NCT06758401, sigvotatug vedotin plus pembrolizumab in PD-L1 high NSCLC", "url": "https://clinicaltrials.gov/study/NCT06758401" }, { "title": "NCT07227298, PF-08634404 combination study in advanced cancers", "url": "https://clinicaltrials.gov/study/NCT07227298" }, { "title": "NCT07222566, PF-08634404 plus chemotherapy in NSCLC", "url": "https://clinicaltrials.gov/study/NCT07222566" }, { "title": "NCT07226999, PF-08634404 in extensive-stage small cell lung cancer", "url": "https://clinicaltrials.gov/study/NCT07226999" }, { "title": "NCT07421700, PF-08634404 plus enfortumab vedotin in urothelial cancer", "url": "https://clinicaltrials.gov/study/NCT07421700" }, { "title": "drugnews.com.tw", "url": "https://drugnews.com.tw/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html", "title": "Off-the-Shelf CAR-T in 2026: Rebounding From the Trough", "language": "en", "datePublished": "2026-07-06", "dateModified": "2026-07-06", "summary": "Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Original Drugnews Facebook post, Off-the-Shelf CAR-T in 2026:", "url": "https://www.facebook.com/permalink.php?story_fbid=pfbid025GPiNgvtt3Bm4sXCkZLuPWfnLRJmp6FELtp6G3TCh4zV3SquoEJvzsDm1PwBykeJl&id=61568446257142" }, { "title": "Caribou Biosciences pipeline, vispa-cel / CB-010 and ANTLER clinical program:", "url": "https://www.cariboubio.com/pipeline/" }, { "title": "Allogene ALPHA3 trial page, cema-cel for MRD-positive LBCL / DLBCL after first-line therapy:", "url": "https://allogene.com/alpha3/" }, { "title": "ClinicalTrials.gov, ALPHA3 study record:", "url": "https://clinicaltrials.gov/study/NCT06127693" }, { "title": "Wugen pipeline, WU-CART-007 allogeneic CD7-targeted CAR-T program:", "url": "https://wugen.com/pipeline/" }, { "title": "Wugen press release, first patients dosed in pivotal WU-CART-007 trial and previously reported response data:", "url": "https://wugen.com/wugen-announces-dosing-of-first-patients-in-pivotal-trial-of-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-wu-cart-007/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "title": "通用型 CAR-T 的 2026 從低谷回暖", "language": "zh-Hant", "datePublished": "2026-07-06", "dateModified": "2026-07-06", "summary": "邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "藥時事 Facebook 原文，通用型 CAR-T 的 2026 從低谷回暖", "url": "https://www.facebook.com/permalink.php?story_fbid=pfbid025GPiNgvtt3Bm4sXCkZLuPWfnLRJmp6FELtp6G3TCh4zV3SquoEJvzsDm1PwBykeJl&id=61568446257142" }, { "title": "Caribou Biosciences pipeline，vispa-cel / CB-010 and ANTLER clinical program", "url": "https://www.cariboubio.com/pipeline/" }, { "title": "Allogene ALPHA3 trial page，cema-cel for MRD-positive LBCL / DLBCL after first-line therapy", "url": "https://allogene.com/alpha3/" }, { "title": "ClinicalTrials.gov，ALPHA3 study record", "url": "https://clinicaltrials.gov/study/NCT06127693" }, { "title": "Wugen pipeline，WU-CART-007 allogeneic CD7-targeted CAR-T program", "url": "https://wugen.com/pipeline/" }, { "title": "Wugen press release，first patients dosed in pivotal WU-CART-007 trial and previously reported response data", "url": "https://wugen.com/wugen-announces-dosing-of-first-patients-in-pivotal-trial-of-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-wu-cart-007/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html", "title": "Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?", "language": "en", "datePublished": "2026-07-05", "dateModified": "2026-07-05", "summary": "In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "marketwatch.com", "url": "https://www.marketwatch.com/story/abbvie-would-gain-an-experimental-eczema-drug-by-buying-biotech-report-caf24728" }, { "title": "barrons.com", "url": "https://www.barrons.com/articles/nuvalent-stock-gsk-deal-89443e68" }, { "title": "barrons.com", "url": "https://www.barrons.com/articles/eli-lilly-stock-painkillers-acquisition-8da0dbbe" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-experimental-lung-cancer-drug-fails-late-stage-study-2026-06-30/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "language": "zh-Hant", "datePublished": "2026-07-05", "dateModified": "2026-07-05", "summary": "2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "marketwatch.com", "url": "https://www.marketwatch.com/story/abbvie-would-gain-an-experimental-eczema-drug-by-buying-biotech-report-caf24728" }, { "title": "barrons.com", "url": "https://www.barrons.com/articles/nuvalent-stock-gsk-deal-89443e68" }, { "title": "barrons.com", "url": "https://www.barrons.com/articles/eli-lilly-stock-painkillers-acquisition-8da0dbbe" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-experimental-lung-cancer-drug-fails-late-stage-study-2026-06-30/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html", "title": "Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition", "language": "en", "datePublished": "2026-07-04", "dateModified": "2026-07-04", "summary": "Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "HHS, *Operation TrialBlazer: HHS Roadmap to Maintaining U.S. Leadership in Early Clinical Research and Development*:", "url": "https://www.hhs.gov/sites/default/files/operation-trialblazer.pdf" }, { "title": "FDA, *FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development*:", "url": "https://www.fda.gov/drugs/development-resources/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development" }, { "title": "Source post on Dcard by Drugnews:", "url": "https://www.dcard.tw/@drugnews/post/261770223" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "language": "zh-Hant", "datePublished": "2026-07-04", "dateModified": "2026-07-04", "summary": "2026 年 6 月 22 日，美國衛生與公共服務部，也就是 HHS，啟動了一項名為 Operation TrialBlazer 的部門級臨床試驗改革計畫。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "hhs.gov", "url": "https://www.hhs.gov/sites/default/files/operation-trialblazer.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html", "title": "RevMed Says No to Being Bought: Biotech's Independent Era", "language": "en", "datePublished": "2026-07-03", "dateModified": "2026-07-03", "summary": "Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Financial Times report on Revolution Medicines, Merck discussions, and management's stance on a sale:", "url": "https://www.ft.com/content/3b1e5908-1cf4-4cc8-ade2-f0636a90739c" }, { "title": "Investors.com coverage of Revolution Medicines and daraxonrasib pancreatic-cancer data:", "url": "https://www.investors.com/news/technology/revolution-medicines-stock-pancreatic-cancer-treatment/" }, { "title": "Royalty Pharma company disclosures and public information:", "url": "https://www.royaltypharma.com/" }, { "title": "U.S. FDA information on Besremi approval for polycythemia vera:", "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-rare-blood-disease" }, { "title": "Foresee Pharmaceuticals public information on CAMCEVI:", "url": "https://www.foreseepharma.com/" }, { "title": "Formosa Pharmaceuticals public information on APP13007:", "url": "https://www.formosapharma.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html", "title": "拒絕被併購的 RevMed：Biotech 的獨立時代", "language": "zh-Hant", "datePublished": "2026-07-03", "dateModified": "2026-07-03", "summary": "圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Financial Times", "url": "https://www.ft.com/content/3b1e5908-1cf4-4cc8-ade2-f0636a90739c" }, { "title": "Royalty Pharma", "url": "https://www.royaltypharma.com/" }, { "title": "Investor's Business Daily", "url": "https://www.investors.com/news/technology/revolution-medicines-stock-pancreatic-cancer-treatment/" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-rare-blood-disease" }, { "title": "Foresee Pharmaceuticals", "url": "https://www.foreseepharma.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html", "title": "Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find", "language": "en", "datePublished": "2026-07-02", "dateModified": "2026-07-02", "summary": "PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html", "title": "合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？", "language": "zh-Hant", "datePublished": "2026-07-02", "dateModified": "2026-07-02", "summary": "2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "coherentmarketinsights.com", "url": "https://www.coherentmarketinsights.com/" }, { "title": "oncodaily.com", "url": "https://oncodaily.com/" }, { "title": "ir.reparerx.com", "url": "https://ir.reparerx.com/" }, { "title": "fiercebiotech.com", "url": "https://www.fiercebiotech.com/" }, { "title": "debiopharm.com", "url": "https://www.debiopharm.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html", "title": "Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology", "language": "en", "datePublished": "2026-07-01", "dateModified": "2026-07-01", "summary": "Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults", "url": "https://www.otsuka-us.com/" }, { "title": "Centanafadine Demonstrates Statistically Significant, Clinically Relevant Improvements in ADHD Symptoms", "url": "https://www.pharmacytimes.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html", "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳", "language": "zh-Hant", "datePublished": "2026-07-01", "dateModified": "2026-07-01", "summary": "Otsuka 的 ADHD 新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期積極結果，FDA 已接受 NDA 並給予優先審查。這不只是新藥進度，也反映 ADHD 治療正在從單一路徑走向更多機制與病人分層。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults", "url": "https://www.otsuka-us.com/" }, { "title": "Centanafadine Demonstrates Statistically Significant, Clinically Relevant Improvements in ADHD Symptoms", "url": "https://www.pharmacytimes.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html", "title": "GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy", "language": "en", "datePublished": "2026-06-30", "dateModified": "2026-06-30", "summary": "GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "The Guardian: GSK to buy US cancer treatment firm Nuvalent in $10bn deal", "url": "https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels" }, { "title": "Investor's Business Daily: Nuvalent stock surges on GSK acquisition", "url": "https://www.investors.com/news/technology/nuvalent-stock-gsk-acquisition/" }, { "title": "MarketWatch: GSK announces its biggest purchase in eight years", "url": "https://www.marketwatch.com/story/gsk-just-announced-its-biggest-purchase-in-eight-years-to-rev-up-cancer-portfolio-it-had-previously-wound-down-a95e6065" }, { "title": "Barron's: Nuvalent stock jumps on GSK cancer deal", "url": "https://www.barrons.com/articles/nuvalent-stock-gsk-cancer-deal-89443e68" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html", "title": "GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌", "language": "zh-Hant", "datePublished": "2026-06-30", "dateModified": "2026-06-30", "summary": "2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "The Guardian: GSK to buy US cancer treatment firm Nuvalent in $10bn deal", "url": "https://www.theguardian.com/business/2026/jun/09/gsk-buy-us-cancer-treatment-firm-nuvalent-luke-miels" }, { "title": "Investor's Business Daily: Nuvalent stock surges on GSK acquisition", "url": "https://www.investors.com/news/technology/nuvalent-stock-gsk-acquisition/" }, { "title": "MarketWatch: GSK announces its biggest purchase in eight years", "url": "https://www.marketwatch.com/story/gsk-just-announced-its-biggest-purchase-in-eight-years-to-rev-up-cancer-portfolio-it-had-previously-wound-down-a95e6065" }, { "title": "Barron's: Nuvalent stock jumps on GSK cancer deal", "url": "https://www.barrons.com/articles/nuvalent-stock-gsk-cancer-deal-89443e68" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html", "title": "The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors", "language": "en", "datePublished": "2026-06-29", "dateModified": "2026-06-29", "summary": "Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Parabilis Medicines official website and investor relations materials,", "url": "https://parabilismed.com/" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Pricing of Upsized Initial Public Offering\", 2026-06-09,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-pricing-upsized-initial-public" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares\", 2026-06-11,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-closing-upsized-initial-public" }, { "title": "Parabilis Medicines, \"About Helicons\",", "url": "https://parabilismed.com/innovation/about-helicons/" }, { "title": "Parabilis Medicines, \"Zolucatetide\",", "url": "https://parabilismed.com/program/fog-001/" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas\", 2026-05-18,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-strategic-collaboration-regeneron" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform\", 2026-01-08,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-oversubscribed-305-million" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html", "title": "美股迎來史上最大 Biotech IPO", "language": "zh-Hant", "datePublished": "2026-06-29", "dateModified": "2026-06-29", "summary": "台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Parabilis Medicines 官方網站與投資人關係資料，", "url": "https://parabilismed.com/" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Pricing of Upsized Initial Public Offering\", 2026-06-09,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-pricing-upsized-initial-public" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares\", 2026-06-11,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-closing-upsized-initial-public" }, { "title": "Parabilis Medicines, \"About Helicons\",", "url": "https://parabilismed.com/innovation/about-helicons/" }, { "title": "Parabilis Medicines, \"Zolucatetide\",", "url": "https://parabilismed.com/program/fog-001/" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas\", 2026-05-18,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-strategic-collaboration-regeneron" }, { "title": "Parabilis Medicines, \"Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform\", 2026-01-08,", "url": "https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-oversubscribed-305-million" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html", "title": "The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer", "language": "en", "datePublished": "2026-06-28", "dateModified": "2026-06-28", "summary": "Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Biotech Shares Are Soaring", "url": "https://www.barrons.com/articles/biotech-shares-xbi-ff82f9cb" }, { "title": "Clinical Trials and Human Subject Protection", "url": "https://www.fda.gov/drugs/development-approval-process-drugs/clinical-trials-and-human-subject-protection" }, { "title": "Vaccines and Related Biological Products Advisory Committee", "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-and-related-biological-products-advisory-committee" }, { "title": "FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says", "url": "https://www.wsj.com/tech/biotech/fda-will-reverse-rejection-of-third-rare-disease-drug-regenxbio-says-d8fff1fc" }, { "title": "RGX-121 / Navsunli program information", "url": "https://www.regenxbio.com/pipeline/rgx-121/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html", "title": "FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起", "language": "zh-Hant", "datePublished": "2026-06-28", "dateModified": "2026-06-28", "summary": "代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Biotech Shares Are Soaring", "url": "https://www.barrons.com/articles/biotech-shares-xbi-ff82f9cb" }, { "title": "Clinical Trials and Human Subject Protection", "url": "https://www.fda.gov/drugs/development-approval-process-drugs/clinical-trials-and-human-subject-protection" }, { "title": "Vaccines and Related Biological Products Advisory Committee", "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-and-related-biological-products-advisory-committee" }, { "title": "FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says", "url": "https://www.wsj.com/tech/biotech/fda-will-reverse-rejection-of-third-rare-disease-drug-regenxbio-says-d8fff1fc" }, { "title": "RGX-121 / Navsunli program information", "url": "https://www.regenxbio.com/pipeline/rgx-121/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html", "title": "Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside", "language": "en", "datePublished": "2026-06-27", "dateModified": "2026-06-27", "summary": "Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "PubMed｜Daraxonrasib / RASolute-302-related research:", "url": "https://pubmed.ncbi.nlm.nih.gov/42223072/" }, { "title": "Tango Therapeutics｜PRMT5 program overview:", "url": "https://www.tangotx.com/programs/prmt5/" }, { "title": "Investor's Business Daily｜Tango Therapeutics / Revolution Medicines combination data coverage:", "url": "https://www.investors.com/news/technology/tango-therapeutics-tngx-stock-revolution-medicines-rvmd-stock-pancreatic-cancer/" }, { "title": "IDEAYA Biosciences｜IDE892 initiates a Phase 1/2 clinical combination study in MTAP-deleted pancreatic and lung cancers:", "url": "https://ir.ideayabio.com/2026-06-15-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-a-Phase-1-2-Clinical-Combination-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers" }, { "title": "IDEAYA Biosciences｜First patient in for Phase 1 trial of IDE892 and MTAP/CDKN2A pipeline update:", "url": "https://ir.ideayabio.com/2026-03-09-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE892,-a-Potential-Best-In-Class-PRMT5-Inhibitor-for-MTAP-Deleted-Solid-Tumors,-and-Provides-MTAP-and-CDKN2A-Pipeline-Update" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "language": "zh-Hant", "datePublished": "2026-06-27", "dateModified": "2026-06-27", "summary": "胰臟癌正在進入 RAS 抑制劑與 PRMT5／MAT2A 合成致死聯合療法的新階段，市場開始重新評估 daraxonrasib 作為治療骨架的價值。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "PubMed｜Daraxonrasib / RASolute-302 相關研究", "url": "https://pubmed.ncbi.nlm.nih.gov/42223072/" }, { "title": "Tango Therapeutics｜PRMT5 program overview", "url": "https://www.tangotx.com/programs/prmt5/" }, { "title": "Investor's Business Daily｜Tango Therapeutics / Revolution Medicines combination data coverage", "url": "https://www.investors.com/news/technology/tango-therapeutics-tngx-stock-revolution-medicines-rvmd-stock-pancreatic-cancer/" }, { "title": "IDEAYA Biosciences｜IDE892 initiates Phase 1/2 clinical combination study in MTAP-deleted pancreatic and lung cancers", "url": "https://ir.ideayabio.com/2026-06-15-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-a-Phase-1-2-Clinical-Combination-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers" }, { "title": "IDEAYA Biosciences｜First patient in for Phase 1 trial of IDE892 and MTAP/CDKN2A pipeline update", "url": "https://ir.ideayabio.com/2026-03-09-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE892,-a-Potential-Best-In-Class-PRMT5-Inhibitor-for-MTAP-Deleted-Solid-Tumors,-and-Provides-MTAP-and-CDKN2A-Pipeline-Update" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html", "title": "Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?", "language": "en", "datePublished": "2026-06-26", "dateModified": "2026-06-26", "summary": "Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "Lilly. Zepbound prescribing information.", "url": "https://uspl.lilly.com/zepbound/zepbound.html#pi" }, { "title": "Lilly. Taltz prescribing information.", "url": "https://uspl.lilly.com/taltz/taltz.html#pi" }, { "title": "Lilly. COMMIT-CD clinical trial page.", "url": "https://trials.lilly.com/en-US/trial/600156" }, { "title": "Lilly. Omvoh prescribing information.", "url": "https://uspl.lilly.com/omvoh/omvoh.html#pi" }, { "title": "AbbVie. Rinvoq prescribing information.", "url": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html", "title": "神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？", "language": "zh-Hant", "datePublished": "2026-06-26", "dateModified": "2026-06-26", "summary": "它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Eli Lilly and Company｜Zepbound (tirzepatide) U.S. prescribing information:", "url": "https://uspl.lilly.com/zepbound/zepbound.html#pi" }, { "title": "Eli Lilly and Company｜Taltz (ixekizumab) U.S. prescribing information:", "url": "https://uspl.lilly.com/taltz/taltz.html#pi" }, { "title": "Eli Lilly and Company｜COMMIT-CD clinical trial: mirikizumab and tirzepatide in Crohn's disease with obesity or overweight:", "url": "https://trials.lilly.com/en-US/trial/600156" }, { "title": "Eli Lilly and Company｜Omvoh (mirikizumab) U.S. prescribing information:", "url": "https://uspl.lilly.com/omvoh/omvoh.html#pi" }, { "title": "AbbVie｜Rinvoq (upadacitinib) U.S. prescribing information:", "url": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html", "title": "Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet", "language": "en", "datePublished": "2026-06-25", "dateModified": "2026-06-25", "summary": "As companion animals age and owners become more willing to pay for serious-disease care, the next major question in pet medicine is whether a platform company can connect drugs, diagnostics, veterinary clinics, regulation, manufacturing, channels, and data into one defensible system.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [ { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/companion-animal-medicine-market-report" }, { "title": "roche.com", "url": "https://www.roche.com/investors/annualreport25" }, { "title": "companiesmarketcap.com", "url": "https://companiesmarketcap.com/roche/marketcap/" }, { "title": "finance.yahoo.com", "url": "https://finance.yahoo.com" }, { "title": "marketbeat.com", "url": "https://www.marketbeat.com/compare-stocks/" }, { "title": "healthforanimals.org", "url": "https://www.healthforanimals.org/reports/innovation-report/" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/animal-veterinary/development-approval-process/new-animal-drug-applications" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/media/106055/download" }, { "title": "moa.gov.tw", "url": "https://www.moa.gov.tw" }, { "title": "law.moa.gov.tw", "url": "https://law.moa.gov.tw/LawContent.aspx?id=GL001397" }, { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/veterinary-oncology-market" }, { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/veterinary-cardiology-market-report" }, { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/companion-animal-diagnostics-market" }, { "title": "gminsights.com", "url": "https://www.gminsights.com/industry-analysis/pet-cancer-therapeutics-market" }, { "title": "gminsights.com", "url": "https://www.gminsights.com/industry-analysis/veterinary-autoimmune-disease-therapeutics-market" }, { "title": "iqvia.com", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicines-2026" }, { "title": "biotech-edu.com", "url": "https://www.biotech-edu.com/protect-over-the-counter/" }, { "title": "genetinfo.com", "url": "https://www.genetinfo.com/investment/featured/item/88559.html" }, { "title": "mountainvet.com.tw", "url": "https://www.mountainvet.com.tw/regenerative/%E7%89%A7%E9%A8%B0%E7%94%9F%E7%89%A9%E8%88%87%E5%AF%B6%E6%B3%B0%E7%94%9F%E9%86%AB%E7%AD%96%E7%95%A5%E7%B5%90%E7%9B%9F-%E6%90%B6%E6%94%BB%E5%B9%B4%E5%8D%83%E5%84%84%E6%AF%9B%E5%AD%A9%E5%95%86%E6%A9%9F/" }, { "title": "beileybiofund.com", "url": "https://www.beileybiofund.com/blogs/portfolio-news/protect20260506" }, { "title": "cnyes.com", "url": "https://www.cnyes.com/twstock/7850" }, { "title": "tpex.org.tw", "url": "https://www.tpex.org.tw/zh-tw/esb/trading/info/stock-pricing.html?code=7850" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html", "title": "邁向「寵物醫療界羅氏」的寶泰生醫", "language": "zh-Hant", "datePublished": "2026-06-25", "dateModified": "2026-06-25", "summary": "當毛孩高齡化趨勢推動癌症、心臟病與自體免疫等重症治療的需求升級，市場的長期觀察核心，在於誰能率先打造一座寵物重症新藥平台，成為『寵物醫療界羅氏』。而這一改寫行業格局的答案，正於台灣的一家生技公司加速浮現。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/companion-animal-medicine-market-report" }, { "title": "roche.com", "url": "https://www.roche.com/investors/annualreport25" }, { "title": "companiesmarketcap.com", "url": "https://companiesmarketcap.com/roche/marketcap/" }, { "title": "finance.yahoo.com", "url": "https://finance.yahoo.com" }, { "title": "marketbeat.com", "url": "https://www.marketbeat.com/compare-stocks/" }, { "title": "healthforanimals.org", "url": "https://www.healthforanimals.org/reports/innovation-report/" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/animal-veterinary/development-approval-process/new-animal-drug-applications" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/media/106055/download" }, { "title": "moa.gov.tw", "url": "https://www.moa.gov.tw" }, { "title": "law.moa.gov.tw", "url": "https://law.moa.gov.tw/LawContent.aspx?id=GL001397" }, { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/veterinary-oncology-market" }, { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/veterinary-cardiology-market-report" }, { "title": "grandviewresearch.com", "url": "https://www.grandviewresearch.com/industry-analysis/companion-animal-diagnostics-market" }, { "title": "gminsights.com", "url": "https://www.gminsights.com/industry-analysis/pet-cancer-therapeutics-market" }, { "title": "gminsights.com", "url": "https://www.gminsights.com/industry-analysis/veterinary-autoimmune-disease-therapeutics-market" }, { "title": "iqvia.com", "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicines-2026" }, { "title": "iqvia.com", "url": "https://www.iqvia.com/newsroom/2021/04/global-medicine-spending-to-reach-16-trillion-in-2025-excluding-spending-on-covid-19-vaccines-accord" }, { "title": "biotech-edu.com", "url": "https://www.biotech-edu.com/protect-over-the-counter/" }, { "title": "genetinfo.com", "url": "https://www.genetinfo.com/investment/featured/item/88559.html" }, { "title": "mountainvet.com.tw", "url": "https://www.mountainvet.com.tw/regenerative/%E7%89%A7%E9%A8%B0%E7%94%9F%E7%89%A9%E8%88%87%E5%AF%B6%E6%B3%B0%E7%94%9F%E9%86%AB%E7%AD%96%E7%95%A5%E7%B5%90%E7%9B%9F-%E6%90%B6%E6%94%BB%E5%B9%B4%E5%8D%83%E5%84%84%E6%AF%9B%E5%AD%A9%E5%95%86%E6%A9%9F/" }, { "title": "beileybiofund.com", "url": "https://www.beileybiofund.com/blogs/portfolio-news/protect20260506" }, { "title": "cnyes.com", "url": "https://www.cnyes.com/twstock/7850" }, { "title": "tpex.org.tw", "url": "https://www.tpex.org.tw/zh-tw/esb/trading/info/stock-pricing.html?code=7850" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html", "title": "Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head", "language": "en", "datePublished": "2026-06-24", "dateModified": "2026-06-24", "summary": "Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html", "title": "AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu", "language": "zh-Hant", "datePublished": "2026-06-24", "dateModified": "2026-06-24", "summary": "過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizu…", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-jjs-oral-psoriasis-pill-2026-03-18/" }, { "title": "schrodinger.com", "url": "https://www.schrodinger.com/design-of-a-highly-selective-allosteric-picomolar-tyk2-inhibitor-using-novel-fep-strategies/" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/takedas-ai-crafted-psoriasis-pill-succeeds-late-stage-studies-2025-12-18/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html", "title": "The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?", "language": "en", "datePublished": "2026-06-22", "dateModified": "2026-06-22", "summary": "Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html", "title": "減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？", "language": "zh-Hant", "datePublished": "2026-06-22", "dateModified": "2026-06-22", "summary": "今年 ADA，也就是美國糖尿病學會年會，減重藥戰場又一次被點燃。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Eli Lilly and Company｜Zepbound (tirzepatide) U.S. prescribing information:", "url": "https://uspl.lilly.com/zepbound/zepbound.html#pi" }, { "title": "Novo Nordisk｜Wegovy U.S. prescribing information:", "url": "https://www.novo-pi.com/wegovy.pdf" }, { "title": "Eli Lilly and Company｜Orforglipron phase 3 / oral GLP-1 investor information:", "url": "https://investor.lilly.com/" }, { "title": "Pfizer｜Danuglipron and obesity pipeline investor information:", "url": "https://www.pfizer.com/science/drug-product-pipeline" }, { "title": "Roche｜CT-388 / Carmot Therapeutics obesity pipeline investor information:", "url": "https://www.roche.com/media/releases/med-cor-2026-03-05" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html", "title": "Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer", "language": "en", "datePublished": "2026-06-21", "dateModified": "2026-06-21", "summary": "Merck's more serious positioning of MK-2010 suggests that PD-1/VEGF bispecifics are moving from a watch item to a strategic option in the post-Keytruda oncology landscape.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html", "title": "默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近", "language": "zh-Hant", "datePublished": "2026-06-21", "dateModified": "2026-06-21", "summary": "在全球腫瘤藥市場裡，很少有一家公司比 Merck（默沙東）更懂 PD-1。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Merck product pipeline", "url": "https://www.merck.com/research/product-pipeline/" }, { "title": "Merck Keytruda prescribing information", "url": "https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf" }, { "title": "Summit Therapeutics: ivonescimab clinical development", "url": "https://www.smmttx.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html", "title": "Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy", "language": "en", "datePublished": "2026-06-20", "dateModified": "2026-06-20", "summary": "Enlivex's paper gain from RAIN tokens shows how fragile biotech business models can create unusual treasury stories when operating revenue is absent and capital markets are difficult.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html", "title": "【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】", "language": "zh-Hant", "datePublished": "2026-06-20", "dateModified": "2026-06-20", "summary": "一家臨床階段 Biotech，沒有藥品銷售收入，卻在一年內做出 12 億美元級別的淨利。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Enlivex Therapeutics｜Investor relations and company filings:", "url": "https://enlivex.com/investors/" }, { "title": "GlobeNewswire｜Enlivex company news releases:", "url": "https://www.globenewswire.com/search/organization/Enlivex%2520Therapeutics" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html", "title": "GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases", "language": "en", "datePublished": "2026-06-19", "dateModified": "2026-06-19", "summary": "GSK is not merely buying three lung-cancer pipelines. It is buying a next-generation precision-oncology strategy around resistance, CNS activity, and cleaner kinase inhibition.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html", "title": "GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法", "language": "zh-Hant", "datePublished": "2026-06-19", "dateModified": "2026-06-19", "summary": "2026 年 6 月 9 日，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元，較 Nuvalent 前一交易日收盤價溢價約 40%。這是 GSK 近年最大型的腫瘤併購之一，也讓它瞬間補上肺癌精準治療版圖中最缺的一塊。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "GSK｜Investor relations and company announcements:", "url": "https://www.gsk.com/en-gb/investors/" }, { "title": "Nuvalent｜Investor relations and company news:", "url": "https://investors.nuvalent.com/" }, { "title": "Nuvalent｜Pipeline overview:", "url": "https://www.nuvalent.com/pipeline/" }, { "title": "Reuters｜Health and pharmaceutical M&A coverage:", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html", "title": "Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King", "language": "en", "datePublished": "2026-06-17", "dateModified": "2026-06-17", "summary": "Ecnoglutide's head-to-head weight-loss data versus semaglutide are interesting, but the GLP-1 race will be decided by long-term outcomes, tolerability, labels, supply, and global evidence.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html", "title": "GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？", "language": "zh-Hant", "datePublished": "2026-06-17", "dateModified": "2026-06-17", "summary": "ADA 2026 剛落幕，GLP-1 賽道又被一組頭對頭資料點燃。Ecnoglutide 在 20 週減重數字上勝出，但真正的競爭不只看短期體重下降，而是長期健康結局、耐受性、產品矩陣與全球商業化。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Novo Nordisk｜Wegovy U.S. prescribing information:", "url": "https://www.novo-pi.com/wegovy.pdf" }, { "title": "Pfizer｜Obesity and metabolic disease pipeline:", "url": "https://www.pfizer.com/science/drug-product-pipeline" }, { "title": "Sciwind Biosciences｜Ecnoglutide / GLP-1 pipeline and company information:", "url": "https://www.sciwind.com/" }, { "title": "U.S. FDA｜Drug approvals and databases:", "url": "https://www.fda.gov/drugs" }, { "title": "World Health Organization｜Essential medicines and health-product updates:", "url": "https://www.who.int/teams/health-product-policy-and-standards/essential-medicines" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html", "title": "Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?", "language": "en", "datePublished": "2026-06-16", "dateModified": "2026-06-16", "summary": "Lilly's vaccine acquisitions show that the company is using obesity-drug cash flow to widen its long-term disease-prevention and immunology strategy.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html", "title": "禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？", "language": "zh-Hant", "datePublished": "2026-06-16", "dateModified": "2026-06-16", "summary": "市場現在最熟悉的禮來，是 Mounjaro、Zepbound 背後那個 GLP-1 巨頭。2026 年第一季，禮來營收達到 198 億美元，年增 56%，主要動能還是來自 Mounjaro 與 Zepbound 的放量。簡單說，禮來現在手上最強的現金流，是減重與糖尿病藥物。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Eli Lilly｜Lilly announces three acquisitions to build infectious disease portfolio:", "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease" }, { "title": "Eli Lilly｜Q1 2026 Financial Results:", "url": "https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2026-financial-results-raises-full" }, { "title": "HHS｜HHS Winds Down mRNA Vaccine Development Under BARDA:", "url": "https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html" }, { "title": "JAMA｜HHS Ends mRNA Vaccine Development:", "url": "https://jamanetwork.com/journals/jama/fullarticle/2838469" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html", "title": "ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle", "language": "en", "datePublished": "2026-06-15", "dateModified": "2026-06-15", "summary": "ASCO 2026 showed that oncology is moving from single-mechanism breakthroughs toward platform combinations across RAS targeting, ADCs, PD-1/VEGF bispecifics, and in vivo CAR-T.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html", "title": "2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代", "language": "zh-Hant", "datePublished": "2026-06-15", "dateModified": "2026-06-15", "summary": "2026 年美國臨床腫瘤學會年會，也就是 ASCO，最該被記住的贏家，並不是任何一家藥廠，而是癌症患者。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "ASCO｜Abstracts and presentations:", "url": "https://www.asco.org/abstracts-presentations/267303" }, { "title": "Revolution Medicines｜Investor relations and clinical updates:", "url": "https://ir.revmed.com/" }, { "title": "BioNTech｜Oncology pipeline and company news:", "url": "https://investors.biontech.de/" }, { "title": "Kelonia Therapeutics｜Company news and presentations:", "url": "https://keloniatx.com/news/" }, { "title": "Reuters｜Healthcare and pharmaceutical industry coverage:", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html", "title": "Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science", "language": "en", "datePublished": "2026-06-14", "dateModified": "2026-06-14", "summary": "Revolution Medicines shows why next-generation biotech companies need to convert clinical momentum into capital momentum if they want to finish expensive global drug-development races.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html", "title": "Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑", "language": "zh-Hant", "datePublished": "2026-06-14", "dateModified": "2026-06-14", "summary": "2026 年，全球最受矚目的 Biotech 之一，毫無疑問是 Revolution Medicines。這家公司站在一個極難、也極誘人的位置：RAS-addicted cancers。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13/" }, { "title": "biospace.com", "url": "https://www.biospace.com/press-releases/revolution-medicines-reports-first-quarter-2026-financial-results-and-update-on-corporate-progress" }, { "title": "ir.revmed.com", "url": "https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit" }, { "title": "ir.revmed.com", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-closing-upsized-public-offering-2/" }, { "title": "ir.revmed.com", "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-inc-announces-proposed-offerings-common" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html", "title": "The Next Phase of AI Drug Development: Making Molecules Survive as Drugs", "language": "en", "datePublished": "2026-06-13", "dateModified": "2026-06-13", "summary": "AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html", "title": "AI製藥下半場：讓藥活下來", "language": "zh-Hant", "datePublished": "2026-06-13", "dateModified": "2026-06-13", "summary": "AI 醫藥上半場比生成分子，下半場比成藥存活率。安宏真正值得被看見的，不是單純曝光，而是用 AI + PROTAC（蛋白質降解技術）、實驗閉環與人體轉譯，嘗試形成高資本效率的 clinical asset engine（臨床資產生成引擎）。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html", "title": "Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check", "language": "en", "datePublished": "2026-06-12", "dateModified": "2026-06-12", "summary": "AI drug discovery has moved beyond the concept stage and into clinical validation. This article reviews Zasocitinib, GB-0895, Zovegalisib, and REC-4881 to examine how different AI strategies are being converted into real drug assets.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html", "title": "盤點整理，AI藥物開發走得如何了？", "language": "zh-Hant", "datePublished": "2026-06-12", "dateModified": "2026-06-12", "summary": "AI 製藥已從概念走向臨床驗證。這篇盤點 Zasocitinib、GB-0895、Zovegalisib、REC-4881 等代表管線，拆解不同 AI 路線如何轉化成真正的藥物資產。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html", "title": "Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital", "language": "en", "datePublished": "2026-06-11", "dateModified": "2026-06-11", "summary": "GLP-1 is no longer only a weight-loss topic. It is redirecting biotech capital, BD urgency, manufacturing attention, and valuation imagination across global pharma.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html", "title": "減肥成王：GLP-1 正在把全球生技資本重新洗牌", "language": "zh-Hant", "datePublished": "2026-06-11", "dateModified": "2026-06-11", "summary": "GLP-1 不只是減重藥題材，而是重新配置全球藥廠研發預算、產能投資、BD 談判與生技估值規則的核心變數。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html", "title": "Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories", "language": "en", "datePublished": "2026-06-10", "dateModified": "2026-06-10", "summary": "Biotech IR is not cosmetic storytelling. Good IR turns clinical, CMC, regulatory, commercial, and financing milestones into a capital-market narrative that investors can actually track.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html", "title": "生醫公司 IR 不是把簡報變漂亮，而是把管線變成可追蹤的資本市場故事", "language": "zh-Hant", "datePublished": "2026-06-10", "dateModified": "2026-06-10", "summary": "好的 IR 內容不是宣傳話術，而是把臨床、CMC、監管、商業化與對標公司轉成投資人可以追蹤的節點。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html", "title": "RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War", "language": "en", "datePublished": "2026-06-10", "dateModified": "2026-06-10", "summary": "Daraxonrasib opens a new pancreatic-cancer window, but the next value question is resistance management. Senhwa's CX-5461 matters if it can become a rational combination partner.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html", "title": "RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰", "language": "zh-Hant", "datePublished": "2026-06-10", "dateModified": "2026-06-10", "summary": "Daraxonrasib 打開胰臟癌 RAS 標靶時代後，真正的下一場戰爭是抗藥性管理；生華科 CX-5461 的價值在於能否成為 RAS 標靶後時代的免疫增敏與聯合治療候選策略。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html", "title": "The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era", "language": "en", "datePublished": "2026-06-09", "dateModified": "2026-06-09", "summary": "Curium's rumored interest in Lantheus is best read as a bid for nuclear-medicine infrastructure: isotope access, hospital channels, imaging workflow, and radiopharma commercialization depth.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html", "title": "70億美元核藥併購傳聞：Curium想買Lantheus，真正買的是一張核藥時代的入場券", "language": "zh-Hant", "datePublished": "2026-06-09", "dateModified": "2026-06-09", "summary": "Curium 傳出有意以約 70 億美元收購 Lantheus。這不只是核藥併購傳聞，而是診斷、製造、配送、院端網絡與治療端能力整合的產業訊號。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html", "title": "CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease", "language": "en", "datePublished": "2026-06-08", "dateModified": "2026-06-08", "summary": "CAR-T's move from blood cancer into autoimmune disease could redefine cell therapy, but the value depends on whether deep immune reset can justify manufacturing complexity, safety risk, and cost.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html", "title": "CAR-T 迎接新時代：從血癌走向自體免疫", "language": "zh-Hant", "datePublished": "2026-06-08", "dateModified": "2026-06-08", "summary": "Kyverna 啟動 mivocabtagene autoleucel 的 BLA 滾動式提交，象徵 CAR-T 從血癌治療走向自體免疫疾病的新階段，也重新打開細胞治療的商業想像。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "ir.kyvernatx.com", "url": "https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-announces-initiation-rolling-sps-bla" }, { "title": "ir.cartesiantherapeutics.com", "url": "https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-highlights-recent-progress-and-outlines" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html", "title": "Drugmakers Without AI Capability May No Longer Be Called Drugmakers", "language": "en", "datePublished": "2026-06-07", "dateModified": "2026-06-07", "summary": "AI is becoming a core operating capability for pharma, but its value comes from improving discovery, translation, trial design, and portfolio decisions rather than from marketing language alone.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html", "title": "沒有 AI 能力的藥廠，將不再被稱作藥廠", "language": "zh-Hant", "datePublished": "2026-06-07", "dateModified": "2026-06-07", "summary": "AI 正在從工具變成製藥公司的底層能力。未來藥廠不只比管線，也會比資料、模型、實驗自動化與決策速度，沒有 AI 能力的公司將愈來愈難被視為現代藥廠。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "hpcwire.com", "url": "https://www.hpcwire.com/2026/05/20/google-advances-ai-for-science-with-new-tools-and-tech/" }, { "title": "isomorphiclabs.com", "url": "https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-extends-partnership-with-insilico-medicine-ai-powered-drug-discovery-2026-03-30/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html", "title": "Old Targets Are Crowded, but They Can Still Make Money", "language": "en", "datePublished": "2026-06-06", "dateModified": "2026-06-06", "summary": "Crowded drug targets can still create value when companies differentiate through patient selection, formulation, route of administration, clinical design, pricing, or commercial channel strategy.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html", "title": "老靶點都很捲，但不是不能賺錢", "language": "zh-Hant", "datePublished": "2026-06-06", "dateModified": "2026-06-06", "summary": "熱門靶點擁擠不代表沒有價值；真正關鍵是公司能否在身位、差異化、適應症切入、技術換代與 BD 對接中找到自己的獲利位置。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html", "title": "Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug", "language": "en", "datePublished": "2026-06-05", "dateModified": "2026-06-05", "summary": "Topical JAK drugs are not won by target biology alone. The real value lies in skin delivery, local exposure, systemic safety, indication choice, and whether the product can fit daily dermatology practice.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html", "title": "從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？", "language": "zh-Hant", "datePublished": "2026-06-05", "dateModified": "2026-06-05", "summary": "外用 JAK 抑制劑的核心不是單純抑制 JAK，而是分子能否穿過皮膚、留在局部、降低全身暴露，並在適應症與製劑設計上建立差異化。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html", "title": "Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena", "language": "en", "datePublished": "2026-06-04", "dateModified": "2026-06-04", "summary": "Retatrutide pushes obesity-drug efficacy toward surgery-level territory, but the real competitive battle will be durability, tolerability, body composition, comorbidity benefit, and access.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html", "title": "Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場", "language": "zh-Hant", "datePublished": "2026-06-04", "dateModified": "2026-06-04", "summary": "Eli Lilly 的 retatrutide 在三期試驗中把減重幅度推向接近手術級別，代表肥胖治療正從單一路徑抑制食慾，走向多受體代謝調控的新戰場。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html", "title": "A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era", "language": "en", "datePublished": "2026-06-03", "dateModified": "2026-06-03", "summary": "AATD is entering a new treatment cycle after decades of limited options, with RNA and gene-based approaches trying to move the field beyond symptom control and protein replacement.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html", "title": "40年沒藥的遺傳病迎來重磅進展", "language": "zh-Hant", "datePublished": "2026-06-03", "dateModified": "2026-06-03", "summary": "AATD 治療在近 40 年後迎來新療法競速，Sanofi、Wave、Beam 分別以長效重組蛋白、RNA 編輯與基因鹼基編輯切入，代表罕見遺傳病治療正從補蛋白走向根源修正。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html", "title": "Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?", "language": "en", "datePublished": "2026-06-02", "dateModified": "2026-06-02", "summary": "Biogen's BIIB080 tau program reflects a broader Alzheimer's reset: the field is no longer only asking whether amyloid matters, but whether tau biology can produce measurable disease-modifying benefit.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html", "title": "Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？", "language": "zh-Hant", "datePublished": "2026-06-02", "dateModified": "2026-06-02", "summary": "Biogen 在 BIIB080 / diranersen 的 Phase 2 CELIA 研究未達主要終點後仍推進 Phase 3，反映 AD 研發裡 tau 靶點的高風險、高需求與策略性押注。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html", "title": "Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means", "language": "en", "datePublished": "2026-06-01", "dateModified": "2026-06-01", "summary": "Pluvicto's rapid growth shows radioligand therapy moving from specialist science into a real commercial infrastructure story, where isotope supply, hospital workflow, and patient selection become strategic assets.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html", "title": "核藥賣爆了", "language": "zh-Hant", "datePublished": "2026-06-01", "dateModified": "2026-06-01", "summary": "Pluvicto 單季銷售達 6.42 億美元，顯示攝護腺癌治療正從荷爾蒙訊號攻防，走向 PSMA 核醫診療一體化與放射配體療法的新階段。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html", "title": "The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal", "language": "en", "datePublished": "2026-05-31", "dateModified": "2026-05-31", "summary": "A Drugnews English brief on The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html", "title": "⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣", "language": "zh-Hant", "datePublished": "2026-05-31", "dateModified": "2026-05-31", "summary": "Tavneos 從罕病明星藥站上撤市邊緣，真正危機不只是日本死亡通報與肝毒性，而是 FDA 對 ADVOCATE 試驗資料完整性的嚴重指控。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/amgens-rare-disease-drug-linked-deaths-liver-injuries-japan-wsj-reports-2026-05-15/" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-liver-injury-cases-tied-amgens-rare-disease-drug-2026-03-31/" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/media/192160/download?attachment=" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html", "title": "The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy", "language": "en", "datePublished": "2026-05-30", "dateModified": "2026-05-30", "summary": "A Drugnews English brief on The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html", "title": "藥王的最佳搭檔？療效翻倍！", "language": "zh-Hant", "datePublished": "2026-05-30", "dateModified": "2026-05-30", "summary": "Keytruda 專利懸崖前，下一代聯合治療能否提高療效天花板與延長生命週期，是藥王商業價值的關鍵問題。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "ascopost.com", "url": "https://ascopost.com/issues/june-25-2019/fda-approves-pembrolizumab-for-the-first-line-treatment-of-hnscc/" }, { "title": "reuters.com", "url": "https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/" }, { "title": "sec.gov", "url": "https://www.sec.gov/Archives/edgar/data/1434265/000094787125000868/ss5386579_exa5a.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html", "title": "Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming", "language": "en", "datePublished": "2026-05-29", "dateModified": "2026-05-29", "summary": "A Drugnews English brief on Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions.html", "title": "減重藥物不只看體重了：下一代療法正在瞄準這些方向", "language": "zh-Hant", "datePublished": "2026-05-29", "dateModified": "2026-05-29", "summary": "下一代減重療法不只比體重下降，也要看肌肉保留、脂肪肝、心血管與代謝共病等更完整臨床價值。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "Our Review on the evolving landscape of obesity pharmacotherapy is now online in Nature Reviews Drug Discovery: Together with Jonas Odgaard Petersen, Valdemar Brimnes Ingemann Johansen, Brian Finan and Timo Müller, we discuss h", "url": "https://lnkd.in/evwpfiV9" }, { "title": "novonordisk.com", "url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-obesity-drug-shows-weight-loss-up-145-mid-stage-study-2025-11-25/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html", "title": "Biotech Investing Needs a Judgment System, Not More News", "language": "en", "datePublished": "2026-05-28", "dateModified": "2026-05-28", "summary": "A Drugnews English brief on Biotech Investing Needs a Judgment System, Not More News, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system.html", "title": "🧬 生技投資圈｜不是更多新聞，是一套生技醫藥判斷系統", "language": "zh-Hant", "datePublished": "2026-05-28", "dateModified": "2026-05-28", "summary": "生技新聞很多。但真正難的不是「知道發生了什麼」，而是看懂：🔍 這件事到底改變了公司的基本面嗎？一個臨床結果，是降低失敗風險，還是市場短線情緒？一個授權案，是有真實商業價值，還是只是在包裝題材？一家公司", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html", "title": "Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers", "language": "en", "datePublished": "2026-05-27", "dateModified": "2026-05-27", "summary": "A Drugnews English brief on Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html", "title": "太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮", "language": "zh-Hant", "datePublished": "2026-05-27", "dateModified": "2026-05-27", "summary": "全球學名藥巨頭面對價格壓力與成長瓶頸，轉型重點從傳統製造規模走向特殊學名藥、創新藥與更高門檻產品。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/sun-pharma-acquire-organon-1175-bln-all-cash-deal-2026-04-27/" }, { "title": "sec.gov", "url": "https://www.sec.gov/Archives/edgar/data/1821825/000110465925108740/tm2530588d2_10qa.htm" }, { "title": "tevausa.com", "url": "https://www.tevausa.com/news-and-media/press-releases/teva-reaffirms-pivot-to-growth-strategy-progress-with-launch-of-acceleration-phase-at-2025-innovation-a/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html", "title": "The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio", "language": "en", "datePublished": "2026-05-27", "dateModified": "2026-05-27", "summary": "A Drugnews English brief on The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html", "title": "台灣生技估值第一步：不要把所有公司都塞進同一個本益比", "language": "zh-Hant", "datePublished": "2026-05-27", "dateModified": "2026-05-27", "summary": "台灣生技股最常見的錯誤，不是模型算錯一點，而是公司類型一開始就分錯。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html", "title": "A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track", "language": "en", "datePublished": "2026-05-26", "dateModified": "2026-05-26", "summary": "A Drugnews English brief on A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track.html", "title": "減肥藥新副作用，意外帶出新賽道？", "language": "zh-Hant", "datePublished": "2026-05-26", "dateModified": "2026-05-26", "summary": "GLP-1 減重潮帶出的掉髮與身體組成問題，正在讓頭皮護理、營養管理與皮膚科成為減重藥外溢新賽道。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html", "title": "Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets", "language": "en", "datePublished": "2026-05-25", "dateModified": "2026-05-25", "summary": "A Drugnews English brief on Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html", "title": "氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!", "language": "zh-Hant", "datePublished": "2026-05-25", "dateModified": "2026-05-25", "summary": "氣喘治療正在從吸入三合一與症狀控制，走向上游免疫靶點、生物製劑與更精準的病人分型。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html", "title": "Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity", "language": "en", "datePublished": "2026-05-24", "dateModified": "2026-05-24", "summary": "A Drugnews English brief on Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html", "title": "OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間", "language": "zh-Hant", "datePublished": "2026-05-24", "dateModified": "2026-05-24", "summary": "【 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間】中樞神經系統藥物開發，很久沒有出現一個這麼清楚、這麼有生物學邏輯、又這麼接近臨床突破的靶點。這個靶點就是 Orexin Recept", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html", "title": "The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market", "language": "en", "datePublished": "2026-05-23", "dateModified": "2026-05-23", "summary": "A Drugnews English brief on The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html", "title": "全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價", "language": "zh-Hant", "datePublished": "2026-05-23", "dateModified": "2026-05-23", "summary": "當台灣資本市場的資金與目光被 AI 半導體全面虹吸時，全球生技產業正悄悄用另一種方式重新定義人類的未來——那就是減肥藥的瘋狂狂潮。我們多次提到，AI 解決的是算力與效率問題，而生技醫療解決的是疾病與生", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html", "title": "How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow", "language": "en", "datePublished": "2026-05-22", "dateModified": "2026-05-22", "summary": "A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html", "title": "這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流", "language": "zh-Hant", "datePublished": "2026-05-22", "dateModified": "2026-05-22", "summary": "在很長一段時間裡，製藥業的 blockbuster drug，似乎是大型藥廠的專屬勳章。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-neurocrine-biosciences-genetic-disorder-drug-2024-12-13/" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-first-drug-fatty-liver-disease-nash-2024-03-14/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html", "title": "How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight", "language": "en", "datePublished": "2026-05-21", "dateModified": "2026-05-21", "summary": "A Drugnews English brief on How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html", "title": "AI半導體掩蓋生技光芒", "language": "zh-Hant", "datePublished": "2026-05-21", "dateModified": "2026-05-21", "summary": "台灣資本市場最近出現一個非 常清楚的現象：AI 半導體正在虹吸一切。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/world/asia-pacific/taiwan-revises-2026-economic-growth-forecast-higher-2026-02-13/" }, { "title": "reuters.com", "url": "https://www.reuters.com/world/asia-pacific/taiwan-plans-ai-projects-boost-economy-by-510-billion-2025-07-23/" }, { "title": "taiwanindex.com.tw", "url": "https://taiwanindex.com.tw/indexes/IX0103" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html", "title": "A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion", "language": "en", "datePublished": "2026-05-20", "dateModified": "2026-05-20", "summary": "A Drugnews English brief on A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html", "title": "破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元", "language": "zh-Hant", "datePublished": "2026-05-20", "dateModified": "2026-05-20", "summary": "Google 系 AI 製藥公司大型融資，真正要看的不是 AI 標籤，而是平台能否把模型轉成可臨床驗證與授權的藥物資產。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "isomorphiclabs.com", "url": "https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html", "title": "HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal", "language": "en", "datePublished": "2026-05-19", "dateModified": "2026-05-19", "summary": "A Drugnews English brief on HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html", "title": "HIV 新藥很好賺呀...吉利德財報披露", "language": "zh-Hant", "datePublished": "2026-05-19", "dateModified": "2026-05-19", "summary": "【Gilead 的 HIV 王朝沒有老去：Yeztugo 超預期，正在把 PrEP 推進「半年打一針」時代】💉 Gilead 最新一季財報，表面看起來只是一份穩健的藥廠成績單。2026 年第一季，Gi", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "tpatw.org.tw", "url": "https://tpatw.org.tw/en/event_page.php" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html", "title": "Where Pfizer Misjudged the Vepdegestrant Strategy", "language": "en", "datePublished": "2026-05-18", "dateModified": "2026-05-18", "summary": "A Drugnews English brief on Where Pfizer Misjudged the Vepdegestrant Strategy, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html", "title": "大藥廠 輝瑞在兩個判斷上栽跟頭？", "language": "zh-Hant", "datePublished": "2026-05-18", "dateModified": "2026-05-18", "summary": "【「賤賣」重磅炸彈，Pfizer 為何在兩個判斷上栽跟頭？】Pfizer 正站在一個很微妙的十字路口。一邊，是它與 Arvinas 聯手研發的 Vepdegestrant（Veppanu） 獲 FDA", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizer-arvinas-breast-cancer-drug-2026-05-01/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html", "title": "Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster", "language": "en", "datePublished": "2026-05-17", "dateModified": "2026-05-17", "summary": "A Drugnews English brief on Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html", "title": "第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？", "language": "zh-Hant", "datePublished": "2026-05-17", "dateModified": "2026-05-17", "summary": "第一三共因 ADC 供應鏈與產能承諾認列高額費用，提醒新藥公司與 CDMO：pipeline 要折現，產能也要折現。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html", "title": "Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs", "language": "en", "datePublished": "2026-05-17", "dateModified": "2026-05-17", "summary": "A Drugnews English brief on Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html", "title": "Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T", "language": "zh-Hant", "datePublished": "2026-05-17", "dateModified": "2026-05-17", "summary": "【嬌生 CAR-T 戰略折戟：不是數據不夠漂亮，而是自體 CD19/CD20 CAR-T 的商業死循環開始反噬】📌 誰能想到，幾個月前還被 Johnson & Johnson 管理層高度看好的淋巴瘤", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "jnj.com", "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-investigational-programs-in-large-b-cell-lymphoma" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html", "title": "The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable", "language": "en", "datePublished": "2026-05-16", "dateModified": "2026-05-16", "summary": "A Drugnews English brief on The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html", "title": "FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測", "language": "zh-Hant", "datePublished": "2026-05-16", "dateModified": "2026-05-16", "summary": "2026 年 5 月 12 日，美國 FDA 局長 Marty Makary 正式辭職，結束他僅約 13 個月的任期。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/fda-commissioner-makary-is-resigning-politico-reports-2026-05-12/" }, { "title": "accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html", "title": "A Complete Map of the New Antidepressant Drug Pipeline", "language": "en", "datePublished": "2026-05-15", "dateModified": "2026-05-15", "summary": "A Drugnews English brief on A Complete Map of the New Antidepressant Drug Pipeline, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html", "title": "全網最全的「抗憂鬱新藥」最新進展盤點", "language": "zh-Hant", "datePublished": "2026-05-15", "dateModified": "2026-05-15", "summary": "【精神科藥物終於走出單胺時代？】📌 憂鬱症從來不是一個小市場。依 WHO 統計，全球約有 2.8 億人受到憂鬱症影響；若加上不同國家、不同診斷口徑下的未診斷與亞臨床族群，實際醫療負擔只會更高。這不是一", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html", "title": "How PharmaEssentia's Besremi Opens a Larger Valuation Imagination", "language": "en", "datePublished": "2026-05-14", "dateModified": "2026-05-14", "summary": "A Drugnews English brief on How PharmaEssentia's Besremi Opens a Larger Valuation Imagination, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html", "title": "藥華藥 打開估值想像空間", "language": "zh-Hant", "datePublished": "2026-05-14", "dateModified": "2026-05-14", "summary": "因為 BESREMi（ropeginterferon alfa-2b）在台灣正式獲衛福部核准用於原發性血小板過多症（Essential Thrombocythemia, ET）成人病人，適用於接受 Hydroxyurea 治療後產生抗藥性或無法耐受的患者。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S2352302619302364" }, { "title": "ema.europa.eu", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/besremi" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html", "title": "Could Neuroinflammation Bring CNS Drug Development Back?", "language": "en", "datePublished": "2026-05-13", "dateModified": "2026-05-13", "summary": "A Drugnews English brief on Could Neuroinflammation Bring CNS Drug Development Back?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html", "title": "中樞神經新藥要靠「神經發炎」？", "language": "zh-Hant", "datePublished": "2026-05-13", "dateModified": "2026-05-13", "summary": "【屢敗屢戰的中樞神經新藥，能否靠「神經發炎」打贏翻身仗？】中樞神經系統新藥研發，一直是創新藥裡最難啃的一塊骨頭。🧠 不是市場不大。恰恰相反，阿茲海默症、帕金森氏症、肌萎縮性脊髓側索硬化症、多發性硬化症", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "media.crai.com", "url": "https://media.crai.com/wp-content/uploads/2024/09/13110655/Approaching-the-final-frontier-golden-decade-of-drug-development-for-the-central-nervous-system-Sept2024.pdf" }, { "title": "biospace.com", "url": "https://www.biospace.com/amgen-closes-out-its-neuroscience-programs-as-it-focuses-on-long-term-growth-areas" }, { "title": "biohaven.com", "url": "https://www.biohaven.com/wp-content/uploads/BIOHAVEN-AAN-BHV-8000-2025_FINAL-Read-Only.pdf" }, { "title": "reuters.com", "url": "https://www.reuters.com/markets/deals/sanofi-acquire-vigil-neuroscience-470-million-deal-2025-05-21/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html", "title": "The Autoimmune Twins That Could Save Johnson & Johnson", "language": "en", "datePublished": "2026-05-12", "dateModified": "2026-05-12", "summary": "A Drugnews English brief on The Autoimmune Twins That Could Save Johnson & Johnson, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html", "title": "自體免疫 雙子星 拯救 嬌生", "language": "zh-Hant", "datePublished": "2026-05-12", "dateModified": "2026-05-12", "summary": "【Johnson & Johnson 自免「雙子星」崛起：Stelara 退場後，Tremfya 與 Icotyde 正在重寫免疫版圖】📌 2026 年第一季，Johnson & Johnson（J&", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-jjs-immune-disorder-drug-2025-04-30/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html", "title": "Could DAC Become the Next Breakout Format in Targeted Therapy?", "language": "en", "datePublished": "2026-05-11", "dateModified": "2026-05-11", "summary": "A Drugnews English brief on Could DAC Become the Next Breakout Format in Targeted Therapy?, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html", "title": "DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？", "language": "zh-Hant", "datePublished": "2026-05-11", "dateModified": "2026-05-11", "summary": "【強強聯手！當 ADC 遇上 PROTAC】生醫圈有兩個絕對頂流。📌 一個是 ADC（Antibody-Drug Conjugate，抗體藥物複合體）。📌 另一個是以 PROTAC（Proteolys", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "preludetx.com", "url": "https://preludetx.com/science/precisiondacs/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html", "title": "Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?", "language": "en", "datePublished": "2026-05-10", "dateModified": "2026-05-10", "summary": "A Drugnews English brief on Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay.html", "title": "川普放政策鴿子，減肥藥價格白降了？", "language": "zh-Hant", "datePublished": "2026-05-10", "dateModified": "2026-05-10", "summary": "【川普政府放了 Eli Lilly（禮來）、Novo Nordisk （諾和諾德）的「鴿子」？GLP-1 進 Medicare，為什麼臨門一腳又卡住了】📌 2026 年 4 月下旬，美國減重藥市場出現", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-health-agency-expand-access-glp-1-weight-loss-drugs-2025-12-23/" }, { "title": "reuters.com", "url": "https://www.reuters.com/legal/litigation/delay-medicare-pilot-obesity-drugs-may-not-hurt-near-term-demand-analysts-say-2026-04-22/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html", "title": "Clinical-Trial Fraud and an FDA Withdrawal Storm", "language": "en", "datePublished": "2026-05-09", "dateModified": "2026-05-09", "summary": "A Drugnews English brief on Clinical-Trial Fraud and an FDA Withdrawal Storm, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal.html", "title": "臨床試驗作假，FDA 撤市風暴！", "language": "zh-Hant", "datePublished": "2026-05-09", "dateModified": "2026-05-09", "summary": "FDA 對 Tavneos 提出撤市程序，核心不是單純療效不足，而是 ADVOCATE 試驗資料完整性與事後重判問題。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "amgen.com", "url": "https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash" }, { "title": "U.S. FDA", "url": "https://www.fda.gov/media/192160/download" }, { "title": "reuters.com", "url": "https://www.reuters.com/legal/litigation/fda-proposes-withdraw-amgens-rare-autoimmune-disease-drug-2026-04-28/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html", "title": "Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money", "language": "en", "datePublished": "2026-05-08", "dateModified": "2026-05-08", "summary": "A Drugnews English brief on Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html", "title": "減肥藥還是太強了，禮來 猛健樂 賺爛！", "language": "zh-Hant", "datePublished": "2026-05-08", "dateModified": "2026-05-08", "summary": "2026 年第一季，Eli Lilly 交出了一份讓整個製藥業都很難忽視的成績單：單季總營收 197.99 億美元，年增 56%；調整後 EPS 達 8.55 美元，大幅優於市場預期。真正撐起這份財報的，仍然是那個已經把全球代謝藥市場打穿的名字：tirzepatide。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "marketwatch.com", "url": "https://www.marketwatch.com/story/lillys-stock-rallies-as-sales-of-glp-1-drugs-nearly-double-09c01977" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html", "title": "The Shadow Behind the Next Century-Defining Drug", "language": "en", "datePublished": "2026-05-07", "dateModified": "2026-05-07", "summary": "A Drugnews English brief on The Shadow Behind the Next Century-Defining Drug, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html", "title": "下一代世紀大藥的陰影？", "language": "zh-Hant", "datePublished": "2026-05-07", "dateModified": "2026-05-07", "summary": "【Pan-RAS 戰爭升級：Erasca 數據驚艷，卻撞上 Revolution 的專利戰與安全性陰影】📌 RAS 賽道，正在從「誰的療效更強」進入「誰能同時守住安全性、IP 與商業化窗口」的新階段。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "sec.gov", "url": "https://www.sec.gov/Archives/edgar/data/1761918/000119312526179214/eras-20260427.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html", "title": "Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points", "language": "en", "datePublished": "2026-05-06", "dateModified": "2026-05-06", "summary": "A Drugnews English brief on Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html", "title": "【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點", "language": "zh-Hant", "datePublished": "2026-05-06", "dateModified": "2026-05-06", "summary": "✨講座介紹，生技醫藥股往往囊括了市場單日最大漲幅與最大跌幅，是極具爆發力的投資領域。然而，多數人將其視為妖股，是因為缺乏一套系統性的估值體系來了解其內在價值。藥時事 作為擁有超過 35，000 名生醫", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html", "title": "What Makes a Pipeline Attractive to Big Pharma?", "language": "en", "datePublished": "2026-05-05", "dateModified": "2026-05-05", "summary": "A Drugnews English brief on What Makes a Pipeline Attractive to Big Pharma?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html", "title": "讓大藥廠心動的管線到底做了什麼？", "language": "zh-Hant", "datePublished": "2026-05-05", "dateModified": "2026-05-05", "summary": "📌 醫藥產業的併購邏輯，正在發生一場非常明顯的結構性變化。過去幾年，許多 Biotech 都想往最大、最熱門、最容易被資本市場理解的賽道擠：腫瘤、ADC、自體免疫、GLP-1、雙抗、細胞治療。這些方向", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/legal/transactional/eli-lilly-buy-centessa-pharma-63-billion-deal-2026-03-31/" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-greenlights-first-ever-treatment-rare-metabolic-disorder-2025-03-26/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html", "title": "The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment", "language": "en", "datePublished": "2026-05-04", "dateModified": "2026-05-04", "summary": "A Drugnews English brief on The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough.html", "title": "最強生髮藥暴漲 47%， 為什麼可能改寫掉髮治療三十年僵局？", "language": "zh-Hant", "datePublished": "2026-05-04", "dateModified": "2026-05-04", "summary": "Veradermics 的緩釋型口服 minoxidil 讀出正向臨床資料，讓掉髮治療從醫師經驗用藥走向正式新藥開發與市場重估。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20834_ROGAINE%20EXTRA%20STRENGTH%20FOR%20MEN%205%25_BIOPHARMR.PDF" }, { "title": "sec.gov", "url": "https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/exhibit991-8xk.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html", "title": "In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?", "language": "en", "datePublished": "2026-05-03", "dateModified": "2026-05-03", "summary": "A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html", "title": "體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？", "language": "zh-Hant", "datePublished": "2026-05-03", "dateModified": "2026-05-03", "summary": "📌 4 月 20 日，Eli Lilly 宣布將以最高 70 億美元收購臨床階段生技公司 Kelonia Therapeutics，其中包含 32.5 億美元現金預付款，其餘則取決於後續臨床、監管與商", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "astrazeneca.com", "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html" }, { "title": "reuters.com", "url": "https://www.reuters.com/legal/litigation/gilead-unit-acquire-cell-therapy-developer-interius-350-million-2025-08-21/" }, { "title": "biospace.com", "url": "https://www.biospace.com/press-releases/magicrnas-first-in-human-clinical-data-demonstrating-feasibility-of-in-vivo-car-t-therapy-in-systemic-lupus-erythematosus-published-in-the-new-england-journal-of-medicine" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html", "title": "The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker", "language": "en", "datePublished": "2026-05-02", "dateModified": "2026-05-02", "summary": "A Drugnews English brief on The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition.html", "title": "印度製藥巨頭的野望！併購美國藥廠！", "language": "zh-Hant", "datePublished": "2026-05-02", "dateModified": "2026-05-02", "summary": "【Sun Pharma 117.5 億美元收購 Organon：印度學名藥巨頭「抄底」百年女性健康平台，全球藥廠版圖正在重新排位】📌 4 月 26 日，印度最大製藥公司 Sun Pharmaceuti", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/sun-pharma-acquire-organon-1175-bln-all-cash-deal-2026-04-27/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html", "title": "Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?", "language": "en", "datePublished": "2026-05-01", "dateModified": "2026-05-01", "summary": "A Drugnews English brief on Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html", "title": "阿茲海默症20年來的假說開始崩盤？", "language": "zh-Hant", "datePublished": "2026-05-01", "dateModified": "2026-05-01", "summary": "【阿茲海默症的 Aβ 信仰，真的開始崩了嗎？】📌 4 月 16 日，一篇來自 Cochrane 的系統性綜述，再次把阿茲海默症領域最核心、也最具爭議的主軸，推回風暴中心。這份綜述的訊息極其刺耳：對輕度", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "cochrane.org", "url": "https://www.cochrane.org/evidence/CD016297_are-medicines-anti-amyloid-monoclonal-antibodies-reduce-build-abnormal-proteins-brain-effective" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html", "title": "Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition", "language": "en", "datePublished": "2026-04-30", "dateModified": "2026-04-30", "summary": "A Drugnews English brief on Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia.html", "title": "亞馬遜（Amazon） 參戰 AI 製藥，挑戰輝達（Nvidia）", "language": "zh-Hant", "datePublished": "2026-04-30", "dateModified": "2026-04-30", "summary": "過去幾年，科技巨頭切入生命科學，大多還停留在兩個角色：一種是賣算力，另一種是賣通用 AI。真正難的，是再往前跨一步，直接碰觸藥物發現這個最核心、也最挑剔的環節。因為這不只是把模型丟給研究員用而已，而是要同時解決模型選擇、資料標準、實驗流程、濕實驗驗證、結果回流與團隊協作這一整串問題。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/amazon-launches-ai-research-tool-speed-early-stage-drug-discovery-2026-04-14/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html", "title": "A Clear Read on Lilly's Current M&A Logic", "language": "en", "datePublished": "2026-04-29", "dateModified": "2026-04-29", "summary": "A Drugnews English brief on A Clear Read on Lilly's Current M&A Logic, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html", "title": "一篇文章講通現在的“禮來”併購邏輯", "language": "zh-Hant", "datePublished": "2026-04-29", "dateModified": "2026-04-29", "summary": "💡 四個月，五筆交易，若把交易上限全部加總，Eli Lilly 在 2026 年前四個月已經丟出超過 187 億美元的併購火力：1 月的 Ventyx Biosciences、2 月的 Orna Therapeutics、3 月的 Centessa Pharmaceuticals、4 月的 Cro…", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/legal/transactional/eli-lilly-buy-ventyx-biosciences-12-billion-deal-2026-01-07/" }, { "title": "reuters.com", "url": "https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-weight-loss-pill-wins-us-approval-2026-04-01/" }, { "title": "sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S2352302624002734" }, { "title": "reuters.com", "url": "https://www.reuters.com/legal/litigation/eli-lilly-advanced-talks-acquire-kelonia-therapeutics-over-2-billion-wsj-says-2026-04-19/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html", "title": "When a Gray-Market Industry Gets a Seat at the Table", "language": "en", "datePublished": "2026-04-28", "dateModified": "2026-04-28", "summary": "A Drugnews English brief on When a Gray-Market Industry Gets a Seat at the Table, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html", "title": "灰色產業上牌桌", "language": "zh-Hant", "datePublished": "2026-04-28", "dateModified": "2026-04-28", "summary": "🌪️ 在一處私人莊園裡，矽谷創業者、生技極客與華爾街資金坐在同一張桌上，話題從 AI、加密貨幣一路滑向更隱密的領域：BPC-157、MOTS-c、TB-500、Semax、Epitalon。這些名字不像藥，更像暗號。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-convene-expert-panel-decide-broader-access-some-peptides-2026-04-15/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-27-car-t-en.html", "title": "Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break", "language": "en", "datePublished": "2026-04-27", "dateModified": "2026-04-27", "summary": "A Drugnews English brief on Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-27-car-t.html", "title": "再見自體CAR-T，台灣的泡沫也該破了", "language": "zh-Hant", "datePublished": "2026-04-27", "dateModified": "2026-04-27", "summary": "當市場還在用過去十年對自體 CAR-T 的理解框架看細胞治療時，異體 CAR-T 其實已經悄悄走到一個更關鍵的節點。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S2352302624002734" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html", "title": "The Healthcare-Giant Spin-Off Wave", "language": "en", "datePublished": "2026-04-26", "dateModified": "2026-04-26", "summary": "A Drugnews English brief on The Healthcare-Giant Spin-Off Wave, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-26-dcard-261370593.html", "title": "醫療巨頭分拆潮？", "language": "zh-Hant", "datePublished": "2026-04-26", "dateModified": "2026-04-26", "summary": "這幾年，全球大型企業在醫療產業做了一個很有意思、而且愈來愈頻繁的動作：把原本放在大集團裡的醫療業務拆出來，讓它獨立上市、獨立融資、獨立做決策。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html", "title": "Why Platform Biotechs Can Generate Five Times More Licensing Revenue", "language": "en", "datePublished": "2026-04-25", "dateModified": "2026-04-25", "summary": "A Drugnews English brief on Why Platform Biotechs Can Generate Five Times More Licensing Revenue, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-25-biotech-5.html", "title": "平台型 Biotech 的授權收入是同業的 5 倍？", "language": "zh-Hant", "datePublished": "2026-04-25", "dateModified": "2026-04-25", "summary": "如果把 Biotech 的商業模式拆開來看，最容易被低估、但其實最值錢的一種公司，往往不是手上只有一顆明星分子的資產型公司，而是那些擁有底層技術引擎的平台型公司。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "us.argenx.com", "url": "https://www.us.argenx.com/news/2019/argenx-announces-closing-exclusive-global-collaboration-and-license-agreement-cusatuzumab-argx" }, { "title": "us.argenx.com", "url": "https://www.us.argenx.com/news/2026/press-release-3245199" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html", "title": "Investors Should Pay Attention: Drug Delivery Is a Blue Ocean", "language": "en", "datePublished": "2026-04-24", "dateModified": "2026-04-24", "summary": "A Drugnews English brief on Investors Should Pay Attention: Drug Delivery Is a Blue Ocean, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html", "title": "投資人請注意，給藥方式是藍海！", "language": "zh-Hant", "datePublished": "2026-04-24", "dateModified": "2026-04-24", "summary": "這幾年，如果你把跨國藥廠的動作連起來看，會發現一個非常一致、幾乎帶著戰略共識的方向：把原本靠靜脈輸注（IV）的重磅生物藥，盡可能改造成皮下注射（SC）版本。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "halozyme.com", "url": "https://halozyme.com/drug-delivery-technologies/enhanze/partners.php" }, { "title": "jnj.com", "url": "https://www.jnj.com/media-center/press-releases/phase-3-columba-study-investigating-a-subcutaneous-formulation-of-darzalex-daratumumab-showed-non-inferiority-to-intravenous-administration-in-patients-with-relapsed-refractory-multiple-myeloma" }, { "title": "subcutaneousconsortium.org", "url": "https://subcutaneousconsortium.org/who-are-we/" }, { "title": "arecor.com", "url": "https://arecor.com/wp-content/uploads/2025/05/2025-05-19-ARECOR-ESTABLISHES-PARTNERSHIP-WITH-SKYE-BIOSCIENCE.pdf" }, { "title": "alteogen.com", "url": "https://alteogen.com/en/sub/ir/news.php" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html", "title": "Do COPD Patients Finally Have Another New Drug Option?", "language": "en", "datePublished": "2026-04-23", "dateModified": "2026-04-23", "summary": "A Drugnews English brief on Do COPD Patients Finally Have Another New Drug Option?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html", "title": "慢性阻塞性肺病患者又有新藥可以用了？", "language": "zh-Hant", "datePublished": "2026-04-23", "dateModified": "2026-04-23", "summary": "2025 年，對 IL-33/ST2 這條曾被寄予厚望的發炎路徑而言，幾乎是一整年的信心潰散。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "astrazeneca.com", "url": "https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-met-primary-endpoint-in-oberon-titania-phase-iii-trials-in-patients-with-copd.html" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-22-ai-en.html", "title": "The Three AI Giants Battling Inside Medicine", "language": "en", "datePublished": "2026-04-22", "dateModified": "2026-04-22", "summary": "A Drugnews English brief on The Three AI Giants Battling Inside Medicine, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-22-ai.html", "title": "AI三巨頭在醫藥裡廝殺", "language": "zh-Hant", "datePublished": "2026-04-22", "dateModified": "2026-04-22", "summary": "ChatGPT、Claude、Gemini 這三大通用大模型，現在打的已經不只是消費端流量，也不是一般企業辦公市場，而是開始往生醫製藥產業鏈的深水區插旗。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "research.google", "url": "https://research.google/blog/advancing-medical-ai-with-med-gemini/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html", "title": "Did Lilly's Oral Drug Ignite the Market?", "language": "en", "datePublished": "2026-04-21", "dateModified": "2026-04-21", "summary": "A Drugnews English brief on Did Lilly's Oral Drug Ignite the Market?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html", "title": "禮來口服藥引爆市場？", "language": "zh-Hant", "datePublished": "2026-04-21", "dateModified": "2026-04-21", "summary": "2026 年 4 月，Eli Lilly 的 Foundayo（orforglipron） 獲 FDA 核准，用於成人肥胖，或合併體重相關共病的過重族群。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "journals.plos.org", "url": "https://journals.plos.org/globalpublichealth/article/file" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-requires-lilly-conduct-post-marketing-studies-obesity-pill-2026-04-14/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html", "title": "A Historic Moment: The Next Century-Defining Drug Has Arrived", "language": "en", "datePublished": "2026-04-20", "dateModified": "2026-04-20", "summary": "A Drugnews English brief on A Historic Moment: The Next Century-Defining Drug Has Arrived, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html", "title": "歷史性一刻，世紀大藥來了", "language": "zh-Hant", "datePublished": "2026-04-20", "dateModified": "2026-04-20", "summary": "4 月 13 日，Revolution Medicines 公布 daraxonrasib（RMC-6236） 在三期臨床 RASolute 302 的頂線結果。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "sciencedirect.com", "url": "https://www.sciencedirect.com/org/science/article/pii/S1520480425002959" }, { "title": "asco.org", "url": "https://www.asco.org/abstracts-presentations/241485" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html", "title": "Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know", "language": "en", "datePublished": "2026-04-19", "dateModified": "2026-04-19", "summary": "A Drugnews English brief on Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-19-neuralink-10.html", "title": "馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！", "language": "zh-Hant", "datePublished": "2026-04-19", "dateModified": "2026-04-19", "summary": "到了 2026 年，腦機介面（brain-computer interface, BCI）已經不再只是科幻敘事或實驗室展示，而是逐漸分化成幾條很清楚的產業路線：一條走侵入式植入，目標是讓癱瘓患者重新溝通、操作設備甚至恢復部分功能；一條走非侵入式穿戴，強調腦訊號量測、認知監測與日常應用；還有一條則更像…", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "biopharmatrend.com", "url": "https://www.biopharmatrend.com/neurotech/top-10-companies-shaping-the-brain-computer-interface-landscape-invasive-vs-non-invasive-bci-technology-650/" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/musks-neuralink-raises-650-million-latest-funding-round-2025-06-02/" }, { "title": "inbrain-neuroelectronics.com", "url": "https://inbrain-neuroelectronics.com/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html", "title": "Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?", "language": "en", "datePublished": "2026-04-18", "dateModified": "2026-04-18", "summary": "A Drugnews English brief on Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html", "title": "台灣這家Biotech將吃下AI基礎建設的所有紅利？", "language": "zh-Hant", "datePublished": "2026-04-18", "dateModified": "2026-04-18", "summary": "AI 吃電，核電回來了：為什麼麗寶新藥，可能站在下一個被重估的位置？", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html", "title": "The Valley of Death in Innovative Drug Development", "language": "en", "datePublished": "2026-04-17", "dateModified": "2026-04-17", "summary": "A Drugnews English brief on The Valley of Death in Innovative Drug Development, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html", "title": "創新藥開發的「死亡之谷」", "language": "zh-Hant", "datePublished": "2026-04-17", "dateModified": "2026-04-17", "summary": "創新藥研發最殘酷的地方，不在於它難，而在於你往往在一開始就知道，它極可能失敗，卻還是必須投入多年時間、巨額資本，以及一整個團隊的職業生涯去把它往前推。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html", "title": "The 2026 Q2 Drug Catalysts Biotech Readers Need to Know", "language": "en", "datePublished": "2026-04-16", "dateModified": "2026-04-16", "summary": "A Drugnews English brief on The 2026 Q2 Drug Catalysts Biotech Readers Need to Know, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-16-2026-q2.html", "title": "生技人必須知道的 2026 Q2 重磅藥物", "language": "zh-Hant", "datePublished": "2026-04-16", "dateModified": "2026-04-16", "summary": "2026 年第二季，全球生技醫藥產業正走進一個少見的高密度催化期。若把臨床讀數、監管決策與關鍵會議節點一起看，從 4 月到 6 月前後，至少有 17 個值得緊盯的重磅資產將陸續揭曉方向；更早一步，Eli Lilly 的口服減重藥 orforglipron（Foundayo） 已在 4 月 1 日獲 …", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-15-biotech-en.html", "title": "The Fall of Two Star Biotechs", "language": "en", "datePublished": "2026-04-15", "dateModified": "2026-04-15", "summary": "A Drugnews English brief on The Fall of Two Star Biotechs, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-15-biotech.html", "title": "兩家明星 Biotech 的隕落", "language": "zh-Hant", "datePublished": "2026-04-15", "dateModified": "2026-04-15", "summary": "2025 年的生技產業，表面上看起來不像 2022 年那麼驚慌，但真正懂產業的人都知道，市場其實正在經歷一場更深層的重估。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "sec.gov", "url": "https://www.sec.gov/Archives/edgar/data/1485003/000110465925091064/tm2526076d1_8k.htm" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html", "title": "Investors Should Pay Attention to the Autoimmune Mega-Drug Race", "language": "en", "datePublished": "2026-04-14", "dateModified": "2026-04-14", "summary": "A Drugnews English brief on Investors Should Pay Attention to the Autoimmune Mega-Drug Race, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html", "title": "投資人請注意，自體免疫超大藥賽道", "language": "zh-Hant", "datePublished": "2026-04-14", "dateModified": "2026-04-14", "summary": "自體免疫藥物市場，從來都不是「穩定但無聊」的成熟市場。恰恰相反，它一直是全球最容易長出重磅藥物的沃土之一，而乾癬（psoriasis），正是這條價值鏈裡最具代表性的試驗場。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "ucb.com", "url": "https://www.ucb.com/sites/default/files/press_files/80f57daf1260cff4.pdf" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-13-78-en.html", "title": "The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?", "language": "en", "datePublished": "2026-04-13", "dateModified": "2026-04-13", "summary": "A Drugnews English brief on The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-13-78.html", "title": "減肥藥之王 78億美元，買下一個「清醒時代」？", "language": "zh-Hant", "datePublished": "2026-04-13", "dateModified": "2026-04-13", "summary": "當 Eli Lilly（禮來） 以最高 78 億美元 收購 Centessa Pharmaceuticals，這筆交易表面上看，是大藥廠再一次用高溢價把一條中期臨床資產收入囊中；但若把時間線再拉長一點，它其實更像是一場很有方向感的提前卡位。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/legal/transactional/eli-lilly-buy-centessa-pharma-63-billion-deal-2026-03-31/" }, { "title": "biospace.com", "url": "https://www.biospace.com/press-releases/centessa-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2025-and-provides-update-on-potential-best-in-class-orexin-receptor-2-ox2r-agonist-program" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html", "title": "Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase", "language": "en", "datePublished": "2026-04-12", "dateModified": "2026-04-12", "summary": "A Drugnews English brief on Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html", "title": "特發性肺纖維化 迎來爆發", "language": "zh-Hant", "datePublished": "2026-04-12", "dateModified": "2026-04-12", "summary": "特發性肺纖維化，idiopathic pulmonary fibrosis（IPF），從來都不是一個容易講出樂觀故事的領域。這是一種慢性、進行性、不可逆的纖維化肺病，預後差、死亡風險高，過去長年幾乎等同於「只能拖慢，不能扭轉」。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "bms.com", "url": "https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMS-JPM-2026-Presentation.pdf?utm_source=chatgpt.com" }, { "title": "endeavorbiomedicines.com", "url": "https://endeavorbiomedicines.com/endeavor-biomedicines-receives-priority-medicines-prime-designation-from-the-european-medicines-agency-for-taladegib-env-101-for-the-treatment-of-idiopathic-pulmonary-fibrosis/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html", "title": "Why Did the Market Like This Company More After a Clinical Failure?", "language": "en", "datePublished": "2026-04-11", "dateModified": "2026-04-11", "summary": "A Drugnews English brief on Why Did the Market Like This Company More After a Clinical Failure?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html", "title": "這家公司臨床試驗失敗，反而被更加看好？", "language": "zh-Hant", "datePublished": "2026-04-11", "dateModified": "2026-04-11", "summary": "甲狀腺相關眼疾（thyroid eye disease, TED）這條賽道，最近又迎來一次很典型、也很殘酷的產業教育。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "biospace.com", "url": "https://www.biospace.com/press-releases/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html", "title": "When Should a Company Decisively Abandon a Clinical Trial?", "language": "en", "datePublished": "2026-04-10", "dateModified": "2026-04-10", "summary": "A Drugnews English brief on When Should a Company Decisively Abandon a Clinical Trial?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html", "title": "何時果斷放棄新藥臨床試驗開發？", "language": "zh-Hant", "datePublished": "2026-04-10", "dateModified": "2026-04-10", "summary": "新藥開發最難的，往往不是立項那一天，而是明明已經看見風險，卻仍不願按下停止鍵的那一天。每一個研發專案開始時，幾乎都帶著同樣的想像：要做到 first-in-class、要走到 pivotal study、要送件、要上市、要成為下一個成長引擎。然而現實比願景殘酷得多。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5478920/" }, { "title": "roivant.com", "url": "https://www.roivant.com/about/company" }, { "title": "astrazeneca.com", "url": "https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/transforming-astrazenecas-rd-productivity.html" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html", "title": "A New Drug Finally Arrives for This Group of Rare-Disease Patients", "language": "en", "datePublished": "2026-04-09", "dateModified": "2026-04-09", "summary": "A Drugnews English brief on A New Drug Finally Arrives for This Group of Rare-Disease Patients, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html", "title": "這一批罕見病患者終於等來新藥！", "language": "zh-Hant", "datePublished": "2026-04-09", "dateModified": "2026-04-09", "summary": "美國 FDA 近日加速核准 Denali Therapeutics 的 AVLAYAH（tividenofusp alfa-eknm），用於治療 Hunter syndrome （韓特氏症），也就是 mucopolysaccharidosis type II（MPS II） 的神經學表現。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "nature.com", "url": "https://www.nature.com/articles/s41587-026-03066-8" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-denalis-genetic-disorder-therapy-2026-03-25/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html", "title": "The Abivax Story: How a European Biotech Became a 14-Fold Market Myth", "language": "en", "datePublished": "2026-04-08", "dateModified": "2026-04-08", "summary": "A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-08-abivax-14.html", "title": "歐洲生技公司Abivax 一年暴漲14倍的神話", "language": "zh-Hant", "datePublished": "2026-04-08", "dateModified": "2026-04-08", "summary": "Abivax 近幾個月的股價與話題熱度，幾乎都圍繞著同一件事打轉：它到底會不會成為下一個大型藥廠出手收購的標的。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/abivax-ceo-dismisses-noise-around-rumored-eli-lilly-bid-2026-01-20/" }, { "title": "biospace.com", "url": "https://www.biospace.com/press-releases/abivax-presents-first-evidence-of-anti-fibrotic-activity-for-obefazimod-alongside-new-clinical-efficacy-and-safety-analyses-in-inflammatory-bowel-disease-at-ecco-2026" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-07-cdc-en.html", "title": "While the US CDC Was Still Looking for a Director", "language": "en", "datePublished": "2026-04-07", "dateModified": "2026-04-07", "summary": "A Drugnews English brief on While the US CDC Was Still Looking for a Director, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-07-cdc.html", "title": "當美國 CDC 還在找主任...", "language": "zh-Hant", "datePublished": "2026-04-07", "dateModified": "2026-04-07", "summary": "真正值得擔心的，從來不只是美國疾病管制與預防中心（CDC）這個位子到底由誰來坐，而是當一個國家的公共衛生指揮中樞長期處於權責模糊、科學威信受損、政策方向反覆擺盪的狀態時，它原本在全球健康治理與醫藥監管上的領導角色，也會跟著一起鬆動。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/bhattacharya-lead-cdc-now-white-house-continues-search-permanent-head-2026-03-25/" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/nih-director-temporarily-run-cdc-new-york-times-reports-2026-02-18/" }, { "title": "reuters.com", "url": "https://www.reuters.com/world/us-judge-blocks-efforts-reshape-childhood-vaccine-policy-2026-03-16/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-06-420-en.html", "title": "The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means", "language": "en", "datePublished": "2026-04-06", "dateModified": "2026-04-06", "summary": "A Drugnews English brief on The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-06-420.html", "title": "骨折價 瘦瘦針來了，每月420塊台幣", "language": "zh-Hant", "datePublished": "2026-04-06", "dateModified": "2026-04-06", "summary": "2026 年 3 月，semaglutide （瘦瘦針）在印度迎來一個足以寫進產業教科書的時刻。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html", "title": "How Far Are We From a Real Anti-Aging Drug?", "language": "en", "datePublished": "2026-04-05", "dateModified": "2026-04-05", "summary": "A Drugnews English brief on How Far Are We From a Real Anti-Aging Drug?, focusing on clinical development, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-05-dcard-261238352.html", "title": "我們離真正的抗老藥，究竟還有多遠？", "language": "zh-Hant", "datePublished": "2026-04-05", "dateModified": "2026-04-05", "summary": "「抗老化」這三個字，很容易讓人聯想到不老神話、富人專屬科技，甚至公平性與可近性的爭議。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "who.int", "url": "https://www.who.int/news-room/questions-and-answers/item/healthy-ageing-and-functional-ability" }, { "title": "who.int", "url": "https://www.who.int/standards/classifications/frequently-asked-questions/old-age" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html", "title": "Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?", "language": "en", "datePublished": "2026-04-04", "dateModified": "2026-04-04", "summary": "A Drugnews English brief on Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html", "title": "瘦瘦針翻車？導致胰臟炎？", "language": "zh-Hant", "datePublished": "2026-04-04", "dateModified": "2026-04-04", "summary": "GLP-1 類藥物近兩年幾乎成了全球醫療市場最耀眼的明星。從 liraglutide（利拉魯肽）、semaglutide（司美格魯肽），到雙重受體機制的 tirzepatide（替爾泊肽），這一波藥物不只改變了第二型糖尿病治療，也快速跨入體重管理、心血管風險降低等更大的市場。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html", "title": "After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?", "language": "en", "datePublished": "2026-04-03", "dateModified": "2026-04-03", "summary": "A Drugnews English brief on After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html", "title": "瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？", "language": "zh-Hant", "datePublished": "2026-04-03", "dateModified": "2026-04-03", "summary": "過去幾年，**司美格魯肽（semaglutide）與替爾泊肽（tirzepatide）**幾乎重寫了肥胖治療的市場想像。它們不只把減重從「意志力問題」拉回醫療管理，更把投資人、藥廠與臨床醫師對減重藥的預期，直接拉高到一個全新標準。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [ { "title": "novonordisk.com", "url": "https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf" }, { "title": "reuters.com", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-next-gen-obesity-drug-shows-reduction-blood-sugar-levels-trial-2026-03-19/" } ] }, { "url": "https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html", "title": "Can Merck Build Another Oncology Empire?", "language": "en", "datePublished": "2026-04-02", "dateModified": "2026-04-02", "summary": "A Drugnews English brief on Can Merck Build Another Oncology Empire?, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-02-dcard-261221419.html", "title": "默沙東還能再造一個腫瘤帝國嗎？", "language": "zh-Hant", "datePublished": "2026-04-02", "dateModified": "2026-04-02", "summary": "2026 年才過了不到三個月，默沙東已經用兩個動作，把自己對「後 Keytruda 時代」的答案講得愈來愈清楚。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html", "title": "Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?", "language": "en", "datePublished": "2026-04-01", "dateModified": "2026-04-01", "summary": "A Drugnews English brief on Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews Editorial Team", "url": "https://drugnews.com.tw/en/team.html" } ], "sources": [] }, { "url": "https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html", "title": "信達的全球化列車，台灣的圓祥搭上了？", "language": "zh-Hant", "datePublished": "2026-04-01", "dateModified": "2026-04-01", "summary": "3 月 24 日，信達生物公布 efdamrofusp alfa（IBI302） 在中國新生血管型老年黃斑部病變（nAMD）關鍵三期 STAR 試驗達成 52 週主要終點。乍看之下，這像是一則典型的臨床里程碑新聞；但若把它放回全球眼科產業的競爭結構裡看，這件事的重要性遠不只是一款新藥在單一市場報捷。", "isAccessibleForFree": true, "authors": [ { "name": "Drugnews 編輯部", "url": "https://drugnews.com.tw/team.html" } ], "sources": [] } ], "homepageCandidates": [ { "url": "https://drugnews.com.tw/articles/2026-10-11-lilly-jaypirca-frontline-cll.html", "title": "禮來血癌藥提前上場，贏的是哪場仗？", "datePublished": "2026-10-11" }, { "url": "https://drugnews.com.tw/articles/2026-10-11-pediatric-obesity-novo-wegovy-lilly-product-strategy.html", "title": "兒少肥胖用藥：Novo 的先發優勢，為何還要靠 Wegovy 接棒？", "datePublished": "2026-10-11" }, { "url": "https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.html", "title": "出血少了，新藥為何還進不了美國？", "datePublished": "2026-10-10" }, { "url": "https://drugnews.com.tw/articles/2026-10-09-sanofi-regeneron-long-acting-alliance.html", "title": "半年打一針？賽諾菲押上10億美元", "datePublished": "2026-10-09" }, { "url": "https://drugnews.com.tw/articles/2026-10-08-2026-nobel-chemistry-chiral-amplification.html", "title": "2026諾貝爾化學獎揭曉！藥也分左右手？", "datePublished": "2026-10-08" }, { "url": "https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human.html", "title": "打一針，身體自己造抗癌細胞？", "datePublished": "2026-10-07" }, { "url": "https://drugnews.com.tw/articles/2026-10-06-nobel-optogenetics-light-gated-channels.html", "title": "諾貝爾獎揭曉！科學家給細胞裝上光開關", "datePublished": "2026-10-06" }, { "url": "https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.html", "title": "明星心臟藥銷售減半，諾華的新藥接棒來得及嗎？", "datePublished": "2026-10-06" }, { "url": "https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.html", "title": "從每天一顆藥到工廠訂單：口服環肽的錢，誰賺得到？", "datePublished": "2026-10-05" }, { "url": "https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026.html", "title": "偏頭痛總挑月經前後來？7天預防研究，能少痛多少？", "datePublished": "2026-10-04" }, { "url": "https://drugnews.com.tw/articles/2026-10-03-hemlibra-hemophilia-lasker-2026.html", "title": "少找一次血管，血友病的日常就多一點自由", "datePublished": "2026-10-03" }, { "url": "https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html", "title": "藥華藥買下予宇，下一步讓細胞造藥？", "datePublished": "2026-10-03" }, { "url": "https://drugnews.com.tw/articles/2026-10-02-glp1-weight-loss-speed-hair-gallbladder-safety.html", "title": "瘦瘦針：想減的是體重，不是頭髮", "datePublished": "2026-10-02" }, { "url": "https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html", "title": "肺癌免疫治療再加ADC：腫瘤更常縮小，為何三期仍未過關？", "datePublished": "2026-10-01" }, { "url": "https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html", "title": "已有瘦瘦針，諾和諾德為何還要布局另一條減重路？", "datePublished": "2026-09-30" }, { "url": "https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html", "title": "藥證到手，錢就到帳？從台新藥、智擎看懂授權金怎麼變成現金", "datePublished": "2026-09-29" }, { "url": "https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.html", "title": "年營收 92 億美元，強生為什麼還想把骨科拆出去？", "datePublished": "2026-09-28" }, { "url": "https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care.html", "title": "B 肝新藥在日本獲准，新藥組約兩成受試者達「功能性治癒」", "datePublished": "2026-09-27" }, { "url": "https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care.html", "title": "肌肉萎縮新藥在美獲准，每四週輸注如何走進生活？", "datePublished": "2026-09-26" }, { "url": "https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free.html", "title": "諾和諾德攜手Anthropic：讓Claude推理、寫程式，投入新藥研發測試", "datePublished": "2026-09-25" }, { "url": "https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html", "title": "禮來與諾華的大交易，為什麼都看上「怎麼給藥」？", "datePublished": "2026-09-24" }, { "url": "https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception.html", "title": "癌症還沒出現，疫苗能先攔截嗎？遺傳高風險族群的早期研究", "datePublished": "2026-09-23" }, { "url": "https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.html", "title": "諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？", "datePublished": "2026-09-22" }, { "url": "https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda.html", "title": "藥華藥新適應症獲准，4,600萬美元設廠計畫布局長期供應", "datePublished": "2026-09-21" }, { "url": "https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.html", "title": "大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升", "datePublished": "2026-09-18" }, { "url": "https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.html", "title": "26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？", "datePublished": "2026-09-17" }, { "url": "https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.html", "title": "Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？", "datePublished": "2026-09-14" }, { "url": "https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.html", "title": "1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？", "datePublished": "2026-09-13" }, { "url": "https://drugnews.com.tw/articles/2026-09-12-autoimmune-car-t-safety-market-reset.html", "title": "自免 CAR-T 第一次被迫重算：療效之外，尾端安全風險如何縮小市場？", "datePublished": "2026-09-12" }, { "url": "https://drugnews.com.tw/articles/2026-09-11-google-coscientist-real-world-lab-loop.html", "title": "AI 一小時做完實驗？Google Co-Scientist 真正跨過的，是「動手」這一關", "datePublished": "2026-09-11" }, { "url": "https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.html", "title": "Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流", "datePublished": "2026-09-10" }, { "url": "https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.html", "title": "「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳", "datePublished": "2026-09-09" }, { "url": "https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.html", "title": "Big Pharma 集體變養馬人！血腦屏障成了 CNS 新藥最貴入口", "datePublished": "2026-09-08" }, { "url": "https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.html", "title": "FDA 還沒任命 AI 副局長，AI 審評已先改寫新藥估值", "datePublished": "2026-09-07" }, { "url": "https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.html", "title": "把抗體級結合力塞進藥片！兩款新藥獲批，大藥廠搶押口服大環肽", "datePublished": "2026-09-06" }, { "url": "https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.html", "title": "18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」", "datePublished": "2026-09-05" }, { "url": "https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html", "title": "Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷", "datePublished": "2026-09-04" }, { "url": "https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard.html", "title": "Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了", "datePublished": "2026-09-03" }, { "url": "https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html", "title": "新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後", "datePublished": "2026-09-02" }, { "url": "https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html", "title": "新藥能先在電腦裡試？「虛擬細胞」來了！", "datePublished": "2026-09-01" }, { "url": "https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift.html", "title": "減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？", "datePublished": "2026-08-31" }, { "url": "https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html", "title": "減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！", "datePublished": "2026-08-30" }, { "url": "https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on.html", "title": "胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥", "datePublished": "2026-08-29" }, { "url": "https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv.html", "title": "藥華藥迎新對手？1 億美元賣分潤", "datePublished": "2026-08-28" }, { "url": "https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels.html", "title": "DNA 不是 AI 製藥的輝達，至少現在還不是", "datePublished": "2026-08-27" }, { "url": "https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html", "title": "默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？", "datePublished": "2026-08-26" }, { "url": "https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html", "title": "主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？", "datePublished": "2026-08-25" }, { "url": "https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html", "title": "核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額", "datePublished": "2026-08-24" }, { "url": "https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html", "title": "Biotech 下一筆重磅併購，會落在誰身上？", "datePublished": "2026-08-23" }, { "url": "https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html", "title": "百濟神州一口氣押上 4 款 RAS 新藥", "datePublished": "2026-08-22" }, { "url": "https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html", "title": "再見癌症？癌症疫苗來了！莫德納單日暴漲176.97%", "datePublished": "2026-08-21" }, { "url": "https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html", "title": "輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元", "datePublished": "2026-08-20" }, { "url": "https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html", "title": "55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？", "datePublished": "2026-08-19" }, { "url": "https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html", "title": "一季狂賣 230 億美元，禮來卻急著買下一個藥王", "datePublished": "2026-08-18" }, { "url": "https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html", "title": "營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？", "datePublished": "2026-08-17" }, { "url": "https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html", "title": "百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？", "datePublished": "2026-08-16" }, { "url": "https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html", "title": "GSK 砸 20 億美元買止咳新藥，三期卻翻車！", "datePublished": "2026-08-15" }, { "url": "https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html", "title": "這家台灣Biotech正在打造人體內奈米火箭", "datePublished": "2026-08-13" }, { "url": "https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html", "title": "諾和諾德大三期慘敗！6,300 人的教科書級教訓", "datePublished": "2026-08-13" }, { "url": "https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd.html", "title": "美國砸 12 億美元，想用 AI 把新藥研發快一倍！", "datePublished": "2026-08-12" }, { "url": "https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html", "title": "20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹", "datePublished": "2026-08-11" }, { "url": "https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html", "title": "禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！", "datePublished": "2026-08-10" }, { "url": "https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html", "title": "嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？", "datePublished": "2026-08-09" }, { "url": "https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html", "title": "不賣給大藥廠，4 家生技公司憑什麼自己做大？", "datePublished": "2026-08-08" }, { "url": "https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html", "title": "22 億美元，買下一個自體免疫藥王？", "datePublished": "2026-08-07" }, { "url": "https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html", "title": "投資人請注意，下一個減肥藥級別賽道來了！", "datePublished": "2026-08-06" }, { "url": "https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html", "title": "一季賣破 10 億，Alnylam 為何崩 28%？", "datePublished": "2026-08-05" }, { "url": "https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html", "title": "超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！", "datePublished": "2026-08-04" }, { "url": "https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3.html", "title": "Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？", "datePublished": "2026-08-03" }, { "url": "https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html", "title": "鬼剃頭新藥，先別封神", "datePublished": "2026-08-02" }, { "url": "https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html", "title": "安邦生技：免疫治療的「星鏈計畫」", "datePublished": "2026-07-31" }, { "url": "https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html", "title": "Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門", "datePublished": "2026-07-30" }, { "url": "https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html", "title": "HORIZON：Lp(a) 降了，心梗會少嗎？", "datePublished": "2026-07-29" }, { "url": "https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability.html", "title": "T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後", "datePublished": "2026-07-28" }, { "url": "https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html", "title": "半年千億，買的是時間", "datePublished": "2026-07-27" }, { "url": "https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html", "title": "羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？", "datePublished": "2026-07-25" }, { "url": "https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines.html", "title": "Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma", "datePublished": "2026-07-24" }, { "url": "https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals.html", "title": "SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金", "datePublished": "2026-07-24" }, { "url": "https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html", "title": "聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒", "datePublished": "2026-07-20" }, { "url": "https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift.html", "title": "動物實驗不是消失，而是藥物研發規則開始換代", "datePublished": "2026-07-19" }, { "url": "https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html", "title": "當 ADC 走進自體免疫：不是殺得更狠，而是調得更準", "datePublished": "2026-07-18" }, { "url": "https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html", "title": "又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代", "datePublished": "2026-07-17" }, { "url": "https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html", "title": "百億美元併購新狂潮", "datePublished": "2026-07-16" }, { "url": "https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html", "title": "諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品", "datePublished": "2026-07-15" }, { "url": "https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html", "title": "ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload", "datePublished": "2026-07-14" }, { "url": "https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery.html", "title": "大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場", "datePublished": "2026-07-13" }, { "url": "https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation.html", "title": "先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰", "datePublished": "2026-07-12" }, { "url": "https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html", "title": "社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格", "datePublished": "2026-07-11" }, { "url": "https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html", "title": "痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度", "datePublished": "2026-07-10" }, { "url": "https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap.html", "title": "日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態", "datePublished": "2026-07-09" }, { "url": "https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html", "title": "GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住", "datePublished": "2026-07-08" }, { "url": "https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html", "title": "【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】", "datePublished": "2026-07-07" }, { "url": "https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html", "title": "通用型 CAR-T 的 2026 從低谷回暖", "datePublished": "2026-07-06" }, { "url": "https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html", "title": "半年併購 1,340 億美元：Big Pharma 到底在搶什麼？", "datePublished": "2026-07-05" }, { "url": "https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html", "title": "美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了", "datePublished": "2026-07-04" }, { "url": "https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html", "title": "拒絕被併購的 RevMed：Biotech 的獨立時代", "datePublished": "2026-07-03" }, { "url": "https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html", "title": "合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？", "datePublished": "2026-07-02" }, { "url": "https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html", "title": "摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳", "datePublished": "2026-07-01" }, { "url": "https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html", "title": "GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌", "datePublished": "2026-06-30" }, { "url": "https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html", "title": "美股迎來史上最大 Biotech IPO", "datePublished": "2026-06-29" }, { "url": "https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html", "title": "FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起", "datePublished": "2026-06-28" }, { "url": "https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html", "title": "胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開", "datePublished": "2026-06-27" }, { "url": "https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html", "title": "神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？", "datePublished": "2026-06-26" }, { "url": "https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html", "title": "邁向「寵物醫療界羅氏」的寶泰生醫", "datePublished": "2026-06-25" }, { "url": "https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html", "title": "AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu", "datePublished": "2026-06-24" }, { "url": "https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html", "title": "減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？", "datePublished": "2026-06-22" }, { "url": "https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html", "title": "默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近", "datePublished": "2026-06-21" }, { "url": "https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html", "title": "【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】", "datePublished": "2026-06-20" }, { "url": "https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html", "title": "GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法", "datePublished": "2026-06-19" }, { "url": "https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html", "title": "GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？", "datePublished": "2026-06-17" }, { "url": "https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html", "title": "禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？", "datePublished": "2026-06-16" }, { "url": "https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html", "title": "2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代", "datePublished": "2026-06-15" }, { "url": "https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html", "title": "Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑", "datePublished": "2026-06-14" }, { "url": "https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html", "title": "AI製藥下半場：讓藥活下來", "datePublished": "2026-06-13" }, { "url": "https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html", "title": "盤點整理，AI藥物開發走得如何了？", "datePublished": "2026-06-12" }, { "url": "https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html", "title": "減肥成王：GLP-1 正在把全球生技資本重新洗牌", "datePublished": "2026-06-11" }, { "url": "https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html", "title": "生醫公司 IR 不是把簡報變漂亮，而是把管線變成可追蹤的資本市場故事", "datePublished": "2026-06-10" }, { "url": "https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html", "title": "RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰", "datePublished": "2026-06-10" }, { "url": "https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html", "title": "70億美元核藥併購傳聞：Curium想買Lantheus，真正買的是一張核藥時代的入場券", "datePublished": "2026-06-09" }, { "url": "https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html", "title": "CAR-T 迎接新時代：從血癌走向自體免疫", "datePublished": "2026-06-08" }, { "url": "https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html", "title": "沒有 AI 能力的藥廠，將不再被稱作藥廠", "datePublished": "2026-06-07" }, { "url": "https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html", "title": "老靶點都很捲，但不是不能賺錢", "datePublished": "2026-06-06" }, { "url": "https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html", "title": "從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？", "datePublished": "2026-06-05" }, { "url": "https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html", "title": "Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場", "datePublished": "2026-06-04" }, { "url": "https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html", "title": "40年沒藥的遺傳病迎來重磅進展", "datePublished": "2026-06-03" }, { "url": "https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html", "title": "Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？", "datePublished": "2026-06-02" }, { "url": "https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html", "title": "核藥賣爆了", "datePublished": "2026-06-01" }, { "url": "https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html", "title": "⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣", "datePublished": "2026-05-31" }, { "url": "https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html", "title": "藥王的最佳搭檔？療效翻倍！", "datePublished": "2026-05-30" }, { "url": "https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions.html", "title": "減重藥物不只看體重了：下一代療法正在瞄準這些方向", "datePublished": "2026-05-29" }, { "url": "https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system.html", "title": "🧬 生技投資圈｜不是更多新聞，是一套生技醫藥判斷系統", "datePublished": "2026-05-28" }, { "url": "https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html", "title": "太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮", "datePublished": "2026-05-27" }, { "url": "https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html", "title": "台灣生技估值第一步：不要把所有公司都塞進同一個本益比", "datePublished": "2026-05-27" }, { "url": "https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track.html", "title": "減肥藥新副作用，意外帶出新賽道？", "datePublished": "2026-05-26" }, { "url": "https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html", "title": "氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!", "datePublished": "2026-05-25" }, { "url": "https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html", "title": "OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間", "datePublished": "2026-05-24" }, { "url": "https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html", "title": "全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價", "datePublished": "2026-05-23" }, { "url": "https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html", "title": "這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流", "datePublished": "2026-05-22" }, { "url": "https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html", "title": "AI半導體掩蓋生技光芒", "datePublished": "2026-05-21" }, { "url": "https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html", "title": "破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元", "datePublished": "2026-05-20" }, { "url": "https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html", "title": "HIV 新藥很好賺呀...吉利德財報披露", "datePublished": "2026-05-19" }, { "url": "https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html", "title": "大藥廠 輝瑞在兩個判斷上栽跟頭？", "datePublished": "2026-05-18" }, { "url": "https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html", "title": "第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？", "datePublished": "2026-05-17" }, { "url": "https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html", "title": "Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T", "datePublished": "2026-05-17" }, { "url": "https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html", "title": "FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測", "datePublished": "2026-05-16" }, { "url": "https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html", "title": "全網最全的「抗憂鬱新藥」最新進展盤點", "datePublished": "2026-05-15" }, { "url": "https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html", "title": "藥華藥 打開估值想像空間", "datePublished": "2026-05-14" }, { "url": "https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html", "title": "中樞神經新藥要靠「神經發炎」？", "datePublished": "2026-05-13" }, { "url": "https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html", "title": "自體免疫 雙子星 拯救 嬌生", "datePublished": "2026-05-12" }, { "url": "https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html", "title": "DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？", "datePublished": "2026-05-11" }, { "url": "https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay.html", "title": "川普放政策鴿子，減肥藥價格白降了？", "datePublished": "2026-05-10" }, { "url": "https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal.html", "title": "臨床試驗作假，FDA 撤市風暴！", "datePublished": "2026-05-09" }, { "url": "https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html", "title": "減肥藥還是太強了，禮來 猛健樂 賺爛！", "datePublished": "2026-05-08" }, { "url": "https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html", "title": "下一代世紀大藥的陰影？", "datePublished": "2026-05-07" }, { "url": "https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html", "title": "【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點", "datePublished": "2026-05-06" }, { "url": "https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html", "title": "讓大藥廠心動的管線到底做了什麼？", "datePublished": "2026-05-05" }, { "url": "https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough.html", "title": "最強生髮藥暴漲 47%， 為什麼可能改寫掉髮治療三十年僵局？", "datePublished": "2026-05-04" }, { "url": "https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html", "title": "體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？", "datePublished": "2026-05-03" }, { "url": "https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition.html", "title": "印度製藥巨頭的野望！併購美國藥廠！", "datePublished": "2026-05-02" }, { "url": "https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html", "title": "阿茲海默症20年來的假說開始崩盤？", "datePublished": "2026-05-01" }, { "url": "https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia.html", "title": "亞馬遜（Amazon） 參戰 AI 製藥，挑戰輝達（Nvidia）", "datePublished": "2026-04-30" }, { "url": "https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html", "title": "一篇文章講通現在的“禮來”併購邏輯", "datePublished": "2026-04-29" }, { "url": "https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html", "title": "灰色產業上牌桌", "datePublished": "2026-04-28" }, { "url": "https://drugnews.com.tw/articles/2026-04-27-car-t.html", "title": "再見自體CAR-T，台灣的泡沫也該破了", "datePublished": "2026-04-27" }, { "url": "https://drugnews.com.tw/articles/2026-04-26-dcard-261370593.html", "title": "醫療巨頭分拆潮？", "datePublished": "2026-04-26" }, { "url": "https://drugnews.com.tw/articles/2026-04-25-biotech-5.html", "title": "平台型 Biotech 的授權收入是同業的 5 倍？", "datePublished": "2026-04-25" }, { "url": "https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html", "title": "投資人請注意，給藥方式是藍海！", "datePublished": "2026-04-24" }, { "url": "https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html", "title": "慢性阻塞性肺病患者又有新藥可以用了？", "datePublished": "2026-04-23" }, { "url": "https://drugnews.com.tw/articles/2026-04-22-ai.html", "title": "AI三巨頭在醫藥裡廝殺", "datePublished": "2026-04-22" }, { "url": "https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html", "title": "禮來口服藥引爆市場？", "datePublished": "2026-04-21" }, { "url": "https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html", "title": "歷史性一刻，世紀大藥來了", "datePublished": "2026-04-20" }, { "url": "https://drugnews.com.tw/articles/2026-04-19-neuralink-10.html", "title": "馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！", "datePublished": "2026-04-19" }, { "url": "https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html", "title": "台灣這家Biotech將吃下AI基礎建設的所有紅利？", "datePublished": "2026-04-18" }, { "url": "https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html", "title": "創新藥開發的「死亡之谷」", "datePublished": "2026-04-17" }, { "url": "https://drugnews.com.tw/articles/2026-04-16-2026-q2.html", "title": "生技人必須知道的 2026 Q2 重磅藥物", "datePublished": "2026-04-16" }, { "url": "https://drugnews.com.tw/articles/2026-04-15-biotech.html", "title": "兩家明星 Biotech 的隕落", "datePublished": "2026-04-15" }, { "url": "https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html", "title": "投資人請注意，自體免疫超大藥賽道", "datePublished": "2026-04-14" }, { "url": "https://drugnews.com.tw/articles/2026-04-13-78.html", "title": "減肥藥之王 78億美元，買下一個「清醒時代」？", "datePublished": "2026-04-13" }, { "url": "https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html", "title": "特發性肺纖維化 迎來爆發", "datePublished": "2026-04-12" }, { "url": "https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html", "title": "這家公司臨床試驗失敗，反而被更加看好？", "datePublished": "2026-04-11" }, { "url": "https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html", "title": "何時果斷放棄新藥臨床試驗開發？", "datePublished": "2026-04-10" }, { "url": "https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html", "title": "這一批罕見病患者終於等來新藥！", "datePublished": "2026-04-09" }, { "url": "https://drugnews.com.tw/articles/2026-04-08-abivax-14.html", "title": "歐洲生技公司Abivax 一年暴漲14倍的神話", "datePublished": "2026-04-08" }, { "url": "https://drugnews.com.tw/articles/2026-04-07-cdc.html", "title": "當美國 CDC 還在找主任...", "datePublished": "2026-04-07" }, { "url": "https://drugnews.com.tw/articles/2026-04-06-420.html", "title": "骨折價 瘦瘦針來了，每月420塊台幣", "datePublished": "2026-04-06" }, { "url": "https://drugnews.com.tw/articles/2026-04-05-dcard-261238352.html", "title": "我們離真正的抗老藥，究竟還有多遠？", "datePublished": "2026-04-05" }, { "url": "https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html", "title": "瘦瘦針翻車？導致胰臟炎？", "datePublished": "2026-04-04" }, { "url": "https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html", "title": "瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？", "datePublished": "2026-04-03" }, { "url": "https://drugnews.com.tw/articles/2026-04-02-dcard-261221419.html", "title": "默沙東還能再造一個腫瘤帝國嗎？", "datePublished": "2026-04-02" }, { "url": "https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html", "title": "信達的全球化列車，台灣的圓祥搭上了？", "datePublished": "2026-04-01" } ] }